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Abstract 
Recent genome sequencing efforts have revealed that a common biosynthetic route to 
peptide natural products involves ribosomally synthesized and posttranslationally modified 
peptides (RiPPs). One of the largest classes of RiPPs is the lanthionine-containing peptides 
(lanthipeptides), which are characterized by intramolecular thioether crosslinks dubbed 
lanthionine (Lan) and methyllanthionine (MeLan). The evolvability and brevity of lanthipeptide 
biosynthetic pathways as well as the substrate tolerance of the biosynthetic machinery facilitates 
the heterologous expression of lanthipeptides and renders the ribosome-derived compounds 
attractive for bioengineering efforts. A major drawback to the production of lanthipeptides, either 
in E. coli or in vitro, is the removal of the leader peptide after posttranslational modification to 
generate the mature natural product. In this thesis, Chapter 2 will discuss a method to introduce a 
photolabile linker between lanthipeptide leader and core regions. Posttranslational modification 
of the lanthipeptide by its cognate synthetase in vitro, followed by UV-light mediated removal of 
the leader peptide, yielded the mature lanthipeptide. Chapter 3 will spotlight a novel way to 
engineer the ribosomal machinery to incorporate a hydroxy acid into the peptide thus generating 
an ester linkage directly between the lanthipeptide leader and core regions, which is selectively 
hydrolyzed under mild alkaline conditions.  
Labeling of natural products with biophysical probes has greatly contributed to 
investigations of their modes of action and has provided tools for visualization of their targets. 
However, the mode of action of only a few lantibiotics has been determined thus far. A general 
challenge is the availability of a suitable functional group for chemoselective modification. 
Chapter 4 will discuss novel methodology to introduce an N-terminal ketone into various 
lanthipeptides by the generation of a cryptic N-terminal dehydro amino acid by the cognate 
  iii 
biosynthetic enzymes. Spontaneous hydrolysis of the N-terminal enamines after leader peptide 
removal results in α-ketoamides that site-specifically react with an aminooxy-derivatized alkyne 
or fluorophore. The fluorescently-modified lantibiotics were added to bacteria, and their cellular 
localization was visualized by confocal fluorescence microscopy as a means to determine their 
modes of action. 
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Chapter 1: Introduction 
Taken in part from Bindman and van der Donk.1 
 
1.1. NATURAL PRODUCTS AS ANTIBIOTICS AGAINST DRUG-RESISTANT 
PATHOGENS 
The emergence of antibiotic-resistant pathogens, such as methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), has amplified 
the need for new classes of antimicrobial compounds. In 2007, MRSA was responsible for over 
100,000 infections and 20,000 deaths in the U.S., more deaths than caused by HIV/AIDS.2 One 
reason for the increase of antibiotic-resistant pathogens is the quick spread of resistance genes. In 
1980, less than five percent of S. aureus isolated from hospitals had a resistance marker for 
methicillin whereas in 2007 that number had jumped to almost sixty percent.2 Alarmingly, with 
the increase of drug-resistant bacteria, very few new classes of antibiotics have been developed 
since the 1960s. Several challenges have contributed to the decline in discovery of novel 
antibiotics. One factor is that pharmaceutical companies are spending less on research and 
development towards new antibiotics, which if administered correctly are used for only a short 
period by a patient, unlike drugs for chronic diseases, which must be taken every day of the 
patients’ life. Furthermore, it is easier and less expensive to modify the structure of a known 
antibiotic than to search for an antibiotic with a novel mode of action.3 Therefore, an immense 
need exists for the discovery and study of novel antibiotics. 
One potential route for the discovery of new antibiotics is to study the natural defensive 
arsenal of bacteria, which has been developed as a consequence of the evolutionary pressure of 
living in nutrient starved conditions. This route has been largely successful in developing 
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clinically useful antibiotics; over two-thirds of all antibiotics on the market are, or are derived 
from, natural products.4 Peptide natural products have been important players in the search for 
novel antibiotics because their unique three-dimensional structures (with many sp3 hybridized 
carbons) allow tight binding and a high degree of specificity and potency to their targets. Indeed, 
the glycopeptide vancomycin, isolated in the 1950s from the soil bacterium Amycolatopsis 
orientalis, has been used as a last line of defense drug against MRSA for over 50 years. More 
recently, peptide natural product based compounds such as telavancin5 and teicoplanin,6 as well 
as the lipopeptide daptomycin,7 were marketed in the U.S. and/or Europe for their ability to kill 
Gram-positive drug resistant bacteria. Many other peptide-based natural products are currently 
under development and some are in clinical trials and may soon assist in the fight against drug-
resistant bacteria.8,9 
 
1.2. RIBOSOMALLY SYNTHESIZED AND POSTTRANSLATIONALLY MODIFIED 
PEPTIDES 
Many peptide natural products, including the antimicrobial compounds vancomycin and 
daptomycin, are non-ribosomal peptides (NRPs) that are biosynthesized by a modular assembly 
line of proteins encoded by relatively large gene clusters (~40-60 kb).10 The recent genome 
sequencing efforts have revealed that another very common biosynthetic route to peptide natural 
products involves ribosomally synthesized and posttranslationally modified peptides (RiPPs) 
(Figure 1.1). These compounds are produced in all domains of life but are most prevalent, or at 
least best studied, in bacteria, serving as natural bio-warfare agents. In retrospect it is not 
surprising that RiPPs are widespread given the potential benefits these biosynthetic pathways 
have for the producing organisms, including evolvability. Evolution of new NRPs requires rare 
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mutations in the biosynthetic enzymes that change the outcome of an enzymatic reaction 
somewhere along the assembly line and requires that all downstream enzymes tolerate this 
change. By contrast, RiPPs can evolve more readily because of a direct link between gene 
sequence and natural product. In addition, the relative brevity of RiPP biosynthetic pathways, as 
well as the substrate tolerance of the biosynthetic machinery, favors molecular evolution. These 
same attributes also facilitate their heterologous expression and render the ribosome-derived 
compounds attractive for bioengineering efforts and for genome-mining strategies to discover 
new compounds.11 
 The majority of peptides synthesized on the ribosome are produced as linear precursor 
peptides of about 20-110 amino acids with an N-terminal leader peptide and C-terminal core 
peptide. Modification of the core peptide by the biosynthetic machinery followed by leader 
peptide removal yields the mature natural product (Figure 1.1, bottom). The leader peptide is 
thought to play several roles in the biosynthesis of mature RiPPs, including serving as a secretion 
signal for export, a recognition motif for the posttranslational modification (PTM) enzymes, and 
a mechanism of self resistance by keeping the biosynthetic intermediates inactive in the native 
producing organism.12 Many different classes of RiPPs are produced by bacteria, each 
characterized by their unique PTMs and gene clusters. Most of these RiPPs are macrocyclic, 
which reduces their proteolytic susceptibility and preorganizes them for target recognition. This 
thesis will focus on the production and maturation of one class of RiPPs, the lanthipeptides; for 
an extensive review of the biosynthesis and bioengineering of other RiPP classes I refer the 
reader to recent reviews.1,13 
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Figure 1.1. RiPP biosynthesis and structures. Top, Representative structures of RiPPs. Bottom, 
General scheme of leader peptide guided synthesis of RiPPs. Figure adapted from Bindman and 
van der Donk.1 
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 1.3. LANTHIPEPTIDE BIOACTIVITIES AND MODES OF ACTION 
 Lanthionine-containing peptides (lanthipeptides) represent the longest known class of 
RiPPs. Nisin (Figure 1.1), the first discovered and most studied lantibiotic (antimicrobial 
lanthipeptide), has been utilized worldwide in the food industry for over 50 years as a 
preservative added to cheese, beer, wine, salad dressing, and many other food items.14 
Interestingly, despite this extensive period of use, no widespread bacterial resistance has 
developed, presumably because of its dual mode of action: binding to lipid II, thereby inhibiting 
transglycosylation during cell wall biosynthesis, and subsequent formation of pores in the cell 
membrane.15,16 Many other lantibiotics, including mersacidin, lacticin 481, lacticin 3147, 
plantaricin C, and haloduracin α, also bind to lipid II but they do not form pores.17-20 Still others 
have the ability to form pores but do not recognize lipid II,21 and may have a range of other 
modes of action.  
 Lantibiotics possess potent activities against a wide range of gram-positive bacteria, 
including clinically relevant strains such as MRSA and VRE.22 Indeed, two lantibiotics are 
already in clinical development for their abilities to treat Clostridium difficile (actagardine 
derivative) and Gram-positive infections (mutacin 1140).23,24 Lanthipeptides in clinical 
development for indications that are not infectious diseases include duramycin, which aids in the 
treatment of cystic fibrosis.25 Finally, the lantibiotic geobacillin was discovered to be active 
against Streptococcus dysgalactiae, one of the causative agents of bovine mastitis.26 Despite the 
success of these peptides, many lantibiotics readily degrade or are insoluble at neutral pH and 
thus cannot be used in the clinic. Current efforts are aimed at bioengineering techniques to 
generate lantibiotic analogues with improved pharmacokinetic properties. 
 6 
1.4. LANTHIPEPTIDE BIOSYNTHESIS 
The bioactivities of lanthipeptides are the result of their extensive posttranslational 
modifications. At present, four compound classes have been reported that differ in the enzymes 
that introduce the characteristic thioether crosslinks. After ribosomal synthesis of the precursor 
peptide LanA (e.g. LctA for lacticin 481, Figure 1.2A), a series of serine and threonine residues 
in the C-terminal core region of LanA are dehydrated to form dehydroalanines and 
dehydrobutyrines, respectively. For class I lanthipeptides, the dehydratase LanB carries out the 
dehydrations. Alternatively, the N-terminal regions of the bifunctional enzymes LanM (class II), 
LanKC (class III), or LanL (class IV) catalyze the dehydration reactions.27-30 The mechanism of 
dehydration has been thoroughly characterized in class II lanthipeptides.31,32 The LanM enzyme 
catalyzes an ATP-dependent phosphorylation event on the side chain hydroxyl of Ser or Thr.31 
This phosphoryl intermediate is then eliminated, producing a dehydro amino acid (Figure 1.2B). 
More recently, the dehydration mechanism of NisB, the dehydratase of the class I lantibiotic 
nisin, was studied and shown to occur via glutamylation of the Ser or Thr residue, rather than 
phosphorylation, followed by glutamate elimination.33 The subsequent Michael-type additions of 
cysteine residues onto the dehydro amino acids are catalyzed by the enzyme LanC (class I) or the 
C-terminal regions of LanM (class II), LanKC (class III), and LanL (class IV) (Figure 1.2B). The 
resulting thioether structures are called lanthionine and methyllanthionine when formed from Ser 
and Thr, respectively. Some class III LanKC synthetases do not protonate the enolate generated 
during the Michael-type addition, but instead catalyze addition of this enolate to another 
dehydroalanine forming a carbon-carbon bond.29 The structures thus formed have been termed 
labionin. 
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 In all known examples, an N-terminal leader peptide on the LanA substrate peptide 
guides at least part of these posttranslational modifications, but the leader peptide must be 
removed from the core peptide in the final step of maturation to produce the natural product 
(Figure 1.2A).12,34 In the native organism, this step is catalyzed by the protease LanP (class I) or 
the protease domain of an ATP-binding cassette transmembrane transporter termed LanT (class 
II), which removes the leader peptide through proteolysis after residue –1 (amino acids in the 
leader peptide are indicated with negative residue numbers counting backwards from the natural 
protease cleavage site and amino acids in the core peptide are indicated with positive residue 
numbers counting forwards from the natural protease cleavage site) (Figure 1.2A).35,36 The 
proteases responsible for leader peptide cleavage in class III and class IV lanthipeptides are 
currently unknown. A host of other, less common posttranslational modifications found in 
individual lanthipeptides will not be covered here but have been described elsewhere.23  
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Figure 1.2. Biosynthesis and proposed mechanisms for dehydration and cyclization of lacticin 
481. A) Biosynthesis of lacticin 481. The synthetase LctM transforms a linear precursor peptide 
LctA into a polycyclic structure. The transporter LctT then removes the leader peptide and 
secretes the product lacticin 481. B) Proposed mechanisms of class II lanthipeptide dehydration 
and cyclization. Figure adapted from Bindman and van der Donk.1 
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1.5. BIOENGINEERING OF LANTHIPEPTIDES 
The biosynthesis of about a dozen lanthipeptides has been thoroughly characterized and 
bioengineering efforts have thus far focused on those peptides. Efforts to construct mutants with 
improved pharmacokinetic properties or biological activities have focused on three approaches: 
1) engineering of lanthipeptides in producing strains and heterologous hosts, 2) engineering of 
lanthipeptides in Escherichia coli, and 3) in vitro engineering of lanthipeptides.23  
 
1.5.1. Bioengineering studies in producing strains and heterologous hosts. 
 The generation of lantibiotic analogues in producing strains or in heterologous bacterial 
hosts has been achieved utilizing two methods; in cis, where the wild type (wt) lanA is modified 
by site-directed mutagenesis or gene replacement, or in trans, where a separate lanA gene is 
added, usually in a plasmid, with concomitant disruption of the endogenous lanA.37 These 
techniques have lead to the discovery of nisin and lacticin 3147 analogues with improved 
bioactivity from large libraries of analogues.38-40 Similarly, the structure-function relationships of 
nukacin ISK-1 and actagardine have been analyzed by site-saturation mutagenesis.41,42 Although 
the production of lantibiotic mutants in producing strains has led to the discovery of peptides 
with improved antibacterial properties, one potential drawback is that particularly active products 
could overwhelm or circumvent the native immunity mechanisms of the producer organism,39 
killing the bacteria before the desired product is expressed or leading to shut-down of expression. 
One means to overcome potential toxicity is to prevent leader peptide removal within the 
producer,43-45 but this strategy then requires subsequent removal of the leader peptide, which is 
often non-trivial and will be discussed throughout this thesis. 
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1.5.2. In vivo engineering of lanthipeptides in E. coli 
 Because of the fast generation time, well-studied fermentation behavior, and ease of 
genetic manipulation, several laboratories, including our own, have developed heterologous 
expression of lanthipeptides in E. coli. The first report in 2005 demonstrated that nukacin ISK-1 
could be successfully produced in E. coli by coexpression of the substrate and its NukM 
modifying enzyme, although in vitro leader peptide removal using a commercial protease 
resulted in a truncated analogue.46 This work was expanded in 2011 as four prochlorosins, both 
components of the two-component lantibiotic haloduracin, and nisin were produced in E. coli 
using a similar strategy of coexpression of substrates with the modification enzymes.43 In this 
study, the leader peptides were also removed in vitro with commercial proteases at engineered 
cleavage sites. Subsequently, several other lanthipeptides have been produced in E. coli using the 
same strategy including lacticin 481 and cinnamycin.47-49 The relatively high titers of modified 
lanthipeptides produced in E. coli by co-expression from pRSFDuet plasmids has also enabled 
the structural characterization of products of silent clusters as well as compounds that are 
produced in very small quantities in the native producers.26,49 A different strategy was used for 
the two-component lantibiotic lichenicidin, which was successfully expressed in E. coli from a 
fosmid carrying the native cluster including the bifunctional protease/transporter. This approach 
resulted in secretion of the mature product without the need of in vitro removal of the leader 
peptide.50,51 Both methods have also allowed incorporation of non-proteinogenic amino acids, 
either by using stop-codon suppression methodology with orthogonal tRNA/tRNA synthetases43 
or by using the natural promiscuity of some of the native tRNA/tRNA synthetase pairs (e.g. 
Met).51 
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1.5.3. In vitro engineering of lanthipeptides. 
 The construction of lanthipeptides and analogues via in vitro reconstitution of the 
activities of the biosynthetic enzymes has been exploited as an alternative to isolation of 
lanthipeptides from bacterial production systems.27 Facilitated by the relative ease of 
heterologous production of the precursor peptides, LanA, and the biosynthetic enzymes, LanM, 
in E. coli, the in vitro route allows for the incorporation of amino acid substitutions into the 
peptide substrates via site-directed mutagenesis (mainly native amino acids), or solid phase 
peptide synthesis (native or non-proteinogenic amino acids),52 providing access to a much larger 
pool of structures than with in vivo methods. The first successful in vitro reconstitution of the 
lanthionine-forming machinery27 allowed studies on the high substrate tolerance and mechanism 
of the posttranslational modification enzymes.18,31,35,53-55 Incorporation of nonproteinogenic 
amino acids into lanthipeptides has been achieved for lacticin 481 by ligation of synthetic 
lacticin 481 core peptides with the leader peptide using either 1,3 dipolar cycloaddition (Figure 
1.3) or native chemical ligation.52,56 Modification by LctM and subsequent leader peptide 
removal with the commercial protease LysC yielded a panel of lacticin 481 analogues, including 
two variants with improved bioactivity. The ability to produce non-native lantibiotic analogues is 
valuable for mode of action and bioactivity studies as well as for understanding the specificities 
and mechanistic details of the posttranslational modification enzymes. 
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Figure 1.3. In vitro engineering of lacticin 481. Copper-catalyzed alkyne/azide cycloaddition 
followed by LctM modification of the core peptide and leader peptide removal allowed the 
incorporation of non-proteinogenic amino acids into lacticin 481 analogues. Sar, sarcosine; 
Acpc, aminocyclopropanoic acid; Cba, 4-cyanoaminobutyric acid; N-Nle, N-butyl glycine; Nal, 
naphthyl alanine; Pal, pyridynyl alanine; hPhe, homophenylalanine. Figure adapted from 
Bindman and van der Donk.1 
 
1.6. SUMMARY AND OUTLOOK 
 A major drawback to the production of lanthipeptides, either in vivo in E. coli or in vitro, 
is the removal of the leader peptide to generate the mature natural product. This step is often 
achieved by engineering a proteolytic cleavage site (Glu, Lys, Ile-Glu-Gly-Arg) at the –1 
position and using a commercial endoprotease (GluC, LysC or trypsin, Factor Xa) to remove the 
entire leader peptide, a process that will be described in more detail in Chapter 4. Although this 
strategy has been effective in several cases, it can be unproductive if the core region contains the 
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same cleavage site. Also, in lacticin 481, the leader peptide has been removed utilizing the 
endoprotease LysC, which cleaves off the N-terminal lysine, yielding Δ1-lacticin 481, a mutant 
with decreased bioactivity.52 Thus, it would be beneficial to develop new strategies to remove the 
leader peptide that are independent of the amino acid sequence of the core region. In this thesis, 
Chapter 2 will discuss a method to introduce a photolabile linker between lanthipeptide leader 
and core regions. Posttranslational modification of the lanthipeptide by its cognate synthetase in 
vitro, followed by UV-light mediated removal of the leader peptide, yielded the mature 
lanthipeptide. This method will also allow the facile incorporation of non-proteinogenic amino 
acids into lanthipeptides as the core peptide is synthesized on the solid phase. Chapter 3 will 
spotlight a novel way to engineer the ribosomal machinery to incorporate a hydroxy acid into the 
peptide thus generating an ester linkage directly between the lanthipeptide leader and core 
regions utilizing the relaxed substrate specificity of pyrrolysyl tRNA synthetase. By incubating 
the peptide under mild alkaline conditions, the subsequent ester bond was selectively hydrolyzed, 
yielding the core region with an N-terminal hydroxyl group. 
 Labeling of natural products with biophysical probes has greatly contributed to 
investigations of their modes of action and has provided tools for visualization of their targets. 
However, the mode of action of only a few lantibiotics has been determined thus far. A general 
challenge is the availability of a suitable functional group for chemoselective modification. 
Chapter 4 will discuss novel methodology to introduce an N-terminal ketone into various 
lanthipeptides by the generation of a cryptic N-terminal dehydro amino acid by the cognate 
biosynthetic enzymes. Spontaneous hydrolysis of the N-terminal enamines after leader peptide 
removal results in α-ketoamides that site-specifically react with an aminooxy-derivatized alkyne 
or fluorophore. The fluorescently-modified lantibiotics were added to bacteria, and their cellular 
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localization was visualized by confocal fluorescence microscopy as a means to determine their 
modes of action. 
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Chapter 2: Photochemical Cleavage of Leader Peptides 
Taken in part from Bindman and van der Donk., Photochemical Cleavage of Leader Peptides, 
Chem. Commun., 2010, 46, 8935-8937.1 Reproduced with permission of The Royal Society of 
Chemistry. 
 
2.1 INTRODUCTION 
 The ability to produce non-native lanthipeptide analogues is valuable for lanthipeptide 
mode of action and bioactivity studies, as well as for investigation of the specificities and 
mechanistic details of the post-translational modification enzymes. Indeed, mutation of a 
conserved Glu or Asp residue to Ala in several lantibiotics either lowered the compounds activity 
or rendered the compound completely inactive, signifying the importance of the residue to the 
lantibiotic mode of action.2-7 Unfortunately, despite the success of these examples, the removal 
of the leader peptide usually presents a major technical hurdle. The native proteases that cleave 
the modified substrates endogenously are often membrane associated as part of ATP-binding 
cassette transporters,8 with soluble domains having low in vitro activity.9,10 Hence, although a 
few successful examples have been reported,11-13 the cognate proteases are not a general solution 
for removal of leader peptides. To address these limitations, various other methods for in vitro 
removal of the leader peptides have been reported.1 The most common strategy has been 
incorporation of Lys or Glu at the –1 position for subsequent treatment with endoproteinases 
LysC or GluC, respectively.14-17 Whereas these approaches have worked in select cases, use of 
GluC and LysC typically does not work if the core peptide contains a Lys or Glu, unless that 
residue is “deactivated” for proteolysis by adjacent posttranslationally modified amino acids. 
Also, the activity of the commercial protease on the –1 position can be sluggish or nonexistent 
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when the cleavage site is proximal to a posttranslationally modified amino acid.7,17-19 Therefore, 
an alternative, general method for the removal of the leader peptides would be valuable. 
 The incorporation of 2-nitrophenyl or 2-nitroveratrole groups at appropriate sites in 
peptides and proteins has allowed the site-specific light-mediated cleavage of the polyamide 
backbone. For instance, introduction of phenylglycine derivative 2.1 (Scheme 2.1) in ion 
channels allowed their temporal photo-activation.20 Other examples of linkers that allow 
photolytic scission of peptide chains are the commercially available β-amino acid 2.2 and a 
series of linkers incorporating a nitrophenyl group in the peptide chain, exemplified by 2.3.21 
These linkers are effective, but they are less attractive for leader peptide removal as their use 
would result in core peptides carrying non-natural nitrosoaryl groups (e.g. 2.7-2.9, Scheme 2.1). 
Therefore, we designed linker 2.4, which was envisioned to generate the native core peptide 2.10 
upon photolysis. 
 
Scheme 2.1. Photochemical cleavage of 2-nitrophenyl derivatives (2.1-2.4) linking N- and C-
terminal peptide fragments. For the purpose of this work, R1 would represent the leader peptide 
and R2 the core peptide. Scheme adapted from Bindman and van der Donk.1  
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2.2. RESULTS AND DISCUSSION 
2.2.1. Design and synthesis of photocleavable linker 2.17. 
 We considered two major criteria in our design of a reagent that could introduce linker 
2.4 into peptides. First, compatibility with fluorenylmethyloxycarbonyl-SPPS (Fmoc-SPPS) was 
desired in order to take advantage of the ease of this approach for the synthesis of peptides and to 
facilitate incorporation of non-canonical amino acids. Second, the linker had to be amenable to 
our previously developed segment coupling strategy that links the leader peptide with the core 
peptide using a Cu(I)-catalyzed alkyne azide cycloaddition (CuAAC)22 between a leader peptide 
with a C-terminal alkyne and a core peptide with an N-terminal azide.23 In this previous work, 
the enzyme LctM was able to process substrate analogues of the precursor peptide LctA in which 
the core and leader peptides had been fused via a triazole.23 Linkers 2.15-2.17 (Scheme 2.2) were 
designed to fulfill both criteria and linker 2.18, a related photolabile compound that required a 
more lengthy synthesis and was not used for SPPS, was reported during the course of this 
study.24 Each linker contained two distinct functionalities; an electrophilic region to trap an N-
terminal amine on a growing peptide chain and an azide, which could be reduced to an amine to 
facilitate peptide elongation by SPPS or coupled to an alkyne-labeled peptide via a CuAAC 
bioconjugation.  
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Scheme 2.2. Synthesis of photolabile linkers 2.15, 2.16, and 2.17. Photolabile linker 2.18 was 
previously synthesized.24 Scheme adapted from Bindman and van der Donk.1  
 
 Photolabile linkers 2.15-2.17 were synthesized starting from commercial diol 2.11 
(Scheme 2.2). Activation of the primary alcohol of 2.11 with p-toluenesulfonyl chloride (TsCl) 
was followed by protection of the secondary alcohol as the trimethylsilyl (TMS) ether to yield 
2.13. The p-toluenesulfonate group of 2.13 was then displaced with sodium azide. TMS 
protection of the primary alcohol of 2.13 was required to prevent epoxide formation and 
subsequent azide addition to the benzylic carbon. Fortuitously, under the displacement reaction 
conditions, the TMS protecting group also was removed, affording secondary alcohol 2.14. 
Compound 2.14 was oxidized to the ketone by Dess-Martin periodinane to generate linker 2.15. 
We postulated that this linker could be incorporated into a resin-bound peptide via a reductive 
alkylation reaction. However, reductive alkylation of primary amines at the N-terminus of 
peptides with linker 2.15, whether on- or off-resin, never produced product. The reductive 
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alkylation strategy was therefore abandoned in favor of a nucleophilic substitution reaction. We 
hypothesized that the secondary bromide of linker 2.16 might be more amenable to reaction with 
the terminal amine of a resin-bound peptide. Thus, linker 2.16 was synthesized by converting the 
secondary alcohol of compound 2.14 to the methylsulfonate followed by displacement with 
lithium bromide. This linker was successfully reacted with the resin-bound pentamer H-GASSA-
O-Wang in the presence of diisopropylethylamine (DIPEA), as determined by electrospray 
ionization mass spectrometry (ESI-MS) (Figure 2.1A,C). However, the nucleophilic substitution 
reaction was only efficient if glycine was the N-terminal amino acid; the reaction with the 
peptide H-AASSA-O-Wang proceeded in low yields (Figure 2.1B), presumably because of a 
steric clash between linker 2.16 and the more bulky amino acid. Therefore, the substitution 
strategy was abandoned for one in which a peptide could be incorporated into the photocleavable 
linker via a carbonyl addition-elimination reaction. Thus, photocleavable linker 2.17 was 
synthesized by reacting the secondary alcohol of 2.14 with disuccinimidyl carbonate. We 
suspected linker 2.17 would be more versatile than linkers 2.15 or 2.16 given the extensive use 
of carbonates in chemical biology. 
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Figure 2.1. ESI-MS spectra of alkylation reactions of linker 2.16 and pentapeptides A) H-
GASSA-O-Wang and B) H-AASSA-O-Wang (H-GASSA-OH [M+H]+ calc’d = 392.2 Da.; N3-
GASSA-OH [M+H]+ calc’d = 582.4 Da.; H-AASSA-OH [M+H]+ calc’d = 406.2 Da.; N3-
AASSA-OH [M+H]+ calc’d = 596.4 Da.) C) Schematic representation of the reaction between 
linker 2.16 and pentapeptides with an N-terminal Ala or Gly. 
 
2.2.2. Differential scanning calorimetry measurements of compounds 2.12-2.14 and 2.17.  
 Because of their large ratio of oxygen and nitrogen atoms to carbon atoms, compounds 
2.12-2.14 and 2.17 were analyzed by differential scanning calorimetry (DSC) to ensure their 
safety under the conditions used (Figure 2.2). The determined heat of decomposition of each 
compound was compared to benzoyl peroxide (BPO) as standard reference material.25 Briefly, if 
the heat quantities of the decomposition reactions of compounds 2.12-2.14 and 2.17 were lower 
than the heat quantity of decomposition of BPO the compound was judged not to be a Class 5 
explosive and thus safe to utilize in the temperature range tested. 
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Figure 2.2. DSC data of 2.12-2.14, 2.17, and BPO. A) Standard reference compound BPO. Peak 
onset = 109 ºC, peak = 110 ºC, exotherm = -2350 J/g. B) Compound 2.12. Peak onset = 170 ºC, 
peak = 191 ºC, exotherm = -1220 J/g. C) Compound 2.13. Peak onset = 170 ºC, peak = 190 ºC, 
exotherm = -860 J/g. D) Compound 2.14. Peak onset = 225 ºC, peak = 252 ºC, exotherm = -1595 
J/g. E) Compound 2.17. Peak onset = 190 ºC, peak = 212 ºC, exotherm = -1220 J/g.  
 
 Each of the compounds tested had heat quantities of decomposition less than that of 
benzoyl peroxide. However, the baseline of each of the spectra increased dramatically after 250 
ºC. Therefore, we cannot rule out exotherms at high temperatures that could have been obscured 
by the baseline. Therefore, care should still be taken before using these compounds at higher 
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temperatures than employed in this study and DSC analysis that is accurate at higher 
temperatures should be utilized prior to use at high temperatures. 
 
2.2.3. Compatibility of linker 2.17 with SPPS. 
 To investigate the compatibility of linker 2.17 with Fmoc-SPPS, a model peptide with the 
sequence AGLSA was assembled on pre-loaded Wang resin using standard Fmoc methodology 
with O-(1H-6-chlorobenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate 
(HCTU) and N-methyl morpholine (NMM) as coupling reagents. The peptide was reacted with 
linker 2.17 in the presence of DIPEA and the resulting product was analyzed by ESI-MS (Figure 
2.3). Unlike the nucleophilic substitution reaction with linker 2.16, linker 2.17 was successfully 
incorporated at room temperature onto a pentapeptide with an N-terminal Ala, yielding 2.19. 
 
 
Figure 2.3. Reaction between photolabile linker 2.17 and pentapeptide H-AGLSA-O-Wang. 
ESI-MS spectrum (top) and schematic representation (bottom) of the reaction between the 
pentapeptide H-AGLSA-O-Wang and photolabile linker 2.17 yielding azidopeptide 2.19 (H-
AGLSA-OH [M+H]+ calc’d = 418.2 Da.; N3-AGLSA-OH [M+H]+ calc’d = 652.4 Da.). 
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 After successful coupling of a C-terminal peptide fragment to the linker, the 
compatibility of the linker with the reactions employed for the installment of an N-terminal 
peptide was evaluated. The azide functionality of 2.19 was reduced in situ with tri-n-
butylphosphine, followed by coupling with Fmoc-Ala-OH to generate peptide 2.20 (Scheme 
2.3). Standard peptide elongation was performed followed by peptide cleavage from resin using 
95% trifluoroacetic acid, and reversed-phase high performance liquid chromatography (RP-
HPLC) purification, producing peptide 2.21. To test the photolability of linker 2.17 the purified 
peptide was irradiated at 365 nm and the N- and C-terminal peptide fragments 2.22 and 2.23 
were obtained successfully as determined by ESI-MS and RP-HPLC (Figure 2.4).  
 
 
Scheme 2.3. Synthesis of decapeptide 2.21 followed by photolysis to generate peptides 2.22 and 
2.23. 
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Figure 2.4. Analysis of the photolysis of decapeptide 2.21. ESI-MS spectra of decapeptide 2.21 
before (A) and after (B) photolysis. C) Analytical RP-HPLC spectrum of decapeptide 2.21 
before (red) and after (blue) photolysis; two diastereomers of H-AGLSA-OH were formed 
presumably as a result of epimerization of the C-terminal alanine as described in section 2.2.4 
(full length decapeptide [M+H]+ calc’d = 968.6 Da; H-AGLSA-OH [M+H]+ calc’d = 418.2 Da.; 
H-EAAA-(2-nitrosophenyl) [M+H]+ calc’d = 506.3 Da.). 
 
 In order to show that the incorporation of photolabile linker 2.17 into peptides 
synthesized by SPPS was general, the amino acids directly preceding and following the linker 
were varied. Thus, a series of short resin-bound pentamers (2.24a-i) (Scheme 2.4) with differing 
N-terminal amino acids (Table 2.1) were synthesized and reacted with linker 2.17. Our results 
showed that the linker was successfully incorporated at room temperature onto all N-terminal 
amino acids tested, including branched amino acids and amino acids containing functionalized 
side chains, to produce 2.25a-i (Table 2.1). The azide functionality of 2.25a-i was then reduced 
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as described above, followed by coupling with Fmoc-Xxx2-OH to yield peptides 2.26a-i. Once 
more, a wide variety of amino acids, including branched amino acids and amino acids containing 
functionalized side chains, were successfully incorporated onto the N-terminal portion of the 
linker. Standard peptide elongation followed by peptide cleavage from resin produced peptides 
2.27a-i in good yields (Table 2.1). The purified peptides were then irradiated at 365 nm and the 
desired C-terminal peptides were obtained successfully and in high yields and purities in all 
cases (Table 2.1; Figures 2.5, 2.6, 2.7). In this and other studies,26-28 photolysis was accompanied 
by the formation of various strongly absorbing decomposition products arising from the 
nitrosoaryl group (Figure 2.5B, Figure 2.6). In the current design, however, these side products 
are not part of the desired C-terminal peptide fragment 2.29 as confirmed by mass spectrometry. 
The ease of the synthesis and high yields of peptides 2.29a-i illustrate the compatibility of linker 
2.17 with SPPS. 
 
Scheme 2.4. Synthesis of decapeptides 2.27a-i followed by photolysis to produce peptides 
2.28a-i and 2.29a-i. Amino acids representing Xxx1 and Xxx2 are described in Table 2.1. 
Scheme adapted from Bindman and van der Donk.1 
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          Yield (%) 
         2.24-2.29       Xxx1                Xxx2               2.27a                2.29b            Per stepc 
a   Thr  Ala             43  70  94 
b   Val  Ala  21  72  90 
c   Lys  Ala  27  87  93 
d   Gly  Gly  39  83  94 
e   Leu  Leu  44  61  93 
f   Tyr  Tyr  16  83  90 
g   Pro  Pro  17  81  90 
h   Trp  Trp  14  70  83 
i   Glu  Glu  21  91  92 
 
Table 2.1. Synthesis and photolysis of decapeptides 2.27a-i using a variety of amino acids 
flanking the photolabile linker. aIsolated yields based on resin loading. bIsolated yields after 
photolysis and RP-HPLC based on 2.27. cYields based on resin loading. Table adapted from 
Bindman and van der Donk.1 
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Figure 2.5. ESI-MS spectra and RP-HPLC traces of 2.27e and photolysis products. A) ESI-MS 
spectrum of 2.27e [M+H]+ calc’d = 1052.5 Da. B) RP-HPLC spectrum of 2.27e before (red) and 
after (blue) the photolysis reaction. C) ESI-MS spectrum of RP-HPLC peak at 16.2 min 
corresponding to purified 2.29e [M+H]+ calc’d = 460.3 Da. D) RP-HPLC spectrum of 2.29e after 
purification. The peak at 3-4 min is associated with salts. 
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Figure 2.6. RP-HPLC spectra of 2.27 before (red) and after (blue) photolysis. A) 2.27b, B) 
2.27f, C) 2.27g, and D) 2.27h. Photolysis reaction generates 2.28 and 2.29. 
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Figure 2.7. RP-HPLC spectra of 2.29 after RP-HPLC purification. A) 2.29a, B) 2.29b, C) 2.29c, 
D) 2.29d, E) 2.29f, F) 2.29g, G) 2.29h, H) 2.29i.  
 
2.2.4. Azide reduction with tri-n-butylphosphine causes racemization at the peptides most 
C-terminal amino acid. 
 After the synthesis of decapeptide 2.21, only peptides with a C-terminal glycine were 
employed in this study because the C-terminal Ala of the pentapeptide AGLSA underwent 
epimerization when subjected to the conditions used to synthesize peptide 2.20 (Figure 2.4C). 
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Epimerization was presumably the result of deprotonation of the α-proton of the C-terminal 
alanine by the strong phosphazene base created by reaction of tri-n-butylphosphine and azide. 
This problem was minimized either by using Gly as the C-terminal residue, instead of Ala, or by 
using 2-chlorotrityl resin preloaded with alanine, which did not result in epimerization, 
presumably due to the steric bulk of the trityl group. 
 
2.2.5. Incorporation of linker 2.17 into LctA to prepare lacticin 481. 
 We next sought to apply the photocleavable linker methodology to the preparation of the 
class II lantibiotic lacticin 481 (see Figure 1.2A). To evaluate whether the light-mediated leader 
peptide removal could yield full length, mature lacticin 481, a mutant of the LctA substrate 
peptide was generated. First, a mutant of the LctA core peptide, LctA(1-27)N15R/F21H(Cys-
StBu) (hereafter referred to as LctA(core)(Cys-StBu), 2.30; for amino acid sequence see legend 
of Scheme 2.5), was synthesized on pre-loaded Wang resin by SPPS. The mutations at positions 
15 and 21 result in an active, and more soluble mutant of lacticin 481.29 Also, the side chain thiol 
functionality of the cysteines were protected as tert-butyl disulfides because the triazole 
cycloaddition reaction with peptides containing free sulfhydryl groups does not proceed.23 
Azidopeptide 2.31 was synthesized by the addition of linker 2.17 to peptide 2.30 in the presence 
of DIPEA, followed by peptide cleavage from resin and RP-HPLC purification (Scheme 2.5). 
The LctA(core)(Cys-StBu) substrate was then cleaved from the resin for use in a CuAAC 
bioconjugation. 
 
 36 
 
Scheme 2.5. CuAAC reaction between LctA(leader) and LctA(core)(Cys-StBu) followed by 
enzymatic modification by LctM and photolysis to afford lacticin 481. The amino acid sequence 
of LctA(leader) is KEQNSFNLLQEVTESELDLILGG. Amino acid sequence of 
LctA(core)(Cys-StBu) is KGGSGVIHTISHEC(StBu)RMNSWQHVFTC(StBu)C(StBu)S. 
Scheme adapted from Bindman and van der Donk.1 
 
 The second substrate in the cycloaddition reaction, the alkyne-linked leader peptide 
(2.32), was synthesized as follows. The leader peptide analogue Fmoc-LctA(–23 - –1)A–1G 
(LctA(leader); for amino acid sequence see legend of Scheme 2.5), lacking the N-terminal Met, 
was synthesized on preloaded 2-chlorotrityl resin. This Met deletion does not interfere with the 
processing of LctA by LctM. After SPPS, the peptide was cleaved from solid support with a 10% 
acetic acid solution. This strategy retains the amino acid side chain protecting groups so that the 
C-terminal carboxylate of the peptide could be coupled to but-3-yn-1-amine. The A–1G mutation 
prevented any possible epimerization of the C-terminal amino acid of the leader peptide during 
activation by HOBt and DIC during the alkyne addition step. With the alkyne functionality in 
place, removal of the N-terminal Fmoc group with 20% piperidine, deprotection of the amino 
acid side chain protecting groups with 95% TFA, and RP-HPLC purification yielded peptide 
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2.32. Substrates 2.31 and 2.32 were conjugated in a CuAAC reaction and analyzed by matrix 
assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (Figure 
2.8, top). Along with the product peak (6131 Da), a peak with molecular weight 3269 Da was 
present, which was generated by the photocleavage of 2.33 by the 337 nm laser on the MALDI-
TOF instrument. The photolysis peak disappeared when the cycloaddition reaction mixture was 
analyzed by ESI-MS, confirming that the cleavage was specific to the MALDI conditions 
(Figure 2.8, bottom). After deprotection of the StBu groups of 2.33 with β-mercaptoethanol and 
TCEP, the resulting substrate analogue was incubated with LctM, resulting in the anticipated 
four dehydrations (Figure 2.9). Subsequent photolysis afforded mature, biologically active 
lacticin 481 (Figure 2.10). 
  
 
Figure 2.8. Formation of triazole-linked LctA. MALDI-TOF (top) and ESI (bottom) MS spectra 
of cycloaddition product 2.33. [M+H]+ calc’d = 6131.9 Da. Peak at 3269.0 Da in MALDI-TOF 
MS spectrum represents the photocleavage product generated by the 337 nm nitrogen laser. 
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Figure 2.9. Modification of triazole-linked LctA by LctM. MALDI-TOF MS spectrum of 
triazole-linked LctA(leader)-LctA(core) before (red) and after (blue) incubation with LctM. 
[M+H]+before calc’d = 5867.8 Da, [M+H]+after calc’d = 5795.7 Da. Figure adapted from Bindman 
and van der Donk.1 
 
 
Figure 2.10. Photolysis of triazole-linked LctA modified by LctM. MALDI-TOF MS spectrum 
of LctM modified-triazole-linked LctA(leader)-LctA(core) before (red) and after (blue) the 
photocleavage reaction. [M+H]+before calc’d = 5795.7 Da, [M+H]+after calc’d = 2934.3 Da. 
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2.3 SUMMARY AND OUTLOOK 
 The successful in vitro reconstitution of the activities of many of the posttranslational 
modification enzymes involved in lanthipeptide biosynthesis has helped researchers study the 
mode of action, bioactivity, and enzyme specificity for a number of the lanthipeptides. Indeed, 
incorporation by SPPS of the non-proteinogenic amino acids naphthylalanine, 4-
pyridynylalanine, and homophenylalanine into the core region of lacticin 481-RH (incorporating 
the N15R/F21H mutations) produced analogues with increased biological activity compared to 
that of wild type lacticin 481-RH.23 However, in that study the commercial protease Lys-C was 
utilized to remove the leader peptide, producing lacticin 481 mutants lacking the N-terminal Lys. 
This N-terminal amino acid deletion decreased the bioactivity of lacticin 481 by 2.5-3-fold.23 
Therefore, a more general method for the removal of the leader peptide, involving the 
incorporation of photolabile linker 2.17 into peptides, was developed. 
 My studies show that photolabile linker 2.17 was appended successfully to several resin-
bound peptides followed by reduction of the azide functionality and the stepwise addition of 
amino acids to the N-terminus. The decapeptides were cleaved from the resin and RP-HPLC 
purified, followed by photolysis at 365 nm to yield the C-terminal peptides. Importantly, the 
identity of the amino acids directly preceding and following linker 2.17 had minimal effect on 
the yield of linker incorporation and peptide elongation, demonstrating the compatibility of 
linker 2.17 with a wide variety of peptides synthesized by SPPS.  
 These studies also demonstrated linker compatibility with a CuAAC reaction because the 
bioorthogonality of the ‘click’ reaction allows the attachment of the core and leader regions of 
lanthipeptides with only the sulfhydryl group of the cysteine side chains needing to be protected. 
My results illustrated that linker 2.17 was successfully incorporated between leader and core 
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regions of the lantibiotic lacticin 481, and that after StBu deprotection, the activity of LctM was 
successfully reconstituted. Photolysis of the modified product afforded mature lacticin 481. 
 This methodology can be utilized for the preparation of native lacticin 481 and can be 
extended to the preparation of lacticin 481 analogues using previously published procedures.23 
This methodology adds one linear step (the addition of linker 2.17) compared to our previous 
approach using a commercial protease to remove the leader peptide. However, unlike use of 
proteases such as Lys-C, light-mediated removal of the leader peptide is not sequence dependent 
and can provide the full-length natural product. It is anticipated that this general methodology 
may also find use for other lanthipeptides and other classes of ribosomally synthesized and 
posttranslationally modified peptides. 
 
2.4. EXPERIMENTAL 
2.4.1. Materials.  
 Fmoc amino acids and resins were purchased from Advanced ChemTech, Novabiochem, 
or Chem-Impex. N,N’-diisopropylcarbodiimide (DIC) and O-(1H-6-Chlorobenzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) were purchased from Advanced 
ChemTech and 1-hydroxybenzotriazole (HOBt) was purchased from Chem-Impex. Solvents 
commonly used in peptide synthesis and purification, including dimethylformamide (DMF), 
dichloromethane (DCM), trifluoroacetic acid (TFA), and acetonitrile (MeCN) were obtained in 
RP-HPLC grade or better and used directly without further purification. Tri-n-butylphosphine, 
piperidine, and N-methyl morpholine (NMM) were purchased from Acros whereas pyridine, 
N,N-diisopropylethylamine (DIPEA), and β-mercaptoethanol were purchased from Sigma 
Aldrich. Tris-(2-carboxyethyl)phosphine (TCEP) was obtained from Molecular Probes as the 
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TCEP-HCl salt. The ligand tris-(benzyltriazolylmethyl)amine (TBTA), tetrakis(MeCN)copper(I) 
hexafluorophosphate, and hydrazine were purchased from Sigma Aldrich and 3-butyn-1-amine 
hydrochloride was purchased from AB Chem Inc. For the synthesis of the photocleavable linker, 
p-toluenesulfonyl chloride, methanesulfonyl chloride, trimethylsilyl chloride, sodium azide, 
lithium bromide, and N-hydroxysuccinimidyl carbonate were purchased from Sigma Aldrich. 
The irradiation used for photochemical reactions was generated using a UVP Blak-Ray lamp 
(Ultraviolet Products, San Gabriel, CA) with a 365 nm filter. 
 
2.4.2. Synthesis of photolabile linkers 2.15-2.17. 
 
 
Synthetic design of photolabile linker 2.15. 
 
 
2-Hydroxy-2-(2-nitrophenyl)ethyl 4-methylbenzenesulfonate (2.12). 
 Into a 50 mL round-bottomed flask was placed p-toluenesulfonyl chloride (1.46 g, 7.64 
mmol, 1.4 equiv) and 1-(2-nitrophenyl)-1,2-ethanediol (2.11, 1.0 g, 5.46 mmol, 1 equiv). The 
flask was sparged with a nitrogen stream for 5 min. Distilled pyridine (25 mL) was added and the 
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reaction flask was placed in a 0 ºC icebath. The mixture was stirred for 18 h at 0 ºC, allowed to 
warm to room temperature, and quenched with H2O (80 mL). Crude product was extracted with 
Et2O (2 × 50 mL) and combined extracts were washed successively with 1 M KHSO4 (3 × 30 
mL), sat. aqueous NaHCO3 (3 × 30 mL), and sat. aqueous NaCl (2 × 50 mL). The organic layer 
was dried over MgSO4, concentrated by rotary evaporation, and purified by SiO2 gel column 
chromatography (eluted with hexanes/EtOAc (4:1); Rf = 0.065) yielding compound 2.12 (1.65 g, 
90%) as an orange oil. See also Notebook II, page 73. 
 
1H NMR: (399.947 MHz, CDCl3) δ=2.43 (s, 3H, CH3), 3.95 (bs, 1H, OH) 4.14 (dd, J = 7.3, 3.2 
Hz, 1H, CH2), 4.36 (dd, J = 2.7, 7.8 Hz, 1H, CH2), 5.51 (dd, J = 2.7, 4.7 Hz, 1H, CH), 7.31 (d, J 
= 8.1 Hz, 2H, CHtosyl), 7.44 (t, J = 7.8 Hz, 1H, CHphenyl), 7.65 (t, J = 7.3 Hz, 1H, CHphenyl), 7.75 
(d, J = 8.3 Hz, 2H, CHtosyl), 7.85 (d, J = 7.8 Hz, 1H, CHphenyl), 7.95 (d, J = 8.1 Hz, 1H, CHphenyl). 
13C NMR: (100.527 MHz, CDCl3) δ=21.9, 67.9, 73.5, 124.9, 128.2, 129.4, 130.3, 132.5, 134.1, 
134.4, 145.4, 147.7. 
HRMS  [M+H]+ C15H16NO6S calcd = 338.0698, found = 338.0704. 
 
 
2-(2-Nitrophenyl)-2-((trimethylsilyl)oxy)ethyl 4-methylbenzenesulfonate (2.13). 
 Into a 50 mL round-bottomed flask was placed tosyl derivative 2.12 (1.69 g, 5.0 mmol, 1 
equiv). The flask was purged with a nitrogen stream for 5 min followed by the addition of 
distilled pyridine (25 mL). To this flask was added TMSCl (2.17 g, 20 mmol, 4 equiv) dropwise 
and the solution was stirred for 1 h at room temperature. At this time the reaction was quenched 
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with H2O (80 mL), crude product was extracted with Et2O (2 × 50 mL), and the combined 
extracts were washed successively with 1 M KHSO4 (3 × 30 mL), sat. aqueous NaHCO3 (3 × 30 
mL), and sat. aqueous NaCl (2 × 50 mL). The organic layer was dried over MgSO4 and 
concentrated by rotary evaporation, yielding compound 2.13 (1.84 g, 90%) as a tan solid. See 
also Notebook II, page 74. 
 
1H NMR: (399.746 MHz, CDCl3) δ=0.01 (s, 9H, CH3), 2.41 (s, 3H, CH3), 4.05 (dd, J = 6.6, 4.4 
Hz, 1H, CH2), 4.16 (dd, J = 2.9, 6.8 Hz, 1H, CH2), 5.47 (dd, J = 6.6, 6.6 Hz, 1H, CH), 7.27 (d, J 
= 8.1 Hz, 2H, CHtosyl), 7.43 (t, J = 7.8 Hz, 1H, CHphenyl), 7.61 (t, J = 7.7 Hz, 1H, CHphenyl), 7.70 
(d, J = 8.3 Hz, 2H, CHtosyl), 7.79 (d, J = 7.9 Hz, 1H, CHphenyl), 7.89 (d, J = 8.3 Hz, 1H, CHphenyl). 
13C NMR: (100.527 MHz, CDCl3) δ=-0.02, 21.8, 68.4, 73.7, 124.6, 128.1, 129.1, 129.8, 130.0, 
133.1, 133.7, 135.6, 144.9, 147.8. 
HRMS [M+Na]+ C18H23N6NaSSi  calcd = 432.0913, found = 432.0917. 
M.P. = 83-87 oC. 
 
 
2-Azido-1-(2-nitrophenyl) ethanol (2.14). 
 Into a 25 mL round-bottomed flask was placed sodium azide (0.52 g, 2.52 mmol, 2 
equiv). The flask was purged with a nitrogen stream for 5 min. To this flask was added 
trimethylsilyl ether derivative 2.13 (0.52 g, 1.26 mmol, 1 equiv) in DMF (9 mL) and the reaction 
was stirred at 80 ºC for 16 h. At this time the reaction was quenched with H2O (80 mL), crude 
product was extracted with Et2O (2 × 50 mL), and the combined extracts were washed with sat. 
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aqueous NaCl (2 × 50 mL). The organic layer was dried with MgSO4, concentrated by rotary 
evaporation, and purified by SiO2 gel column chromatography (eluted with hexanes/EtOAc 
(4:1); Rf = 0.29) yielding 2.14 (0.23 g, 85%) as a red oil. See also Notebook IV, page 41. 
 
1H NMR: (399.947 MHz, CDCl3) δ=2.64 (d, J = 3.7 Hz, 1H, OH), 3.44 (dd, J = 7.6, 4.9 Hz, 1H, 
CH2), 3.74 (dd, J = 3.0, 9.5 Hz, 1H, CH2), 5.49 (m, 1H, CH), 7.47 (t, J = 7.8 Hz, 1H, CHphenyl), 
7.69 (t, J = 8.0 Hz, 1H, CHphenyl), 7.90 (d, J = 7.8 Hz, 1H, CHphenyl), 8.00 (d, J = 8.3 Hz, 1H, 
CHphenyl). 
13C NMR: (100.527 MHz, CDCl3) δ=57.4, 69.2, 125.0, 128.8, 129.2, 134.1, 136.3, 147.9. 
HRMS [M + Na]+ C8H8N4O3Na  calcd = 231.0494, found = 231.0483. 
 
 
2-Azido-1-(2-nitrophenyl)ethanone (2.15). 
 Into a 50 mL round-bottomed flask was added 2.14 (50 mg, 0.24 mmol, 1 equiv) in 
CH2Cl2 (10 mL) followed by Dess-Martin periodinane (119 mg, 0.28 mmol, 1.2 equiv) and the 
reaction was stirred for 3 h at room temperature. At this time the solution was concentrated by 
rotary evaporation, crude product was passed over a short SiO2 plug and eluted with CH2Cl2 (200 
mL). The eluent was then concentrated by rotary evaporation yielding 2.15 as a light yellow 
solid (80% yield). See also Notebook I, Page 61. 
 
1H NMR: (399.947 MHz, CDCl3) δ=4.29 (s, 2H, CH2), 7.40 (d, J = 8.0 Hz, 1H, CHphenyl), 7.67 (t, 
J = 8.0 Hz, 1H, CHphenyl), 7.78 (t, J = 7.8 Hz, 1H, CHphenyl), 8.21 (d, J = 8.3 Hz, 1H, CHphenyl). 
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Synthetic design of photolabile linker 2.16 from intermediate 2.14. 
 
 
2-Azido-1-(2-nitrophenyl)ethyl methanesulfonate (2.14a). 
 Into a 10 mL round-bottomed flask was placed azide derivative 2.14 (93.7 mg, 0.45 
mmol, 1 equiv). The flask was purged with a nitrogen stream for 5 min followed by the addition 
of DCM (3 mL). Triethylamine (68.8 mg, 94.8 µL, 0.68 mmol, 1.5 equiv) was then added and 
the solution was cooled to 0 ºC. MsCl (57.3 mg, 38.7 µL, 0.50 mmol, 1.1 equiv), dissolved in dry 
DCM (1 mL), was added dropwise via a syringe pump over 5 min. The reaction was stirred at 0 
ºC for 1 h. At this time, solvent was evaporated under reduced pressure and the solid residue was 
dissolved in ethyl acetate (45 mL). The solution was washed with 5% aqueous NaHCO3 (w/v) (2 
× 40 mL) and sat. aqueous NaCl (2 × 40 mL), dried with MgSO4, and concentrated by rotary 
evaporation yielding 2.14a (103 mg, 80%) as a light green oil. See also Notebook I, Page 99. 
 
1H NMR: (399.947MHz, CDCl3) δ=3.09(s, 3H, CH3), 3.64 (dd, 1H, CH2), 3.82 (dd, 1H, CH2), 
6.29 (dd, 1H, CH), 7.57 (t, 1H, CHphenyl), 7.73 (t, 1H, CHphenyl), 7.82 (d, 1H, CHphenyl), 8.09 (d, 
1H, CHphenyl). 
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1-(2-Azido-1-bromoethyl)-2-nitrobenzene (2.16). 
 Into a 10 mL round-bottomed flask was placed LiBr (94.7 mg, 1.09 mmol, 5.8 equiv). 
The flask was sparged with a nitrogen stream for 5 min followed by the addition of mesylate 
derivative 2.14a (54.3 mg, 0.19 mmol, 1 equiv) dissolved in DMF (2 mL). The reaction was 
stirred at 70 ºC for 2 h. At this time the reaction was quenched with H2O (40 mL), crude product 
was extracted with Et2O (2 × 50 mL), and combined extracts were washed with H2O (3 × 30 mL) 
and sat. aqueous NaCl (40 mL). The organic layer was dried with MgSO4 and concentrated by 
rotary evaporation yielding 2.16 (41.0 mg, 80%) as an orange oil. See also Notebook II, Page 20. 
 
1H NMR: (399.947MHz, CDCl3) d=3.43 (dd, 1H, CH2), 3.90 (dd, 1H, CH2), 5.73 (t, 1H, CH), 
7.47 (t, 1H, CHphenyl), 7.64 (t, 1H, CHphenyl), 7.84 (d, 1H, CHphenyl), 7.87 (d, 1H, CHphenyl). 
 
 
Synthetic design of photolabile linker 2.17 from intermediate 2.14. 
 
2-Azido-1-(2-nitrophenyl)ethyl (2,5-dioxopyrrolidin-1-yl) carbonate (2.17). 
 Into a 10 mL round-bottomed flask was added a solution of azide derivative 2.14 (41.6 
mg, 0.2 mmol, 1 equiv) in DMF (1.0 mL). N-hydroxysuccinimidyl carbonate (85.0 mg, 0.33 
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mmol, 1.65 equiv) was then added followed by NEt3 (83.6 µL, 0.60 mmol, 3 equiv). The reaction 
was stirred at room temperature for 16 h. At this time solvent was removed by rotary evaporation 
and crude product was purified by SiO2 gel column chromatography (eluted with hexanes/EtOAc 
(1:1); Rf = 0.45). Fractions were collected and concentrated by rotary evaporation yielding 2.17 
(55.9 mg, 80% yield) as a yellow oil. See also Notebook III, Page 26. 
 
1H NMR: (499.947 MHz, CDCl3) δ=2.80 (s, 4H, CH2), 3.76 (dd, J = 6.4, 7.1 Hz, 1H, CH2), 3.93 
(dd, J = 3.0, 10.7 Hz, 1H, CH2), 6.46 (dd, J = 3.0, 3.7 Hz, 1H, CH), 7.57 (m, J = 4.3 Hz, 1H, 
CHphenyl), 7.77 (d, J = 4.1 Hz, 2H, CHphenyl) 8.11 (d, J = 8.3 Hz, 1H, CHphenyl). 
13C NMR: (100.578 MHz, CDCl3) δ=25.6, 54.5, 77.8, 125.5, 128.3, 130.4, 131.2, 134.7, 147.5, 
150.9, 168.4. 
HRMS [M+H]+ C13H12N5O7 calcd = 350.0737, found = 350.0727. 
M.P. = 110-115 oC. 
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2.4.3. Peptide synthesis and subsequent reactions to determine the compatibility of linker 
2.17 with SPPS. 
 
Synthetic design of decapeptides 2.27a-i followed by photocleavage resulting in peptides 
2.28a-i and 2.29a-i. 
 
General procedure for solid-phase peptide synthesis. 
 C-terminal peptides (2.24a-i) were synthesized using standard Fmoc based SPPS 
techniques using an automated peptide synthesizer (either Aapptec 396 or Rainin PS3 
synthesizers). Preloaded Wang resin (0.1 mmol) was first swollen in dimethylformamide (DMF) 
(3 × 5 mL × 10 min). Fmoc-amino acids (0.4 mmol, 4 equiv) were coupled to resin-bound 
peptide using HCTU (165 mg, 0.4 mmol, 4 equiv) as coupling reagent and 0.4 M NMM (2 mL) 
as activating reagent (45 min per coupling step). Fmoc deprotection was performed with 
piperidine (20% in DMF; 3 × 5 mL × 3 min). After completion of the coupling of the final amino 
acid, the Fmoc group was removed to produce the free amino group. See also Notebook IV, Page 
18. 
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Peptide attachment to photocleavable linker (2.25a-i). 
 For the synthesis of azidopeptides 2.25a-i, into a 5 mL round-bottomed flask was added 
pre-swelled resin containing a five-mer peptide (2.24a-i, 0.1 mmol, 1 equiv). The flask was 
sparged with a nitrogen stream for five min followed by the addition of photocleavable linker 
2.17 (70 mg, 0.2 mmol, 2 equiv) dissolved in DMF (3 mL). DIPEA (64.5 mg, 87 µL, 0.5 mmol, 
5 equiv) was then added and the solution was stirred at room temperature with a non-ridged 
silica coated stir bar for 12-16 h. A non-ridged stir bar was used to assure no resin damage would 
occur while stirring. At this time, the resin was filtered and washed with DMF (3 × 5 mL). See 
also Notebook IV, Page 21. 
 
 
One pot azide reduction and amino acid coupling (2.26a-i). 
 Pre-swelled resin containing the azidopeptides 2.25a-i (0.1 mmol, 1 equiv) was added to 
a 5 mL round-bottomed flask. To this flask was added a solution of various Fmoc protected 
amino acids (Fmoc-Xxx-OH, 0.4 mmol, 4 equiv), and HOBt (54 mg, 0.4 mmol, 4 equiv) in THF 
(3 mL). DIC (50.2 mg, 62 µL, 0.4 mmol, 4 equiv) was then added followed by the addition of tri-
n-butylphosphine (101.2 mg, 125 µL, 0.5 mmol, 5 equiv). The reaction was stirred at room 
temperature with a non-ridged silica coated stir bar for 1 h. At this time the resin was filtered and 
washed with DMF (3 × 5 mL). See also Notebook IV, Page 22. 
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Extension of the peptide chain. 
 The final amino acids were added by standard Fmoc based SPPS techniques as described 
above starting and ending with an Fmoc deprotection. See also Notebook IV, Page 23. 
 
General procedure for peptide cleavage from resin and purification. 
 Peptides prepared on Wang resin were cleaved from the resin by adding a solution of 
trifluoroacetic acid (TFA) (5 mL), triisopropylsilane (TIPS) (100 µL), and H2O (100 µL) to the 
resin (0.1 mmol) and stirring the solution for 2 h at room temperature. The solution was 
concentrated by purging with a nitrogen stream and peptide was precipitated with cold diethyl 
ether and pelleted by centrifugation (5 min, 22,789 ×g). The crude peptides were dissolved in an 
aqueous 0.1% TFA solution, lyophilized, and purified by preparative RP-HPLC on a Waters 
Delta-PakTM C18 column (2.5 cm × 10.0 cm) employing a water-acetonitrile solvent system. A 
linear gradient was used from 2% to 80% solvent B over 45 min (solvent A = 0.1% TFA in H2O; 
solvent B = 80% acetonitrile in H2O, 0.086% TFA). Peptides were monitored by their 
absorbance at 220 nm. Fractions containing product 2.27a-i as analyzed by MALDI-TOF or ESI-
MS were collected, lyophilized, and weighed to determine yield. See also Notebook IV, Page 23. 
Note: The linker contains a stereogenic center and was prepared in racemic form, resulting in 
two diastereomers of peptides 2.27a-i (as seen in Figure 2.6A,B). 
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Characterization of peptides 2.27a-i. 
H—EAAA—Linker—TALSG—OH (2.27a). RP-HPLC; Rt = 20.2-21.4 min. LRMS (ESI): calcd 
C41H63N11O18, [M+H]+ 998.4, observed 998.1. 
H—EAAA—Linker—VALSG—OH (2.27b). RP-HPLC; Rt = 23.0-24.0 min. LRMS (ESI): 
calcd C42H65N11O17, [M+H]+ 996.4, observed 996.1. 
H—EAAA—Linker—KALSG—OH (2.27c). RP-HPLC; Rt = 19.2-20.6 min. LRMS (MALDI): 
calcd C43H68N12O17, [M+H]+ 1025.5, observed 1027.3. 
H—EAAG—Linker—GALSG—OH (2.27d). RP-HPLC; Rt = 19.7-21.0 min. LRMS (ESI): 
calcd C38H57N11O17, [M+H]+ 940.4, observed 940.1. 
H—EAAL—Linker—LALSG—OH (2.27e). RP-HPLC; Rt = 28.0-29.2 min. LRMS (MALDI): 
calcd C46H73N11O17, [M+H]+ 1052.5, observed 1052.9.  
H—EAAY—Linker—YALSG—OH (2.27f). RP-HPLC; Rt = 23.6-25.0 min. LRMS (MALDI): 
calcd C52H69N11O19, [M+H]+ 1152.5, observed 1152.9.  
H—EAAP—Linker—PALSG—OH (2.27g). RP-HPLC; Rt = 22.0-23.9 min. LRMS (MALDI): 
calcd C44H65N11O17, [M+H]+ 1020.5, observed 1021.2. 
H—EAAW—Linker—WALSG—OH (2.27h). RP-HPLC; Rt = 29.9-31.2 min. LRMS (MALDI): 
calcd C56H71N13O17, [M+H]+ 1198.5, observed 1199.4. 
H—EAAE—Linker—EALSG—OH (2.27i). RP-HPLC; Rt = 19.0-20.2 min. LRMS (MALDI): 
calcd C44H65N11O21, [M+H]+ 1084.4, observed 1085.7. 
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General procedure for photocleavage of the polypeptide backbone. 
 Into a 5 mL round-bottomed flask was added a solution of peptide 2.27a-i (4-20 mg) 
dissolved in 0.1% TFA (1.0-2.0 mL). The solution was irradiated at 365 nm for 1-2 h (until 
starting material had disappeared as shown by MALDI-TOF MS); the UV irradiation from the 
MALDI-TOF did not cleave the linker in peptides 2.27a-i. The crude material was then purified 
by preparative RP-HPLC on a C18 column employing a water-acetonitrile solvent system. 
Peptides were monitored by their absorbance at 220 nm. Fractions containing product 2.29a-i (as 
analyzed by ESI-MS) were collected, lyophilized, and weighed to determine the yield. Purity 
was assessed by analytical RP-HPLC (Figure 2.7) (Grace Vydac® C18 column (4.6 x 250 mm); 
a linear gradient was used from 2% to 80% solvent B over 45 min (solvent A = 0.1% TFA in 
H2O; solvent B = 80% acetonitrile in H2O, 0.086% TFA)). See also Notebook IV, Page 86. 
 
Characterization of peptides 2.29a-i. 
H—TALSG—OH (2.29a). Analytical RP-HPLC; Rt = 10.8-12.0 min. LRMS (ESI): calcd 
C18H33N5O8, [M+H]+ 448.2, observed 448.0. 
H—VALSG—OH (2.29b). Analytical RP-HPLC; Rt = 13.2-14.4 min. LRMS (ESI): calcd 
C19H35N5O7, [M+H]+ 446.3, observed 446.1. 
H—KALSG—OH (2.29c). Analytical RP-HPLC; Rt = 10.1-11.0 min. LRMS (ESI): calcd 
C20H38N6O7, [M+H]+ 475.3, observed 475.1. 
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H—GALSG—OH (2.29d). Analytical RP-HPLC Rt = 11.2-12.2 min. LRMS (ESI): calcd 
C16H29N5O7, [M+H]+ 404.2, observed 404.0.  
H—LALSG—OH (2.29e). Analytical RP-HPLC Rt = 16.2-17.1 min. LRMS (ESI): calcd 
C20H37N5O7, [M+H]+ 460.3, observed 460.1. 
H—YALSG—OH (2.29f). Analytical RP-HPLC Rt = 14.7-15.8 min. LRMS (ESI): calcd 
C23H35N5O8, [M+H]+ 510.3, observed 510.1. 
H—PALSG—OH (2.29g). Analytical RP-HPLC Rt = 11.9-13.0 min. LRMS (ESI): calcd 
C19H33N5O7, [M+H]+ 444.2, observed 444.0. 
H—WALSG—OH (2.29h). Analytical RP-HPLC Rt = 19.4-20.4 min. LRMS (ESI): calcd 
C25H36N6O7, [M+H]+ 533.3, observed 533.1. 
H—EALSG—OH (2.29i). Analytical RP-HPLC Rt = 11.5-12.5 min. LRMS (ESI): calcd 
C19H33N5O9, [M+H]+ 476.3, observed 476.1. 
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2.4.4. Incorporation of linker 2.17 into LctA. 
 
CuAAC bioconjugation between alkyne-linked LctA(leader) and azide-linked 
LctA(core)(Cys-StBu) followed by photolysis to afford lacticin 481. 
 
 
Synthesis of linker modified LctA(core)(Cys-StBu) (2.31). 
 The core peptide of LctA with its Cys residues protected as StBu disulfides 
(LctA(core)(Cys-StBu) (2.30)) was synthesized as described above using a Rainin PS3 peptide 
synthesizer (0.1 mmol). StBu protected Fmoc-cysteine residues were coupled to the growing 
peptide manually using HOBt (54 mg, 0.4 mmol, 4 equiv) as coupling reagent and DIC (50.2 
mg, 62 µL, 0.4 mmol, 4 equiv) as activating reagent (45 min). The terminal Fmoc group was 
removed at the end of the synthesis. See also Notebook IV, Page 73. 
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 For the synthesis of azidopeptide-LctA(core)(Cys-StBu) (2.31), into a 10 mL round-
bottomed flask was placed pre-swelled resin containing peptide 2.30 (0.1 mmol, 1 equiv). To this 
flask was added photocleavable linker 2.17 (70 mg, 0.2 mmol, 2 equiv) dissolved in DMF (5 
mL). DIPEA (64.5 mg, 87 µL, 0.5 mmol, 5 equiv) was added and the solution was stirred at 
room temperature with a non-ridged silica coated stirbar for 12-16 h. At this time the resin was 
filtered, washed with DMF (3 × 5 mL), and pipetted into a 20 mL scintillation vial with DMF. 
After removal of DMF, the peptide was cleaved from resin by adding a solution of TFA (5 mL), 
thioanisole (200 µL), H2O (200 µL), and TIPS (100 µL) and stirring for 2 h at room temperature. 
The solution was concentrated by purging with a nitrogen stream and the peptide was 
precipitated with cold diethyl ether. The crude peptide was dissolved in 10% MeCN in 0.1% 
aqueous TFA, lyophilized, and purified by preparative RP-HPLC on a C18 column (solvent A = 
0.1% TFA in H2O; solvent B = 80% acetonitrile in H2O, 0.086% TFA). Fractions containing 
product were collected and lyophilized yielding 2.31 (42.5 mg, 12%, 96% yield per step based 
on resin loading). See also Notebook V, Page 09. 
 
N3—Linker—LctA(core)(Cys-StBu)—OH (2.31). RP-HPLC; Gradient, 10-48% solvent B in 25 
min, 48-68% solvent B in 15 min, Rt = 39.4-41.4 min. LRMS (MALDI): calcd 
C147H225N44O42S7[M+H]+ 3503.5, observed 3504.0. 
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Coupling of C-terminal alkyne to LctA(leader) (2.32). 
 Fmoc-LctA(leader) peptide was prepared on 2-chlorotrityl chloride resin (0.1 mmol) on a 
CEM Liberty microwave peptide synthesizer. Preloaded 2-chlorotrityl glycine resin (0.1 mmol) 
was first swollen in a 1:1 DMF:DCM mixture (10 mL). Fmoc-amino acids (0.2 M in DMF, 2.5 
mL) were coupled using HCTU (0.5 M in DMF, 1 mL) as coupling reagent and DIPEA (2.0 M 
in 1-methyl-2-pyrrolidinone, 0.5 mL) as activating reagent with microwave irradiation (3 min, 20 
W, 75 ºC). Fmoc deprotection was performed with piperidine (20% in DMF) with microwave 
irradiation (3 min, 30 W, 75 oC). After completion of the coupling of the final amino acid, the 
Fmoc group was not removed. See also Notebook, Page 98. 
 Peptide cleavage from resin was achieved by stirring the resin in a mixture of methylene 
chloride (8 mL), acetic acid (1 mL), and trifluoroethanol (1 mL) at room temperature for 1 h. 
(Note: peptide cleavage from 2-chlorotrityl chloride resin in 10% acetic acid does not remove the 
amino acid protecting groups). At this time, the solid resin was removed by filtration, the 
methylene chloride and TFE in the filtrate were removed by rotary evaporation, and the 
remaining solution was concentrated by azeotropic removal of AcOH with hexanes (3 × 8 mL). 
The peptide was then dissolved in THF (10 mL) and DMF (10 mL). 
 In a separate 50 mL round-bottomed flask was added but-3-yn-1-amine hydrochloride 
(52.5 mg, 0.5 mmol, 5 equiv) and DIPEA (64.6 mg, 87.1 µL, 0.5 mmol, 5 equiv) in THF (5 mL). 
To this solution was added a premixed solution of HOBt (67.6 mg, 0.5 mmol, 5 equiv) and DIC 
(63.1 mg, 77.1 µL, 0.5 mmol, 5 equiv) in THF (5 mL) and DMF (5 mL). This mixture was then 
added to the flask containing the purified leader peptide and the reaction mixture was stirred for 
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12 h at room temperature. At this time, the solution was concentrated by rotary evaporation and a 
20% piperidine/DMF solution (15 mL) was added to remove the terminal Fmoc group. The 
solution was stirred for 30 min followed by the removal of the piperidine and DMF under 
reduced pressure. The protecting groups were then removed from the amino acid side chains by 
adding a solution of TFA (7 mL), EDT (100 µL), TIPS (100 µL) and H2O (200 µL) and stirring 
the solution for 2 h at room temperature. The solution was concentrated by purging with a 
nitrogen stream and was precipitated with cold diethyl ether. The peptide was dissolved in a 1:1 
solution of MeCN and H2O, lyophilized, and purified by preparative RP-HPLC on a 
Phenomenex C18 column (1.0 cm × 25.0 cm) employing a water-acetonitrile solvent system. 
The gradient used was from 2-80% solvent B in 45 min (solvent A = 0.1% TFA in H2O; solvent 
B = 80% acetonitrile in H2O, 0.086% TFA). Peptides were monitored by their absorbance at 220 
nm. Fractions containing product as analyzed by MALDI-TOF MS were collected and 
lyophilized yielding 2.32 as a white powder. See also Notebook VI, Page 10. 
H—LctA(leader)—Alkyne (2.32). Preparative RP-HPLC;  Rt = 38.6-39.4 min. LRMS (MALDI): 
calcd C116H187N29O40, [M+H]+ 2627.4, observed 2623.2  
 
 
Preparation of triazole-linked substrate (2.33). 
 Peptides 2.31 (2.0 mg, 0.76 µmol, 1 equiv) and 2.32 (1.5 mg, 0.76 µmol, 1 equiv) were 
placed in a 3 mL pear-shaped flask equipped with a septum and the flask was sparged with a 
nitrogen stream for 3 min. The peptides were then dissolved in a degassed solution of 1:1 Tris 
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buffer (5 mM, pH 7.0):dioxane (1 mL), and DMSO (100 µL). In a separate 5 mL round-
bottomed flask was placed TBTA (0.1 mg, 0.19 µmol, 0.25 equiv). This flask was sparged with a 
nitrogen stream for 3 min followed by the addition of 500 µL of a 1:1 mixture of Tris buffer (5 
mM, pH 7.0) and dioxane. To this solution was added 
tetrakis(MeCN)copper(I)hexafluorophosphate (40 µL of a 1.25 mg/mL aqueous solution). After 
brief stirring, a hydrazine solution (20 µL of a 1% hydrazine solution in 1:1 Tris (5 mM, pH 7.0): 
dioxane) was added to the cupric solution followed by the addition of the peptide solution. The 
reaction solution turned cloudy either after the addition of hydrazine or after addition of the 
peptide solution. The solution was stirred under an inert nitrogen atmosphere for 1.5 h and 
analyzed by MALDI-TOF MS after diluting with 50% MeCN. The lyophilized crude peptide 
was purified by preparative RP-HPLC on a Phenomenex C18 column employing a water-
acetonitrile solvent system. A linear gradient was used from 2% to 80% solvent B over 45 min 
(solvent A = 0.1% TFA in H2O; solvent B = 80% acetonitrile in H2O, 0.086% TFA). Fractions 
containing product (as analyzed by MALDI-TOF MS) were lyophilized yielding 2.33 (1.6 mg, 
46%) as a white powder. See also Notebook VI, Page 85. 
Triazole-linked LctA(leader)-LctA(core)(Cys-StBu) (2.33). Rt = 34.4-35.4 min LRMS (ESI): 
calcd C262H415N71O79S07 [M+H]+ 6131.85, observed 6131.6. 
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Deprotection of StBu protected triazole-linked substrate. 
 Into a 10 mL microwave flask was added RP-HPLC purified triazole-linked LctA 
substrate (2.33; 3.0 mg, 0.49 µmol, 1 equiv) dissolved in 40% MeCN, 60% Tris (37.5 mM, pH 
8.3) (1.3 mL). To this flask was added β-mercaptoethanol (167 mg, 150 µL, 2.13 mmol, 4300 
equiv) and TCEP (6 mg, 0.24 mmol, 490 equiv). The reaction was heated to 60 ºC for 30 min 
using a CEM Discover microwave reactor (100 W, 250 psi). The crude product was acidified 
(pH 1-2) with 1 M HCl and the lyophilized crude product was purified by preparative RP-HPLC 
on a C18 column employing a water-acetonitrile solvent system. The gradient used was from 2% 
to 80% solvent B in 45 min (solvent A = 0.1% TFA in H2O; solvent B = 80% acetonitrile in 
H2O, 0.086% TFA). Peptides were monitored by their absorbance at 220 nm. Fractions 
containing product (as analyzed by ESI-MS) were collected and lyophilized yielding StBu 
deprotected triazole-linked LctA(leader)-LctA(core) substrate as a white powder. See also 
Notebook VI, Page 87. 
Triazole-linked LctA(Leader)-LctA(core) Rt = 35.0-36.5 min. LRMS (ESI): calcd 
C254H391N70O82S4 [M+H]+ 5867.75, observed 5867.3. 
 
General procedure for LctM assays. 
His6-LctM was overexpressed and purified as previously reported.30 To a 1.6 mL 
Eppendorf tube was added Tris-HCl (100 µL, 500 mM, pH 7.5), MgCl2 (100 µL, 100 mM), ATP 
(40 µL, 50 mM), BSA (12.5 µL, 2 mg/mL), and sterile deionized H2O (665.9 µL). Triazole-
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linked LctA(leader)-LctA(core) substrate (40 µL, 500 µM in H2O) was then added followed by 
LctM (41.5 µL, 34.1 µM) and the solution was incubated for 12 h. At this time the solution was 
acidified to pH 1-2 with 5% TFA and the crude product was purified by analytical RP-HPLC on 
a C4 column employing a water-acetonitrile solvent system. The gradient used was from 2% to 
80% solvent B in 45 min (solvent A = 0.1% TFA in H2O; solvent B = 80% acetonitrile in H2O, 
0.086% TFA). Peptides were monitored by their absorbance at 220 nm. Fractions containing 
product (as analyzed by ESI-MS were collected and lyophilized yielding LctM-modified 
triazole-linked LctA(leader)-LctA(core) substrate as a white powder. See also Notebook VI, Page 
89. 
LctM-modified triazole-linked LctA(leader)-LctA(core) Rt = 34.4-35.2 min. LRMS (ESI): calcd 
C254H383N70O78S4 [M+H]+ 5795.67 g/mol, observed 5795.0 g/mol. 
 
 
Photolysis of LctM-modified, triazole-linked LctA(leader)-LctA(core). 
Purified LctM modified peptide in RP-HPLC solvent was irradiated at 365 nm for 20 
min. The product was analyzed by MALDI-TOF MS and ESI-MS. See also Notebook VI, Page 
90. 
Lacticin 481.  LRMS (MALDI): calcd C126H186N40O34S4 [M+H]+ 2934.3, observed 2936.1 
 
 
 
 61 
Bioactivity assay of photocleaved lacticin 481. 
M17 agar media (4 g M17 media, 1.5 g agar per 100 mL H2O) was liquefied in the 
microwave and 20 mL were dispensed into a 50 mL conical vial. The vial was incubated at 42 ºC 
for 5 min at which time 20% glucose (500 µL) and L. lactis HP cells (200 µL; OD = 1.0) were 
added. The solution was poured into a sterile Nunc dish and allowed to solidify near a flame for 
30 min. To a second 50 mL conical vial was added liquefied M17 agar media (30 mL), which 
was again incubated at 42 oC for 5 min. To this vial was added 20% glucose (750 µL) and L. 
lactis HP cells (300 µL; OD = 1.0) and the contents were poured on top of the solidified first 
layer of M17 media. A sterile 96 well PCR rack was immediately added to the upper layer and 
the media was allowed to solidify for 45 min near a flame. At this time the PCR rack was 
removed and the surface was air-dried near a flame for 3-4 h. Finally, 15 µL aliquots of lacticin 
481, non-photocleaved product and photocleaved product were added to separate wells. The 
bioassay plate was then incubated at 30 oC for 16-24 h. See also Notebook VII, Page 15. 
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Chapter 3: Facile Removal of Leader Peptides from Lanthipeptides by 
Incorporation of a Hydroxy Acid 
 
3.1. INTRODUCTION 
 As discussed in Chapter 1, the ability to produce lanthipeptides by the in vitro 
reconstitution of their biosynthetic enzymes has allowed researchers to generate lanthipeptide 
analogues with increased solubility and activity, thus improving their therapeutic potential.1,2 
The in vitro methodology is also attractive because it allows a facile way to introduce non-
proteinogenic amino acids into lanthipeptides during solid phase peptide synthesis (SPPS) of the 
precursor peptide.2,3 Unfortunately, several drawbacks still exist that challenge the construction 
of lanthipeptides in vitro. For instance, the solubilities of the unmodified precursor peptides are 
often quite low, which depresses the yield of the in vitro reaction. Also, because of the 
complexity of the cellular milieu, the cofactors necessary to achieve full lanthipeptide 
modification in vitro are not always known. Alternatively, our laboratory, along with Sonomoto 
and coworkers, has pioneered the in vivo coexpression of LanA precursor peptides with their 
cognate biosynthetic enzymes (LanM or LanB/LanC) in Escherichia coli.4,5 After cell lysis, the 
modified precursor peptides, which generally can be obtained in higher yields when compared to 
the in vitro lanthipeptide production method, are purified from the cellular lysate by immobilized 
metal affinity chromatography (IMAC) via an N-terminal hexahistidine tag. Removal of the 
leader peptide from the core region results in the mature lanthipeptide. However, as discussed in 
Chapter 2, no general solutions exist for the removal of the leader peptide in lanthipeptides 
because the native proteases have rarely been reconstituted in vivo or in vitro. Moreover, the use 
of commercial proteases to remove the leader peptide is only productive if the core peptide does 
 66 
not contain the proteolytic cleavage site, which is often a Lys, Glu, or Arg. The photocleavable 
linker discussed in Chapter 2 is a general solution for leader peptide removal in that it can be 
inserted into any lanthipeptide and its photoactivation does not cleave any other regions of the 
biomolecule. However, the linker can only be introduced by SPPS and is not amenable to 
lanthipeptide biosynthesis in vivo.  
For a leader peptide removal strategy to be general for lanthipeptides modified in vivo, 
two criteria have to be met. First, a labile linkage needs to be incorporated into the peptide 
backbone between the leader and core peptides during ribosomal synthesis of the peptide. 
Second, the chemistry required to cleave this linkage must be orthogonal to the rest of the 
peptide and yield the core region without any adornments. To the best of our knowledge, no 
photolabile compounds exist that meet both of these criteria. The 2-nitrophenyl glycine 
derivative 2.1 discussed in Chapter 2 can be genetically incorporated into the peptide backbone,6 
but yields a nitrosoaryl-containing N-terminus on the C-terminal fragment of the precursor 
peptide (which would constitute the core region of lanthipeptides) upon irradiation. Other labile 
linkages have cleavage reactivities orthogonal to the functionalities present in peptides and 
proteins, but their incorporation into the peptide backbone during ribosomal synthesis has not yet 
been achieved. 
Interestingly, the biosynthetic machinery of E. coli can recognize hydroxy acids and 
incorporate them into the backbone of proteins or peptides7 and the subsequent ester bonds can 
be site-specifically cleaved by alkaline hydrolysis,8,9 fulfilling both criteria as outlined above. 
Unfortunately, the incorporation of hydroxy acids into proteins has usually been accomplished 
via cell-free translation systems,8,10-12 which are more complicated and suffer from lower yields 
when compared to site-specific genetic incorporation strategies involving orthogonal aminoacyl-
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tRNA synthetase (aaRS)-amber suppressor tRNA pairs in E. coli. Recently, a novel aaRS-tRNA 
pair from Methanosarcina mazei, pyrrolysyl-tRNA synthetase (PylRS)-
€ 
tRNACUAPyl  (PylT),13 which 
naturally incorporates pyrrolysine (Pyl) in response to the amber stop codon (UAG), was shown 
to incorporate several non-proteinogenic lysine derivatives into proteins, including the hydroxy 
acid of Bocε-L-lysine.14 In the case of the incorporation of the hydroxy acid, the new ester 
linkage was then site-specifically fragmented by an alkaline-catalyzed hydrolysis reaction. We 
envisioned that a similar strategy could be used to cleave off the leader peptide after in vivo 
lanthipeptide production. Replacing the first residue of the core peptide with a hydroxy acid via 
the genetic incorporation of the residue at an amber stop codon with PylRS-PylT would install an 
ester linkage directly between the leader and core regions of the modified lanthipeptide (Scheme 
3.1). Site-specific hydrolysis of the ester bond would produce the core peptide with an N-
terminal hydroxyl group. We demonstrate herein that this methodology is successful for the in 
vivo production and leader peptide removal of the lantibiotic lacticin 481, two analogues of 
lacticin 481 with N-terminal mutations, and nukacin ISK-1. The methodology was also 
attempted with the prochlorosins 1.1 and 1.6, however in this system the PylRS-PylT pair did not 
suppress the amber stop codon to a large extent and truncated ProcA analogues were produced. 
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Scheme 3.1. Biosynthesis of lacticin 481 with an N-terminal hydroxyl group by incorporation of 
a hydroxy acid between leader and core peptides. Left, biosynthesis of lacticin 481 incorporating 
a hydroxy acid at the amber stop codon (tag). After modification of the LctA precursor peptide 
by LctM, alkaline hydrolysis of the ester bond yields lacticin 481 with an N-terminal hydroxyl 
group. Wild type (wt) lacticin 481 contains a lysine at its N-terminus. Right, structures of non-
proteinogenic amino and hydroxy acids (3.1-3.6) introduced into lanthipeptides in this chapter. 
 
3.2. RESULTS AND DISCUSSION 
3.2.1. Production of modified Δ1-lacticin 481 in vivo. 
We first sought to test the incorporation of an ester bond between the leader and core 
regions of the class II lantibiotic lacticin 481. As discussed in Chapter 1, nukacin-ISK1, several 
prochlorosins, and the lantibiotics haloduracin and nisin, among others, have been 
biosynthesized in E. coli by coexpressing the lanthipeptide precursor peptides with their 
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biosynthetic enzyme(s).4,5 Previous work on the biosynthesis of lacticin 481 has focused on the 
in vitro modification of the lacticin 481 precursor peptide, LctA, by its cognate biosynthetic 
enzyme, LctM.15 However, for the current methodology to be successful, the activity of the 
biosynthetic enzyme must be reconstituted in vivo. To test the production of lacticin 481 in E. 
coli BL21 (DE3) cells, the gene sequence encoding His6-LctA was cloned into MCS1 of a 
pRSFDuet vector containing lctM in MCS2. After induction of coexpression by the addition of 
IPTG, the culture was incubated for 4 h at 37 ºC, at which point the cells were harvested and 
lysed. Purification of the lanthipeptide by IMAC and removal of the leader peptide and the first 
residue of the core peptide with LysC yielded a small amount of Δ1-lacticin 481 that had been 
completely processed (four dehydrations and three cyclizations) and a large amount of 
unprocessed product (no dehydrations) (Figure 3.1, left). To increase the production of fully 
processed Δ1-lacticin 481, the coexpression was repeated except the culture was incubated at 18 
ºC overnight after induction with IPTG. We anticipated that the lower temperature would slow 
the production of LctA, decreasing the opportunity for aggregates of the unmodified LctA 
precursor peptide to form inclusion bodies, which are not modified. Analysis of the LysC-
cleaved product by MALDI-TOF MS showed production of Δ1-lacticin 481 in greater amounts 
(Figure 3.1, right).16  
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Figure 3.1. Biosynthesis of Δ1-lacticin 481 produced in E. coli. MALDI-TOF MS spectra of 
LysC-cleaved His6-LctA modified by LctM in E. coli grown at 37 ºC (left) and 18 ºC (right). 
LysC-cleaved His6-LctA –4 H2O [M+H]+ calc’d = 2772.2 Da.; LysC-cleaved His6-LctA –0 H2O 
with disulfide [M+H]+ = 2842.2 Da. 
 
3.2.2. Incorporation of H-Lys(Boc)-OH (3.1) into LctA. 
We next investigated the incorporation of a non-canonical amino acid into a modified 
lanthipeptide using PylRS in E. coli. This strategy requires first the suppression of the amber 
codon by the PylRS-PylT pair and then the successful modification of the lanthipeptide analogue 
by its cognate synthetase. To this end, plasmids were designed to incorporate lctA, lctM, pylRS, 
and pylT into a coexpression system in E. coli. A pEVOL plasmid17 incorporating the latter two 
genes was donated by Professor Wenshe Liu (Texas A&M). PylRS production from the plasmid 
is induced by the addition of arabinose and PylT expression is under the control of a strong proK 
promoter. A pRSFDuet plasmid was then constructed integrating genes encoding His6-
LctA(K1tag) and LctM into MCS1 and MCS2, respectively. The first amino acid of the core 
region in the LctA analogue, Lys, was replaced with a tag codon so that the non-canonical amino 
acid H-Lys(Boc)-OH (3.1, Scheme 3.1) (for synthesis see section 3.4.2), which has previously 
been used as a substrate for PylRS-PylT,18 could be incorporated at that position. Finally, an 
additional copy of pylT was inserted into the pRSFDuet plasmid to increase the efficiency of 
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incorporation of the non-canonical amino acid into the lanthipeptide (personal communication 
with Professor Wenshe Liu). Coexpression of His6-LctA(K1tag), LctM, PylRS, and PylT was 
achieved by the addition of IPTG and arabinose to the cells and 2 mM 3.1 to the growth medium. 
The coexpression culture was then incubated at 37 ºC for 4 h. After purification of the His6-
tagged peptide by IMAC, analysis by MALDI-TOF MS showed that H-Lys(Boc)-OH had been 
successfully incorporated into His6-LctA(K1tag) (3.1-LctA) (Figure 3.2A). The extent of 
modification of the LctA analogue by LctM was determined by MALDI-TOF MS after GluC 
cleavage and Boc removal and LctA was found to be dehydrated four times (wt lacticin 481 has 
four dehydrations) (Figure 3.2B). Although this result was unexpected as a large portion of wt 
LctA was not fully processed at 37 ºC, the introduction of a second plasmid to the coexpression 
system may have the same effect on slowing the expression of LctA and disrupting its ability to 
form inclusion bodies as lowering the temperature after IPTG induction. Importantly, a leader 
peptide truncation peak at 4531 Da, corresponding to the translation of LctA halting at the amber 
stop codon, was not observed. When the coexpression was repeated in the absence of 3.1, the 
full-length LctA analogue was not detected. Several peaks were seen in the 7300-7600 Da region 
(Figure 3.2C solid line), however these masses were frequently observed in our coexpression 
reactions and likely represent E. coli proteins purified during IMAC (see also Figure 3.12A). 
These results indicate that the PylRS-PylT pair readily introduces 3.1 into lacticin 481 but does 
not incorporate any of the twenty canonical amino acids native to E. coli cells.19 
 
 72 
 
Figure 3.2. MALDI-TOF MS spectra of LctM-modified LctA(K1tag) in the presence or absence 
of 3.1. 3.1-LctA before (A) and after (B) GluC cleavage and Boc removal. C) MALDI-TOF MS 
spectra of LctM-modified His6-LctA(K1tag) in the presence (dashed line) and absence (solid 
line) of 3.1. Mass ions seen in the absence of 3.1 are likely E. coli proteins. –Boc represents loss 
of the Boc group from 3.1-LctA during analysis by MALDI-TOF MS. LctM-modified 3.1-LctA 
[M+H]+ calc’d = 7389 Da.; GluC-cleaved, Boc-removed, and LctM-modified 3.1-LctA [M+H]+ 
calc’d = 3595.7 Da. 
  
3.2.3. Incorporation of HO-Lys(Boc)-OH (3.2) into LctA. 
 PylRS recognizes the α-amino group of its substrate loosely because the amine is 
stabilized in the active site of PylRS by a single hydrogen bond to a water molecule.20 By 
contrast, in phenylalanyl-tRNA synthetase, a close structural analogue of PylRS, the side chains 
of three active site residues form hydrogen bonds with the α-amino group of L-phenylalanine and 
non-α-amino substrates are not recognized.21 Based on these studies, and as mentioned in the 
introduction of this chapter, Yokoyama and coworkers used the PylRS-PylT pair to incorporate 
 73 
several non-α-amino Boc-Lys derivatives, including the hydroxy acid HO-Lys(Boc)-OH (3.2) 
(Scheme 3.1), into a protein of interest.14 They were then able to site-specifically cleave the 
resulting ester bond by mild alkaline hydrolysis. 
With the ability of PylRS/PylT to incorporate hydroxy acid 3.2 into proteins and the 
initial success of LctM modification of 3.1-LctA, the incorporation of hydroxy acid 3.2 into 
His6-LctA(K1tag) was tested using the coexpression system outlined above. Unfortunately, after 
IMAC purification, very little full-length LctA analogue (3.2-LctA) was observed by MALDI-
TOF MS (Figure 3.3, left). Instead, the major mass ion corresponded to the leader peptide 
truncation product. This result could have come about in two different ways; 1) the amber stop 
codon was not suppressed by the PylRS-PylT pair, halting translation at the UAG codon or 2) 
hydroxy acid 3.2 was successfully incorporated into His6-LctA(K1tag) but the subsequent ester 
bond was hydrolyzed before or during IMAC purification, allowing the core region, without a 
His6-tag, to pass through the nickel column without binding. To probe the latter possibility, the 
last amino acid of the leader peptide (i.e. the residue immediately preceding the ester bond in 
His6-LctA(K1tag)) was mutated from Ala to Ile (His6-LctA(A–1I/K1tag)). The rationale for this 
substitution was that cleavage of an ester bond in the peptide backbone at near-neutral pH is 
strongly prevented when the ester is directly preceded by a large hydrophobic residue, such as 
Ile.9 His6-LctA(A–1I/K1tag) was coexpressed with LctM, PylRS, and PylT in the presence of 2 
mM 3.2, purified by IMAC, and analyzed by MALDI-TOF MS. Gratifyingly, the hydroxy acid 
was incorporated into the LctA analogue, which was fully modified by LctM (3.2-LctA(A–1I)) 
(Figure 3.3, right). Further analysis of 3.2-LctA(A–1I) by RP-HPLC showed only one peak, 
which corresponded to the full-length LctA analogue and not the leader peptide truncation 
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product (Figure 3.4, right). As before, when the coexpression was repeated in the absence of 3.2 
full-length LctA analogue was not observed. 
 
 
Figure 3.3. Incorporation of 3.2 into LctA(tag) and LctA(A–1I/K1tag). MALDI-TOF MS 
spectra of (left) LctM-modified His6-LctA(K1tag) incorporating hydroxy acid 3.2 and (right) 
LctM-modified His6-LctA(A–1I/K1tag) incorporating hydroxy acid 3.2. His6-LctA(K1tag) 
leader peptide truncation [M+H]+ calc’d = 4533 Da.; LctM-modified 3.2-LctA [M+H]+ calc’d = 
7390 Da.; LctM-modified 3.2-LctA(A–1I) [M+H]+ calc’d = 7427 Da. 
 
To produce lacticin 481 with an N-terminal hydroxyl group (HO-lacticin 481), the Boc 
group in 3.2-LctA(A–1I) was removed by incubating the fully modified peptide in 5% TFA at 50 
ºC. The pH of the peptidic solution was then increased to 10.5, catalyzing the site-specific 
release of the leader peptide via ester hydrolysis. Analysis of these reactions by MALDI-TOF 
MS and analytical RP-HPLC showed depletion of the full-length LctA analogue and a buildup of 
peaks corresponding to the leader peptide and HO-lacticin 481 (Figure 3.4), which was obtained 
in a typical yield of 0.1 mg/L culture. The bioactivity of HO-lacticin 481 against Lactococcus 
lactis HP was tested and will be discussed in section 3.2.5. 
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Figure 3.4. Production of HO-lacticin 481. Left, MALDI-TOF MS spectrum of LctM-modified 
3.2-LctA(A–1I) after Boc removal and alkaline hydrolysis yielding HO-lacticin 481. Right, 
analytical RP-HPLC trace of LctM-modified 3.2-LctA(A–1I) before (red) and after (blue) Boc 
removal and alkaline hydrolysis. HO-lacticin 481 [M+H]+ calc’d = 2901.3 Da. 
 
3.2.4. Incorporation of HO-Phe(3Br)-OH (3.4) and HO-Tyr(propargyl)-OH (3.6) into LctA. 
 A previous study incorporating non-proteinogenic amino acids into lacticin 481 found 
several positions where a point mutation increased the bioactivity against L. lactis HP cells.2 
However, the effect of point mutations to the N-terminal lysine of lacticin 481 on bioactivity has 
not been tested because, in the methodology used, this residue is removed during cleavage of the 
leader peptide by the endoprotease LysC, yielding Δ1-lacticin 481. We anticipated that the 
proposed methodology could enable us to study the bioactivities of lacticin 481 analogues with 
N-terminal Lys mutations because removal of the leader peptide by alkaline hydrolysis (rather 
than LysC) would yield the entire core peptide. 
 Lacticin 481 fortuitously contains a Lys as its N-terminal residue. To investigate whether 
this strategy might also work for other amino acids, we investigated a mutation at residue 1. 
Recently, Liu and coworkers developed a PylRS mutant (mut-PylRS; N346A/C348A) that 
successfully loads Phe analogues with small meta substituents and Tyr analogues with larger 
para substituents onto 
€ 
tRNACUAPyl .22,23 For our studies we chose 3-bromo-L-phenylalanine (H-
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Phe(3-Br)-OH), O-propargyl-L-tyrosine (H-Tyr(propargyl)-OH), and their corresponding 
hydroxy acid analogues (Scheme 3.1) as substrates for incorporation into LctA. 
 To ensure mut-PylRS could suppress the amber stop codon in lanthipeptides produced in 
vivo, we first sought to incorporate the amino acids 3.3 and 3.5 (Scheme 3.1) into His6-LctA(A–
1I/K1tag). Coexpression of the LctA precursor with LctM, mut-PylRS, and pylT in enriched LB 
media (for composition see section 3.4.4) supplemented with 3.3 or 3.5 resulted in full-length 
LctA analogues without discernible detection of leader peptide truncation products (3.3-LctA(A–
1I) and 3.5-LctA(A–1I)) (Figure 3.5A,C). After GluC cleavage, the major ions observed 
corresponded to the 4-fold dehydrated products (Figure 3.5B,D). Interestingly, when 3.3 or 3.5 
were not added to the media, a very small peak corresponding to full-length LctA was sometimes 
observed, indicating suppression of the stop codon. Analysis of this GluC-cleaved substrate by 
MALDI-TOF MS demonstrated that Phe had been incorporated into LctA at the amber codon, a 
result that was not surprising as mut-PylRS weakly recognizes L-Phe.23 However, the 
incorporation of L-Phe into His6-LctA(A–1I/K1tag) was negligible in the presence of 2 mM 3.3 
or 3.5 (Figure 3.5B,D), even in rich media, suggesting the non-proteinogenic amino acid 
outcompetes L-Phe in vivo. 
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Figure 3.5. MALDI-TOF MS spectra of full-length and GluC-cleaved LctM-modified His6-
LctA(A–1I/K1tag) incorporating 3.3 or 3.5. A) LctM-modified 3.3-LctA(A–1I) ([M+H]+ calc’d 
= 7428 Da.). B) LctM-modified and GluC-cleaved 3.3-LctA(A–1I) ([M+H]+ calc’d = 3734.7 
Da.). C) LctM-modified 3.5-LctA(A–1I) ([M+H]+ calc’d = 7403 Da). D) LctM-modified and 
GluC-cleaved 3.5-LctA(A–1I) ([M+H]+ calc’d = 3710.7 Da.). 
 
 The incorporation of HO-Phe(3Br)-OH (3.4) or HO-Tyr(propargyl)-OH (3.6) into His6-
LctA(A–1I/K1tag) was then attempted. Coexpression of the LctA precursor peptide with LctM, 
mut-PylRS, and PylT in enriched LB containing 3.4 or 3.6 was followed by IMAC and RP-
HPLC purification. The products displayed major mass ions corresponding to fully modified 
LctA analogues (3.4-LctA(A–1I) and 3.6-LctA(A–1I)) (Figure 3.6A,C). Alkaline hydrolysis of 
the full-length peptides produced lacticin 481 analogues with the desired N-terminal mutations 
(3.4-HO-lacticin 481, 3.6-HO-lacticin 481) in typical yields of 0.04 mg/L and 0.05 mg/L culture, 
respectively (Figure 3.6B,D).  
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Figure 3.6. MALDI-TOF MS spectra of full-length and base-hydrolyzed LctM-modified His6-
LctA(A–1I/K1tag) incorporating 3.4 or 3.6. A) LctM-modified 3.4-LctA(A–1I) ([M+H]+ calc’d 
= 7429 Da.). B) LctM-modified and base-hydrolyzed 3.4-LctA(A–1I) ([M+H]+ calc’d = 2998.1 
Da.). C) LctM-modified 3.6-LctA(A–1I) ([M+H]+ calc’d = 7404 Da). D) LctM-modified and 
base-hydrolyzed 3.6-LctA(A–1I) ([M+H]+ calc’d = 2974.2 Da.). 
 
3.2.5. Antimicrobial activities of wt lacticin 481, Δ1-lacticin 481, HO-lacticin 481, 3.4-HO-
lacticin 481, and 3.6-HO-lacticin 481. 
We first compared the bioactivity of wt lacticin 481, isolated from L. lactis subsp. lactis 
CNRZ 481, with Δ1-lacticin 481 by agar diffusion antimicrobial assays and liquid growth media 
assays against L. lactis HP (Figure 3.7, left). Originally, it appeared that Δ1-lacticin 481 (IC50 = 
105 nM ± 16 nM) was approximately 4-fold more active than wt lacticin 481 (IC50 = 444 nM ± 
51 nM). This result was surprising as lacticin 481-N15R/F21H was previously found to be 5-fold 
more active than its corresponding analogue lacking an N-terminal lysine.2,16 To ensure the 
amounts of wt lacticin 481 and Δ1-lacticin 481 used for the liquid growth assay were equivalent, 
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equal amounts of both compound stocks were injected into an analytical RP-HPLC instrument 
and the corresponding absorbances at 220 nm were compared (Figure 3.7, right). Interestingly, 
the amount of wt lacticin 481 observed was much less than that of Δ1-lacticin 481 suggesting 
that the wt lacticin 481 used in the bioactivity studies was not pure and that the stock 
concentration was overestimated; the wt lacticin 481 was presumably contaminated by 
ammonium acetate, which was used to buffer the mobile phase in the final step of purification. 
To remove the ammonium acetate, the impure stock of wt lacticin 481 was desalted by RP-
HPLC and eluted with an MeCN mobile phase lacking ammonium acetate and lyophilized 
(Figure 3.7, right). The new stock of wt lacticin 481 was tested against L. lactis HP in a liquid 
media growth assay and its antimicrobial activity (IC50 = 120 nM ±15 nM) was 4-fold greater 
than the impure wt lacticin 481 and similar to Δ1-lacticin 481. Thus, wt lacticin 481 isolated 
from the native producer has an IC50 at least 4-fold greater against L. lactis HP than originally 
reported by our laboratory.16 
The bioactivities of wt lacticin 481 and Δ1-lacticin 481 were then compared with HO-lacticin 
481, 3.4-HO-lacticin 481, and 3.6-HO-lacticin 481 by agar diffusion antimicrobial assays and 
liquid media growth assays (Figure 3.7, left). HO-lacticin 481 (IC50 = 224 nM ± 65 nM) showed 
similar activity to that of wt lacticin 481 and Δ1-lacticin 481 suggesting the introduction of a 
hydroxyl group at the N-terminus of lacticin 481 has just a small effect on bioactivity. However, 
the bioactivity of HO-lacticin 481 was decidedly higher than that of 3.4-HO-lacticin 481 (IC50 = 
3,870 nM ± 55 nM) and 3.6-HO-lacticin 481 (IC50 = 720 nM ± 170 nM). This result supports 
previous findings that the N-terminal lysine of lacticin 481 is important, but not essential, for 
bioactivity.2 
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Figure 3.7. Zones-of-growth-inhibition displayed by and purification of lacticin 481 and 
analogues. Left, zones-of-growth-inhibition displayed by (clockwise from red star) impure-wt 
lacticin 481, wt-lacticin 481, Δ1-lacticin 481, HO-lacticin 481, 3.4-HO-lacticin 481, and 3.6-HO-
lacticin 481 against L. lactis HP. A total of 10 µL of 12.5 µM compound solution was added to 
each spot. Right, analytical RP-HPLC trace of impure-wt lacticin 481 (red), lacticin 481 after 
HPLC purification in mobile phase lacking ammonium acetate (black), and Δ1-lacticin 481 
(blue) to determine purities and relative concentrations of compounds used in the antimicrobial 
assays. A total of 100 µL of 34 µM substrate was injected. 
 
3.2.6. Incorporation of non-proteinogenic amino and hydroxy acids between the leader and 
core regions of nukacin ISK-1. 
 Given the success of incorporation of non-proteinogenic amino and hydroxy acids into 
lacticin 481, we sought to show the leader peptide removal strategy by ester hydrolysis was 
general for other lanthipeptides. We chose nukacin ISK-1 (precursor peptide is NukA; Figure 
3.8) because it is a close structural analogue of lacticin 481 and, like lacticin 481, has an N-
terminal lysine. Moreover, in all previous attempts to biosynthesize nukacin ISK-1 in E. coli the 
removal of the leader peptide was achieved by incubating the modified precursor peptide with 
the endoprotease LysC, which also removed the first three residues of the core peptide 
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(LysLysLys) yielding Δ1-3-nukacin ISK-1.4,24 Using our hydroxy acid incorporation strategy, we 
sought to produce nukacin ISK-1 without an N-terminal truncation. 
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Figure 3.8. Structures of lanthipeptides lacticin 481 and nukacin ISK-1. Residues in nukacin 
ISK-1 that differ from lacticin 481 are highlighted in red. 
  
3.2.6.1. Production of modified Δ1-3 nukacin ISK-1 in vivo. 
 Previous attempts to biosynthesize nukacin ISK-1 in our lab have focused on the in vitro 
modification of an LctA leader/NukA core chimeric peptide (LctNukA) with LctM.24 Although 
NukA is not the native substrate for LctM, the core region of the chimeric peptide was 
successfully dehydrated and cyclized.24 For our ester incorporation strategy to be successful, 
nukacin ISK-1 must be produced in vivo in E. coli so the gene sequence encoding LctNukA was 
introduced into MCS1 of a pRSFDuet vector incorporating the gene for LctM in MCS2. After 
induction of coexpression by the addition of IPTG, harvesting of the cells, lysis, IMAC, and 
removal of the leader peptide and the first three residues of the core peptide with LysC yielded a 
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mixture of fully and partially modified Δ1-3-nukacin ISK-1. Unfortunately, during the LysC 
cleavage step a large amount of Δ1-3-nukacin ISK-1 was oxidized (Figure 3.9, left). The 
LctNukA expression was then repeated and all solutions were sparged with nitrogen before 
addition to the peptide. After LysC cleavage, the major mass ion corresponded to Δ1-3-nukacin 
ISK-1 with no oxidation product (Figure 3.9, right). 
 
 
Figure 3.9. Biosynthesis of Δ1-3-nukacin ISK-1 in E. coli. Coexpression cultures containing a 
pRSFDuet plasmid encoding LctNukA and LctM were incubated at 18 ºC after IPTG induction. 
Left, LysC assay solution was not sparged with nitrogen. Right, LysC assay solution was sparged 
with nitrogen. The peak at +16 Da likely represents oxidized Δ1-3-nukacin ISK-1, however 
incomplete dehydration of one Ser/Thr residue and the formation of one disulfide bond cannot be 
ruled out. The peak at +34 Da represents the incomplete dehydration of two Ser/Thr residues 
(+36 Da) and the formation of one disulfide bond (–2 Da). The peak at Na+ represents a sodium 
adduct. Δ1-3-nukacin ISK-1 [M+H]+ calc’d = 2574.1 Da. 
 
3.2.6.2. Incorporation of 3.1 and 3.2 into nukacin ISK-1. 
 To produce nukacin ISK-1 with a non-proteinogenic amino or hydroxy acid inserted 
between its leader and core peptides, a gene sequence encoding LctNukA(A–1I/K1tag) was 
incorporated into a pRSFDuet vector. As before, a pEVOL plasmid carried genes encoding 
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PylRS and PylT. Coexpression of LctNukA(A–1I/K1tag), LctM, PylRS, and PylT in the 
presence of 3.1 yielded an LctNukA analogue incorporating 3.1 between its leader and core 
regions (3.1-LctNukA(A–1I); Figure 3.10A). Removal of a portion of the leader peptide of 3.1-
LctNukA(A–1I) by GluC showed that the core peptide was dehydrated four times (Figure 3.10B) 
(the same number of dehydrations as in wt nukacin ISK-1). Interestingly, as seen in our studies 
with lacticin 481, no partially modified LctNukA core peptide was observed when LctNukA was 
coexpressed with LctM, PylRS, and PylT (Figure 3.10B). 
 The incorporation of hydroxy acid 3.2 into LctNukA(A–1I/K1tag) was then attempted. 
Analysis by MALDI-TOF MS of the coexpression of the LctNukA mutant with LctM, PylRS, 
and PylT in the presence of 3.2 showed a large peak corresponding to full-length LctNukA 
without detection of leader peptide truncation product (3.2-LctNukA(A–1I); Figure 3.10C). The 
Boc-group of 3.2-LctNukA(A–1I) was then removed with acid followed by alkaline-catalyzed 
hydrolysis of the leader peptide from the core peptide yielding nukacin ISK-1 with an N-terminal 
hydroxyl group (HO-nukacin ISK-1; Figure 3.10D). 
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Figure 3.10. Incorporation of 3.1 and 3.2 into LctNukA(A–1I/K1tag). MALDI-TOF MS spectra 
of A) LctM-modified 3.1-LctNukA(A–1I/K1tag) ([M+H]+ calc’d = 7484 Da.), B) Boc-
deprotected GluC-cleaved 3.1-LctNukA(A–1I/K1tag) that was modified by LctM ([M+H]+ 
calc’d = 3695.8 Da.), C) LctM-modified 3.2-LctNukA(A–1I/K1tag) ([M+H]+ calc’d = 7485 
Da.), D) Boc-deprotected and alkaline hydrolyzed 3.2-LctNukA(A–1I/K1tag) that was modified 
by LctM producing HO-nukacin ISK-1 ([M+H]+ calc’d = 2959.3 Da. Peak at +16 Da represents 
oxidation of 3.2-nukacin ISK-1. Na+ represents sodium adduct. 
 
3.2.6.3. Antimicrobial activities of Δ1-3 nukacin ISK-1 and HO-nukacin ISK-1. 
 The bioactivities of Δ1-3-nukacin ISK-1 and HO-nukacin ISK-1 were first tested by agar 
diffusion antimicrobial assays against L. lactis HP and Bacillus coagulans. Unfortunately, no 
bioactivity was observed even at concentrations up to 250 µM for each peptide. The 
antimicrobial activities of the nukacin analogues were then tested against L. lactis HP in liquid 
media growth assays. At concentrations of 12.5 and 25 µM HO-nukacin ISK-1 retarded cell 
growth whereas normal cell growth was observed when the same concentrations of Δ1-3-nukacin 
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ISK-1 were added (Figure 3.11). These results are in agreement with a previous study showing 
the removal of the N-terminal LysLysLys of nukacin ISK-1 reduced the bioactivity of the 
compound.25 
 
 
Figure 3.11. Growth of L. lactis HP cells in liquid media in the presence of HO-nukacin ISK-1 
and Δ1-3-nukacin ISK-1. For all compounds tested n = 3 except HO-nukacin ISK-1 and Δ1-
nukacin ISK-1 at 25 µM (n = 1). 
 
3.2.7. Incorporation of non-proteinogenic amino and hydroxy acids between the leader and 
core regions of prochlorosins. 
 We then attempted our ester bond incorporation strategy on the prochlorosin (Pcn) group 
of lanthipeptides.26 We chose the prochlorosins as substrates because they are unrelated to 
lacticin 481 and nukacin ISK-1 and the native protease responsible for leader peptide removal 
has not been identified. Hence, a hydrolytic removal of the leader peptide would be valuable. 
The prochlorosin precursor peptides ProcA1.1 and ProcA1.6 (corresponding to Pcn1.1 and 
Pcn1.6 after leader peptide removal) are ideally suited for this methodology because their core 
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peptides begin with Phe and Lys, respectively. Therefore, the incorporation of 3.2 or 3.4 into 
ProcA1.1 or ProcA1.6, respectively, followed by alkaline hydrolysis, would yield Pcn1.1 and 
Pcn1.6 with N-terminal hydroxyl groups. 
 
3.2.7.1. Incorporation of 3.1 and 3.3 into ProcA1.1. 
 The prochlorosins are members of the class II lanthipeptides and, like lacticin 481 and 
nukacin ISK-1, are modified by a single bifunctional enzyme (ProcM). To produce a ProcA1.1 
analogue incorporating non-proteinogenic amino or hydroxy acids between its leader and core 
regions, a gene encoding ProcA1.1(G–1I/F1tag) was inserted into MCS1 of a pRSFDuet vector 
with ProcM in MCS2. Analysis of the coexpression of ProcA1.1(G–1I/F1tag) with ProcM, mut-
PylRS, and PylT in enriched LB containing 3.3 by MALDI-TOF MS and analytical RP-HPLC 
showed two distinct peaks: a very small peak corresponding to full-length ProcA1.1 
incorporating 3.3 (3.3-ProcA1.1(A–1I)) and a much larger peak corresponding to translation 
halting at the amber stop codon (Figure 3.12). Several potential causes for the low level of amber 
codon suppression by mut-PylRS-PylT in ProcA1.1 were investigated and will be discussed 
below. 
 We hypothesized that the amount of mut-PylRS being produced in the coexpression was 
too low to efficiently suppress the amber stop codon in ProcA1.1. Indeed, in this work and other 
studies, ProcA was expressed in much greater yields than lacticin 48127,28 so higher 
concentrations of mut-PylRS, or lower concentrations of the ProcA1.1 transcript, might be 
necessary to achieve the same level of amber suppression as seen for lacticin 481. We first 
sought to decrease the amount of ProcA1.1 produced during coexpression by modifying the 
composition of the media from enriched LB to minimal media (for composition of minimal 
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media see section 3.4.4). The decrease in nutrients in minimal media should slow the 
biosynthesis of ProcA1.1, giving mut-PylRS more time to incorporate 3.3. Gratifyingly, the 
amount of leader peptide truncation product, after coexpression of His6-ProcA1.1(G–1I/F1tag) 
with ProcM, mut-PylRS, and PylT in minimal media, was dramatically reduced; the yield of full-
length ProcA1.1 incorporating 3.3 after coexpression was also reduced, but by much less (Figure 
3.12). This result gave credibility to our hypothesis that influencing the concentration of the 
ProcA1.1 transcript, or mut-PylRS, during coexpression could increase the amount of full-length 
ProcA1.1 produced. 
 
 
Figure 3.12. Comparison of enriched LB and minimal media for the incorporation of 3.3 into 
His6-ProcA1.1(G–1I/F1tag). Left, MALDI-TOF MS spectrum of ProcM-modified His6-
ProcA1.1(G–1I/F1tag) incorporating 3.3 in enriched LB (3.3-ProcA1.1(A–1I) [M+H]+ calc’d = 
11753 Da.; His6-ProcA1.1(G–1I/F1tag) leader peptide truncation [M+H]+ calc’d = 9744 Da.). 
Right, analytical RP-HPLC trace of ProcM-modified His6-ProcA1.1(G–1I/F1tag) incorporating 
3.3 in enriched LB (blue) or minimal media (red). MALDI-TOF MS analysis of the analytical 
RP-HPLC purification of His6-ProcA1.1(G–1I/F1tag) in enriched media confirmed the elution of 
the leader peptide truncation product began at 28.6 min and ended around 31.0 min. 
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The expression of ProcA1.1 and mut-PylRS is dependent on two different small 
molecules, IPTG and arabinose respectively, and hence the level of expression of either gene 
product can be independently manipulated. We hoped that either an increase in arabinose 
concentration (from 0.2%), and consequently an increase in the expression of mut-PylRS, or a 
decrease in the amount of IPTG (from 250 µM), leading to lower levels of ProcA1.1 production, 
would increase the amber codon suppression ability in the coexpression system. We first 
increased the concentration of arabinose to 0.5% and 1.0% during coexpression of His6-
ProcA1.1(G–1I/F1tag) with ProcM, PylRS, and PylT, in minimal media in the presence of 3.3. 
Each coexpression product was purified by IMAC and analyzed by MALDI-TOF MS and 
analytical RP-HPLC (Figure 3.13, left). Unfortunately, the concentration of arabinose had no 
effect on the incorporation of 3.3, a result that was not unexpected because induction with 0.2% 
arabinose is already considered saturating for plasmids containing the araBAD promoter.29 Next, 
we decreased the concentration of IPTG during coexpression to 250 µM, 50 µM, and 25 µM 
while keeping the concentration of arabinose constant (0.2%). We hoped slowing down the 
expression of ProcA1.1 would allow the ribosome more time to incorporate the non-
proteinogenic amino acid at the tag codon. For these experiments we attempted the introduction 
of the Lys analogue 3.1 into His6-ProcA1.1(G–1I/F1tag) using wt PylRS as this system gave 
higher yields with lacticin 481. Analysis of the coexpression experiments by analytical RP-
HPLC showed that a decrease in the concentration of IPTG did reduce the amount of ProcA1.1 
produced during coexpression, however the ratio of full-length ProcA1.1 to leader peptide 
truncation product remained largely unchanged (Figure 3.13, right). Hence, varying the 
concentration of IPTG in the coexpression had no beneficial effect on the efficiency of stop 
codon suppression. 
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Figure 3.13. Comparison of different concentrations of arabinose or IPTG on incorporation of 
3.1 or 3.3 into His6-ProcA1.1(G–1I/F1tag). Left, analytical RP-HPLC traces of His6-
ProcA1.1(G–1I/F1tag) incorporating 3.3 with 1.0% (blue) and 0.5% (red) arabinose in the 
coexpression culture. Right, analytical RP-HPLC traces of His6-ProcA1.1(G–1I/F1tag) 
incorporating 3.1 with 250 µM (blue), 25 µM (red), and 5 µM (black) IPTG in the coexpression 
culture. 
 
3.2.7.2. Incorporation of 3.1 into ProcA1.6. 
 After our unsuccessful attempts at efficiently incorporating 3.1 or 3.3 into ProcA1.1, we 
sought instead to incorporate 3.1 into ProcA1.6 using wt PylRS. A gene encoding His6-
ProcA1.6(G–1I/K1tag) was introduced into MCS1 of a pRSFDuet vector with ProcM integrated 
into MCS2. Coexpression of the ProcA1.6 mutant with ProcM, PylRS, and PylT in the presence 
of 3.1 in minimal media again yielded mostly leader peptide truncation product with a small 
amount of full-length ProcA1.6 (3.1-ProcA1.6(A–1I)) (Figure 3.14, left). To assess if the 
incorporation of 3.1 into His6-ProcA1.6(G–1I/K1tag) was affected by the bulky residue at the –1 
position, the Ile was mutated to Gly (ProcA1.6(K1tag)) and the coexpression was repeated. 
Unfortunately, the mutation at the –1 position had no effect on amber codon suppression as the 
major peak still corresponded to the leader peptide truncation product (Figure 3.14, right). 
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Figure 3.14. MALDI-TOF MS spectra of the incorporation of 3.1 into ProcA1.6 mutants. Left, 
MALDI-TOF MS spectrum of ProcM-modified His6-ProcA1.6(G–1I/K1tag) incorporating 3.1. 
Right, MALDI-TOF MS spectrum of His6-ProcA1.6(K1tag) incorporating 3.1 after modification 
by ProcM. Leader peptide truncation product for His6-ProcA1.6(A–1I/K1tag) [M+H]+ calc’d = 
8820 Da.; ProcM-modified 3.1-ProcA1.6(A–1I) [M+H]+ calc’d = 11482 Da.; Leader peptide 
truncation product for His6-ProcA(K1tag) [M+H]+ calc’d = 8764 Da.; ProcM-modified 3.1-
ProcA1.6 [M+H]+ calc’d = 11426 Da. 
 
3.3. SUMMARY AND OUTLOOK. 
 When compared with lanthipeptide biosynthesis in vitro, the coexpression of 
lanthipeptides with their biosynthetic enzymes in E. coli produces the biomolecules in higher 
yields and purities, allowing many studies that were previously not possible. Indeed, the in vivo 
route to lanthipeptide production facilitated recent work on the mode of action,28 ring 
topology,30,31 and stereochemistry27 of lanthipeptides, as well as the characterization of important 
biosynthetic proteins32,33 and new lanthipeptide gene clusters.30,34 In these studies, the removal of 
the leader peptide to produce the mature lanthipeptide/lantibiotic was achieved by engineering a 
proteolytic cleavage site at the –1 position followed by leader peptide removal using a 
commercial protease. However, in several cases the protease could not cleave at the desired 
location, hindering further studies on the peptides.27,28 Thus, the ability to more easily control the 
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release of the leader region from the core region after lanthipeptide production in vivo would be 
beneficial. 
 My studies described in this chapter show the incorporation of six non-proteinogenic 
amino or hydroxy acids directly between the leader and core regions of the lantibiotic lacticin 
481 using amber suppression technology with PylRS and mut-PylRS. In nearly every case, the 
suppression of the amber codon was excellent as substantial amounts of leader truncation 
product were not detected. The observation of truncated product when hydroxy acid 3.2 was 
incorporated into LctA(K1tag) was likely the result of premature ester bond cleavage and not the 
translation of LctA halting at the amber codon. Indeed, when the residue immediately preceding 
the ester bond in LctA was mutated to Ile, truncation product was not detected, presumably 
because the bulky amino acid prevented hydrolysis at neutral pH. Mild alkaline conditions 
promoted full cleavage of the ester linkages allowing the production of lacticin 481, and 
analogues, with an N-terminal hydroxyl group. Although lanthipeptides normally contain N-
terminal amines, incorporation of lactate is a posttranslational modification at the N-terminus of 
some lanthipeptides and is thought to protect those compounds from aminopeptidases.35,36  
The incorporation of amino and hydroxy acids 3.1 and 3.2 into nukacin ISK-1 was also 
successful. Ester hydrolysis of 3.2-LctNukA(A–1I) yielded fully modified nukacin ISK-1 with 
an N-terminal hydroxyl group. The formation of oxidized nukacin ISK-1 lowered the total yield 
of nukacin ISK-1 produced in E. coli, however sparging the LysC and base hydrolysis assay 
solutions largely prevented oxidation. This biosynthesis marked the first time that nukacin ISK-
1, and not Δ1-3-nukacin ISK-1, had been produced after expression of its modified precursor 
peptide in E. coli. 
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 The incorporation of the non-proteinogenic amino acids 3.1 and 3.3 into prochlorosins 
1.1 and 1.6 was unsuccessful. In every case, the leader peptide truncation peak, corresponding to 
translation halting at the amber stop codon, was dominant over full-length ProcA. Reducing the 
amount of ProcA synthesized during coexpression by replacing rich with minimal media seemed 
to increase the ratio of full-length ProcA to truncation product, likely because the expression of 
ProcA was slowed. However, decreasing the concentration of IPTG to further reduce the amount 
of ProcA produced was not beneficial, and the amber codon suppression product was never 
obtained as major product. 
The amber codon suppression of PylRS-PylT in E. coli has to compete with innate 
release factors (RFs) that recognize stop codons and terminate translation. Prokaryotes have two 
RFs that recognize stop codons; RF1 recognizes UAA and UAG while RF2 recognizes UAA and 
UGA.37 Thus, knocking out RF1 should slow, and possibly even eliminate, the ability of E. coli 
to terminate gene expression at a UAG codon. Indeed, when RF1 was suppressed or knocked out 
in E. coli cells, incorporation efficiency of non-proteinogenic amino acids into proteins using 
PylRS or tyrosyl-tRNA synthetase was increased, even when multiple UAG codons were 
introduced into the gene being expressed.38,39 This technology could aid incorporating non-
proteinogenic amino or hydroxy acids into prochlorosins or other lanthipeptides. 
 In conclusion, we have successfully produced lacticin 481, nukacin ISK-1, and analogues 
incorporating N-terminal mutations, with N-terminal hydroxyl groups in vivo. Given the ease of 
site-directed mutagenesis, this methodology could be extended to lantibiotic analogues with 
improved activity or solubility. Importantly, unlike peptide cleavage using commercial proteases, 
the ester bond hydrolysis reaction is not sequence dependent and is completely site-selective. 
After optimization of the incorporation of the non-proteinogenic amino and hydroxy acids, we 
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anticipate that, like the photocleavable linker in Chapter 2, this general methodology may find 
use for other lanthipeptides and other classes of ribosomally synthesized and posttranslationally 
modified peptides. 
 
3.4. EXPERIMENTAL 
3.4.1 Materials 
All compounds used in the synthetic schemes were purchased from Sigma Aldrich with 
the exception of L-lysine monohydrochloride (Eastman Chemical Company), 8-quinolinol 
(Fisher Scientific), di-tert-butyl dicarbonate (Boc2O, Fluka Analytical), propargyl bromide (TCI 
America), and 3-bromo-L-phenylalanine (H-Phe(3Br)-OH, Chem Impex Int.). Solvents 
commonly used in peptide purification, including trifluoroacetic acid (TFA) and acetonitrile 
(MeCN), were obtained in RP-HPLC grade or better and used directly without further 
purification. Oligonucleotide primers used for molecular cloning were purchased from Integrated 
DNA Technologies. Phusion High-Fidelity DNA polymerase, T4 DNA ligase, Gibson Assembly 
master mix, and all restriction endonucleases were purchased from New England Biolabs. Gel 
extraction, plasmid miniprep, and PCR purification kits were purchased from QIAGEN. 
Endoproteinases LysC and GluC were purchased from Roche Applied Science and 3-
(cyclohexylamino)-1-propanesulfonic acid (CAPS) was purchased from Sigma Aldrich. Other 
items procured for cell culture and peptide work included isopropyl β-D-1-thiogalactopyranoside 
(IPTG) (Gold Biotechnology), kanamycin monosulfate (IBI Scientific), chloramphenicol (IBI 
Scientific), and L(+)-arabinose (Fisher Scientific). MALDI-TOF MS analyses were conducted at 
the Mass Spectrometry Facility (UIUC) using an UltrafleXtreme TOF/TOF (Bruker Daltonics).  
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3.4.2. Synthesis of amino and hydroxy acids 3.1-3.6. 
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Synthetic design of HO-Lys(Boc)-OH (3.2) 
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H-Lys(Boc)-OH (3.1).  
Into a 250 mL round-bottomed flask was added L-lysine monohydrochloride (3.74 g, 20.5 
mmol, 1 equiv) in 1 M aqueous NaHCO3 (41 mL). To this mixture was slowly added CuSO4⋅5 
H2O (2.56 g, 10.25 mmol, 0.5 equiv) followed by solid NaHCO3 (1.72 g, 20.5 mmol). Finally, 
Boc2O (5.82 g, 26.7 mmol, 1.3 equiv) in acetone (24.6 mL) was added and the reaction was 
stirred overnight (ON) at room temperature. The reaction was then quenched with MeOH (6.0 
mL) and was stirred for 2 h followed by the addition of H2O (20 mL) and EtOAc (20 mL). The 
blue solid was then filtered, washed with H2O, dried and used immediately in the subsequent 
reaction.  
To a vigorously stirred solution of the intermediate just generated dissolved in H2O (200 
mL) was added 8-quinolinol (3.88 g, 26.7 mmol). The reaction was stirred ON at which time the 
green suspension was filtered and the solid was washed with H2O (100 mL) and discarded. The 
filtrate was washed with DCM (2 × 100 mL), concentrated to a smaller volume by rotary 
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evaporation, and lyophilized yielding compound 3.1 (3.74 g, 75%) as a fluffy white solid. See 
also Notebook XIII, page 38.40 
 
1H NMR: (499.695 MHz, 1:1 D2O:CD3OD) δ=1.40 (m, 11H), 1.49 (m, 2H, CH2) 1.76 (m, 2H, 
CH2), 3.04 (t, J = 7 Hz, 2H, CH2) 3.52 (t, J = J Hz, 1H, CH). 
13C NMR: (499.434 MHz, 1:1 D2O:CD3OD) δ = 22.4, 27.9, 29.3, 31.8, 40.0, 55.4, 80.1, 158.1, 
176.8. 
HRMS  [M+Na] + C11H23N2O4+ calc’d = 266.9632, found = 266.9642. 
 
H2N
O
OH
N
H
O
O
NaNO2, 
4:1 H2O:AcOH
73% HO
O
OH
N
H
O
O
3.1 3.2  
HO-Lys(Boc)-OH (3.2). 
Into a 250 mL round-bottomed flask was placed 3.1 (1.4 g, 5.69 mmol) dissolved in 57 
mL of 4:1 H2O:AcOH and the vial was added to a 0 ºC icebath. To this mixture was slowly 
added sodium nitrite (12 mL, 1 M) via a syringe pump over 30 min. The reaction was stirred for 
4 h at room temperature at which point methylamine (40% in H2O, 0.9 mL) was added and the 
reaction was stirred for 10 min. The reaction was then acidified with 1 M HCl (until the pH 
reached 2.5) and product was extracted with EtOAc (3 × 50 mL). The organic layer was dried 
with MgSO4, filtered, and the filtrate was concentrated via rotary evaporation. To the yellow 
liquid was added 60% aqueous MeCN/0.1% TFA (2 mL) and this solution was lyophilized to 
yield 3.2 (1.02 g, 73% yield) as a yellow oil.41 See also Notebook XIII, Page 48. Characterization 
data matched that previously reported.42 
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H2N
OH
O
Br
NaNO2, 
4:1 H2O:AcOH
93%
HO
OH
O
Br
3.3 3.4  
Synthetic design of HO-Phe(3Br)-OH (3.4) 
HO-Phe(3Br)-OH (3.4). 
 Into a 250 mL round-bottomed flask was placed 3.3 (0.8 g, 3.4 mmol) dissolved in 32 mL 
of 4:1 H2O:AcOH and the flask was added to a 0 ºC icebath. To this mixture was slowly added 
sodium nitrite (6.6 mL, 1 M) via a syringe pump over 30 min. The reaction was stirred for 4 h at 
room temperature at which point methylamine (40% in H2O, 0.5 mL) was added and the reaction 
was stirred for 10 min. The reaction was then acidified with 1 M HCl (until the pH reached 2.5) 
and product was extracted with EtOAc (3 × 50 mL). The organic layer was dried with MgSO4, 
filtered, and the filtrate was concentrated via rotary evaporation. To the orange liquid was added 
60% aqueous MeCN/0.1% TFA (2 mL), which was lyophilized to yield 3.4 (750 mg, 93% yield) 
as an orange oil. See also Notebook XIII, Page 47.41 
 
1H NMR: (499.434 MHz, CD3OD) δ=2.90 (dd, J = 14.0, 8.0 Hz, 1H, CH2), 3.09 (dd, J = 14.0, 
4.0 Hz, 1H, CH2) 4.35 (m, 1H, CH), 7.16 (m, 1H, CHphenyl) 7.22 (m, 1H, CHphenyl), 7.33 (dt, J = 
10.0, 1.8 Hz, 1H, CHphenyl), 7.43 (t, J = 2.5 Hz, 1H, CHphenyl). 
13C NMR: (499.434 MHz, CD3OD) δ = 39.9, 71.2, 122.0, 128.3, 129.5, 129.8, 132.5, 140.4, 
175.7. 
HRMS  [M+Na] + C9H9BrNaO3+ calc’d = 266.9632, found = 266.9642. 
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3.5 3.6  
Synthetic design of HO-Tyr(propargyl)-OH (3.6) 
 
N
H
OH
O
OH
H2N
OH
O
OH
Boc
+ Boc2O
NaOH,
Dioxane/H2O
Quantitative
3.5a
 
Boc-Tyr-OH (3.5a). 
Into a 500 mL round-bottomed flask was placed L-tyrosine (4.0 g, 22.0 mmol, 1 equiv) 
dissolved in dioxane:H2O (2:1, 150 mL). To this solution was added aqueous NaOH (1 M, 50 
mL) and Boc2O (5.28 g, 24.2 mmol, 1.1 equiv) sequentially. The reaction was stirred at room 
temperature for 3 h, acidified to pH 2.3 with 5 M HCl, and product was extracted with EtOAc (3 
× 50 mL). The organic layer was washed with sat. aqueous NaCl (50 mL), dried with MgSO4, 
and concentrated via rotary evaporation yielding 3.5a (6.18 g, quantitative) as a crystalline white 
solid. Characterization data matched that previously reported.43 See also Notebook XIII, Page 22.  
 
 
 
 98 
N
H
OH
O
OH
1) Propargyl Bromide,
K2CO3
2) Acetyl chloride,
MeOH H2N
O
O
O
Boc
3.5a 3.5b
 
H-Tyr(propargyl)-O-propargyl (3.5b). 
 Into a 250 mL round-bottomed flask was placed 3.5a (6.2 g, 22.1 mmol, 1 equiv) and 
K2CO3 (9.16 g, 66.3 mmol, 3.0 equiv) suspended in anhydrous DMF (37 mL). The flask was 
cooled in a 0 ºC ice bath and propargyl bromide (7.89 g, 5.03 mL, 66.3 mmol, 3 equiv) was 
added dropwise. The reaction was warmed to room temperature and stirred for 20 h. At this time, 
H2O (150 mL) was added and the aqueous layer was extracted with Et2O (3 × 100 mL). The 
organic layer was washed with H2O (100 mL) and sat. aqueous NaCl (2 × 100 mL), dried with 
MgSO4, and concentrated by rotary evaporation yielding a yellow-orange oil. Characterization 
data matched that previously reported.44 
 Into a separate 250 mL round-bottomed flask containing anhydrous MeOH (74.6 mL) at 
0 ºC was slowly added acetyl chloride (9.54 g, 8.64 mL, 121.6 mmol). This solution was added 
to the oil isolated above, warmed to room temperature, and stirred for 16 h. All volatile 
components were removed on a vacuum line yielding 3.5b, which was immediately used in the 
subsequent step. See also Notebook XIII, Page 72. 
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NaOH, H2O
MeOH
62% over 3 steps
H2N
OH
O
O
3.5
H2N
O
O
O
3.5b
 
H-Tyr(propargyl)-OH (3.5). 
 Into a 250 mL round-bottomed was placed intermediate 3.5b dissolved in MeOH (22 mL) 
followed by aqueous NaOH (2 M, 32 mL). The reaction was stirred at room temperature for 20 
h, acidified to pH 3.0 with concentrated HCl, and cooled at 4 ºC overnight. The following 
morning a tan precipitate had formed, which was filtered, washed with acidified cold H2O (pH 
3.0), and dried yielding 3.5 (3.0 g, 62% over 3 steps) as a tan solid. Characterization data 
matched that previously reported.44 See also Notebook XII, page 73. 
 
H2N
OH
O
O
NaNO2
4:1 H2O:AcOH
85%
HO
OH
O
O
3.5 3.6  
HO-Tyr(propargyl)-OH (3.6). 
Into a 250 mL round-bottomed flask was placed 3.5 (2.55 g, 10 mmol) dissolved in 100 
mL of 4:1 H2O:AcOH and the flask was added to a 0 ºC icebath. To this mixture was slowly 
added sodium nitrite (20 mL, 1 M) via a syringe pump over 30 min. The reaction was stirred for 
4 h at room temperature at which point methylamine (40% in H2O, 1.56 mL) was added and the 
reaction was stirred for 10 min. The reaction was then acidified with 1 M HCl (until the pH 
reached 2.5) and product was extracted with EtOAc (3 × 50 mL). The organic layer was dried 
with MgSO4, filtered, and the filtrate was concentrated via rotary evaporation. To the orange 
liquid was added 60% aqueous MeCN/0.1% TFA (2 mL), which was lyophilized to yield 3.6 
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(2.2 g, 85% yield) as an orange oil. Characterization data matched that previously reported.44 See 
also Notebook XIII, Page 77.  
 
3.4.3. Construction of plasmids for coexpression. 
DNA constructs were assembled by overlap extension PCR, followed either by digestion 
and ligation or Gibson Assembly of the PCR product into the appropriate plasmid. 
 
Overlap extension PCR. 
A 5’ gene fragment was amplified by PCR using Phusion High-Fidelity DNA polymerase 
from a template containing the sequence of interest using a forward primer with the desired 
restriction site and a reverse primer either incorporating the internal mutation or insertion or 
beginning at the first nucleotide immediately after the internal mutation or insertion. An 
overlapping 3’ gene fragment was amplified by PCR from the same template using a reverse 
primer with the desired restriction site and a forward primer incorporating the internal mutation. 
For primers used, see Table 3.1. Then, a PCR with the overlapping gene fragments and the 
primers with the desired restriction sites, was used to generate the full-length mutants; the 
overlapping gene fragments were first added to the PCR mixture and after 8 rounds of 
amplification the primers with the desired restriction sites were added. After digestion of the 
mutant gene fragment and the appropriate vector with the desired restriction enzymes, the PCR 
products containing point mutations, insertions, or deletions were ligated into the plasmid using 
T4 DNA ligase. Incorporation of the correct mutation into the plasmid DNA was confirmed by 
sequencing at ACGT, Inc. 
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General protocol for PCR. 
To a 0.2 mL PCR tube was added H2O (34 µL), buffer HF (10 µL, 5X stock solution, 
provided with Phusion High-Fidelity DNA polymerase), template (0.5 µL, 100 ng/µL), primers 
(1 µL each, 100 µM), DMSO (1 µL), dNTPs (1 µL, 10 mM), and Phusion High-Fidelity DNA 
polymerase (0.5 µL, 2,000 U/mL, NEB). The DNA template was amplified using the following 
protocol. The reaction was 1) heated to 95 ºC for 2 min; 2) heated at 95 ºC for 30 s; 3) heated at 
annealing temperature (see individual cases below) for 30 s; 4) heated at 72 ºC for the elongation 
time (see below); 5) steps 2-4 were repeated for 29 cycles; 6) heated at 72 ºC for 10 min. 
 
Construction of inserts for plasmids pRSFDuet(lctA(K1tag)/lctM/pylT) and 
pRSFDuet(lctA(A–1I/K1tag)/lctM/pylT). 
The lctA mutants were generated in MCS1 of a pRSFDuet vector with lctM in MCS2 
using pRSFDuet(lctAwt/lctM)16 as template by overlap extension PCR. The primers lctA EcoRI 
FMP 5’ and lctA(K1tag) FMP (or A–1I FMP) 3' were used to make the 5’ overlapping fragment 
and the primers lctA(K1tag) RMP (or A–1I RMP) 5' and lctA NotI RMP 3' were used to make the 
3’ overlapping fragment. The restriction sites were EcoRI and NotI. The annealing temperature 
was 60 oC with an elongation time of 20 s. After overlap extension PCR, the inserts were ligated 
into MCS1 of a pRSFDuet vector as described below. 
pylT was amplified by PCR from pEVOL(pylRS/pylT) using pylT AgeI 5’ and pylT DrdI 
3’ as primers and the product was digested using AgeI and DrdI. The gene fragment was then 
ligated into the lctA plasmids from above that had been treated with the same restriction enzymes 
generating pRSFDuet(lctA(K1tag)/lctM/pylT) and pRSFDuet(lctA(A–1I/K1tag)/lctM/pylT).  
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Construction of inserts for plasmids pRSFDuet(procA1.1(F1tag)/procM/pylT) and 
pRSFDuet(procA1.1(G–1I/F1tag)/procM/pylT). 
The procA1.1 mutants were generated in MCS1 of a pRSFDuet vector with procM in 
MCS2. The procA1.1 inserts were obtained by PCR overlap extension PCR using 
pET15b(procA1.1(G–1E))26 as template. The primers procA1.1 EcoRI FMP 5’ and 
procA1.1(F1tag) FMP (or G–1I FMP) 3' were used to make the 5’ overlapping fragment and the 
primers procA1.1(F1tag) RMP (or G–1I RMP) 5' and procA1.1 NotI RMP 3' were used to make 
the 3’ overlapping fragment. The restriction sites were EcoRI and NotI. The annealing 
temperature was 60 oC with an elongation time of 20 s. After overlap extension PCR, the inserts 
were ligated into MCS1 of a pRSFDuet vector as described below. 
 pylT was inserted into the pRSFDuet vectors exactly as described for the lctA mutants. 
 
Construction of insert for plasmid pRSFDuet(procA1.6(G–1I/K1tag)/procM/pylT). 
 The procA1.6 mutant was generated in MCS1 of a pRSFDuet vector with procM in 
MCS2. The procA1.6 insert was obtained by overlap extension PCR using pET15b(procA1.6(G–
1R)) (unpublished work from our laboratory) as template. The primers procA1.6 EcoRI FMP 5’ 
and procA1.6(G–1I/K1tag) FMP 3' were used to make the 5’ overlapping fragment and the 
primers procA1.6(G–1I/K1tag) RMP 5' and procA1.6 NotI RMP 3' were used to make the 3’ 
overlapping fragment. The restriction sites were EcoRI and NotI. The annealing temperature was 
60 oC with an elongation time of 20 s. After overlap extension PCR, the insert was ligated into 
MCS1 of a pRSFDuet vector as described below. 
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Construction of inserts for plasmids pRSFDuet(lctNukA)/lctM/pylT) and 
pRSFDuet(lctNukA(A–1I/K1tag)/lctM/pylT). 
 lctNukA was amplified by PCR from pET15b(lctNukA)24 using lctNukA Gibson 5’ and 
lctNukA Gibson 3’ as primers. The gene fragment was then ligated by Gibson Assembly into 
MCSI of pRSFDuet(lctA(K1tag)/lctM/pylT), which had been treated with EcoRI and NotI, 
producing pRSFDuet(lctNukA)/lctM/pylT). The annealing temperature was 58 oC with an 
elongation time of 20 s. 
 The lctNukA(A–1I/K1tag) mutant was generated using pET15b(lctNukA) as template by 
overlap extension PCR and ligated into MCS1 of pRSFDuet(lctA(K1tag)/lctM/pylT) by Gibson 
Assembly. The primers lctNukA Gibson 5’ and lctNukA(A–1I/K1tag) FMP 3' were used to make 
the 5’ overlapping fragment and the primers lctNukA(A–1I/K1tag) RMP 5' and lctNukA Gibson 
3' were used to make the 3’ overlapping fragment. The parent plasmid was treated with EcoRI 
and NotI. The annealing temperature was 58 oC with an elongation time of 20 s. 
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Table 3.1. Primers used in molecular cloning. 
lctA EcoRI FMP 5’: CCT CTG GCG GAT CCG AAT TCG ATG AAA TGA AAG AAC AAA AC 
lctA(K1tag) FMP 3’: CTT ATT TTA GGT GCA TAG GGC GGC AGT GGA GTT 
lctA(K1tag) RMP 5’:   AAC TCC ACT GCC GCC CTA TGC ACC TAA AAT AAG 
lctA(A–1I/K1tag FMP 3’: TCC ACT GCC GCC CTA AAT ACC TAA AAT AAG G 
lctA(A–1I/K1tag RMP 5’: CCT TAT TTT AGG TAT TTA GGG CGG CAG TGG A 
lctA NotI RMP 3’:  CGG TTA AAG CGG CCG CTT AAG AGC AGC AAG TAA ATA C 
  
procA1.1 EcoRI FMP 5’: GGT GAG TGG AAT TCG ATG AAA AAG CGA CTC AAC 
procA1.1(G–1I/F1tag) FMP 3’: CTG CAC ACA GAA CTA AAT CCC AGC CAC ACC T 
procA1.1(G–1I/F1tag) RMP 5’: AGG TGT GGC TGG GAT TTA GTT CTG TGT GCA G 
procA1.1 NotI RMP 3’: AAT AAA TAT GCG GCC GCT CAG CAC ACA TTG ATA GT 
  
procA1.6 EcoRI FMP 5’: GGT GAG TGG AAT TCG ATG ATG TCA GAA GAA CAA CTC 
procA1.6(K1tag) FMP 3’: CAT CCA TTA GTA GAC TAA CCG CCA GCT ACA CCT TC 
procA1.6(K1tag) RMP 5’: GAA GGT GTA GCT GGC GGT TAG TCT ACT AAT GGA TG 
procA1.6(G–1I/K1tag) FMP 3’: CAT CCA TTA GTA GAC TAA ATG CCA GCT ACA CCT TC 
procA1.6(G–1I/K1tag) RMP 5’: GAA GGT GTA GCT GGC ATT TAG TCT ACT AAT GGA TG 
procA1.6 NotI RMP 3’: AAT AAA TAT GCG GCC GCT CAC AGC CAA CAC TCT AG 
  
pylT AgeI 5’: GAG TAT GAA CCG GTT GTG CTT CTC AAA TGC CTG A 
pylT DrdI 3’: GTA CTG AGA GAC AGT CTA GTC CAT GCA AAA AAG CCT GCT C 
  
lctNukA Gibson 5’ 
CAC AGC CAC AGC CAG GAT CCG ATG AAA GAA CAA AAC TCT 
TTT AAT C 
lctNukA Gibson 3’ 
CGA CTT AAG CAT TAT GCT TAT GAA CAA CAA GTA AAT ACA 
AAT TG 
lctNukA(A–1I/K1tag) FMP 3’ GAT TAC TCC TGA CTT TTT CTA AAT ACC TAA AAT AAG GTC C 
lctNukA(A–1I/K1tag) RMP 5’ GGA CCT TAT TTT AGG TAT TTA GAA AAA GTC AGG AGT AAT C 
 
Digestion of plasmids and DNA inserts. 
To a 1.7 mL Eppendorf tube with insert or plasmid DNA (40 µL, 100-250 ng/µL) was 
added digestion buffer (5 µL; NEB, provided with the restriction enzymes), digestion enzyme(s) 
(1.5 µL, concentrations are below), BSA (if necessary, 0.5 µL, 100X, provided with digestion 
enzyme), and H2O (to 50 µL). The components were incubated at 37 oC for 2-4 h. At this time 
calf intestine phosphatase (CIP) (1 µL) was added to plasmid DNA only and the sample was 
incubated for an additional 1 h. The samples were then analyzed by DNA gel electrophoresis and 
the desired band was purified by a QIAGEN Gel Extraction kit eluting in buffer EB (30 µL). 
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Note: Both digestion enzymes were added in one single digest if the buffer was compatible. If 
buffer was not compatible, two successive digests were performed. 
NotI = 10,000 U/mL, EcoRI = 20,000 U/mL, AgeI = 5000 U/mL, DrdI = 5000 U/mL, CIP = 
10,000 U/mL. 
 
Ligation of digested plasmid and DNA insert. 
To three 0.6 mL Eppendorf tubes was added plasmid DNA (1 µL, 100 ng/µL). Insert 
DNA (1 µL of a solution of different concentrations to give a ratio of plasmid to insert of 1:1, 
1:10 and 1:100) was then added as well as T4 DNA ligase reaction buffer (0.7 µL, provided with 
the ligation enzyme), T4 DNA ligase (0.8 µL, 400,000 cohesive end U/mL), and H2O (to 5 µL). 
The samples were incubated at 18 oC for 16-20 h at which time the entire reactions were used to 
transform E. coli DH5α cells. 
 
Gibson Assembly. 
 To a 0.6 mL Eppendorf tube was added plasmid DNA (1 µL, 25 ng/µL), insert DNA 
(equal mol amount), Gibson Assembly Mastermix (2.5 µL, NEB), and H2O (to 5 µL). The 
samples were incubated at 18 ºC for 1 h at which time the entire reaction was used to transform 
E. coli DH5α cells. 
 
3.4.4. Heterologous production, purification, and characterization of LanA analogues. 
The lanthipeptides were expressed using E. coli BL21 (DE3) cells transformed with a 
pRSFDuet plasmid containing the lanA, lanM, and pylT genes and a pEVOL plasmid containing 
the pylRS (2 copies of either wt or N346A/C348A mutant) and pylT genes. For production of Δ1-
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lacticin 481 and Δ1-3-nukacin ISK1 only the pRSFDuet plasmid was used because non-
canonical amino or hydroxy acid was not incorporated. All coexpression cultures were incubated 
at 18 ºC ON after induction with IPTG except for the coexpression cultures in which 3.1-3.6 
were incorporated into LctA, which were incubated at 37 ºC for 4 h after induction. Composition 
of 1 L enriched LB: 35 g tryptone, 20 g yeast extract, 5 g NaCl. Composition of 25 mL minimal 
media with supplements: 5X minimal media (5 mL), glycerol (20%, 1.25 mL, 1% final 
concentration), MgSO4 (1 M, 50 µL), CaCl2 (1 M, 2.5 µL), NaCl (20%, 250 µL), all amino acid 
solution except Phe, Tyr, and Cys (5 mg/mL, 1 mL), and H2O (to 25 mL). 
 
Overexpression and purification of His6-tagged modified peptide mutants. 
An overnight culture of E. coli BL21 (DE3) cells was added to a culture flask containing 
either enriched LB (35 g tryptone, 20 g yeast extract, 5 g NaCl), LB broth, or minimal media 
(1:100; volume overnight culture: volume overexpression culture for rich media; 1:20 for 
minimal media) and appropriate antibiotics depending on the plasmids used (1:1000 v:v; 
kanamycin (50 mg/mL), chloramphenicol (25 mg/mL)). The culture was then incubated in a 37 
ºC shaker (220 rpm) until the optical density reached 1.0 (enriched LB), 0.6 (LB) or 0.3 (minimal 
media). For LctA and LctNukA, overexpression was immediately induced with arabinose (0.2% 
final concentration) and isopropyl β-D-1-thiogalactopyranoside (IPTG, 0.25 mM final 
concentration) in the presence of non-proteinogenic amino or hydroxy acid (2 mM final 
concentration) and the flask was incubated for 4 h in a shaker at 37 ºC and 220 rpm. Conversely, 
for ProcA1.1 and ProcA1.6, the culture was first placed on ice (5 min) to cool to around 30 ºC. 
Overexpression was then induced by the addition of arabinose and IPTG in the presence of non-
proteinogenic amino or hydroxy acid and the flask was incubated overnight in a shaker at 30 ºC 
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and 220 rpm. The following morning the cells were harvested by centrifugation (11,867 ×g, 4 ºC, 
20 min), the supernatant was discarded and the cells were lysed using a cell homogenizer 
(Avestin Emulsiflex-C3; 5,000 PSI) in LanA start buffer (2 mL per 100 mL culture; 20 mM 
NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol, pH 7.5). The soluble and insoluble 
layers were then separated by centrifugation (22,789 ×g, 4 oC, 20 min) and the soluble layer was 
saved for purification. The insoluble layer was suspended in LanA lysis buffer (1 mL per 100 
mL culture; 6 M guanidine HCl, 20 mM NaH2PO4, pH 7.5, 500 mM NaCl, 0.5 mM imidazole) 
and the suspension was sonicated. The soluble and insoluble layers were again separated by 
centrifugation (22,789 ×g, 4 oC, 20 min) and the modified His6-LanA peptide was purified from 
the combined soluble layers using a Ni HisTrap HP column (5 mL, GE Healthcare). The column 
was washed with LanA wash buffer (4 M guanidine-HCl, 20 mM NaH2PO4, pH 7.5, 500 mM 
NaCl, 30 mM imidazole) to remove non-specific binding proteins. The His6-LanA peptide was 
eluted with LanA elute buffer (3 × 5 mL, 20 mM NaH2PO4, 100 mM NaCl, 500 mM imidazole, 
pH 7.5). Finally, the peptide was further purified by preparative reversed phase high-
performance liquid chromatography (RP-HPLC) and lyophilized. 
 
GluC cleavage of LctA(K1tag) and LctA(A–1/K1tag) incorporating 3.1, 3.3, or 3.5. 
To lyophilized peptide was added HEPES buffer (500 µL, pH 7.5, 50 mM final 
concentration) and GluC (1 µL, 2 mg/mL). The reaction was incubated for 2 h at 37 ºC. The 
reaction was analyzed by MALDI-TOF MS. 
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Boc removal of LctA(A–1I) and nukacin ISK-1 incorporating 3.2. 
To RP-HPLC purified and lyophilized peptide was added aqueous 5% TFA (2 mL). The 
reaction was incubated for 4 h at 50 ºC. The peptidic solution was then concentrated by purging 
with a nitrogen stream and used in the alkaline hydrolysis reaction without further purification. 
 
Alkaline hydrolysis of 3.2-,  3.4-, and 3.6-LctA(A–1I) and 3.2-nukacin ISK-1. 
 To the concentrated peptide solution from the Boc-removal reaction or RP-HPLC 
purified and lyophilized peptide, was added CAPS buffer (4 mL, 250 mM, pH 10.5) and 1 M 
NaOH (until pH reached 10.5). The reaction was incubated for 2 h at 37 ºC and purified by 
preparative RP-HPLC on a C18 column (solvent A = 0.1% TFA in H2O; solvent B = 80% 
acetonitrile in H2O, 0.086% TFA). Fractions containing product were collected and lyophilized. 
 
Isolation of authentic lacticin 481.  
Lactococcus lactis subsp. lactis CNRZ 481 was grown for 9 h at 30 ºC in EG’P media 
(1.74 L, Elliker broth medium without gelatin) supplemented with sodium β-glycerophosphate 
(26.1 g, (15 g/L)) maintaining the culture pH at 5.5 by adding aliquots of 3 M ammonium 
hydroxide every hour. After 9 h the pH was again adjusted to 5.5 and cells were removed by 
centrifugation (11,900 × g, 20 min). The culture supernatant was heat-treated (80 ºC, 1 h) to 
deactivate proteases, cooled to 4 ºC, and the lantibiotic was concentrated with an ammonium 
sulfate precipitation step, saturating the solution at 60% at 4 oC (649.4 g of ammonium sulfate 
into 1.74 L culture supernatant). The sample was vigorously stirred for 4 h and then centrifuged 
(17,100 × g, 45 min, 4 ºC). After resuspension of the pellet in Sorensen buffer (20 mL, 176 mM 
NaH2PO4, 24 mM Na2HPO4, pH 6.0), lacticin 481 was further purified by solid phase extraction 
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using a Vydac 214SPE3000 C4 column, with 20 mM ammonium acetate and MeCN as eluting 
solvents. After addition of the lantibiotic solution, the column was washed with 20 mM 
ammonium acetate and 20 mM ammonium acetate with 30% MeCN. Peptide was then eluted 
with 20 mM ammonium acetate with 40% MeCN. The fraction containing product was 
concentrated by lyophilization and further purified by analytical RP-HPLC (Grace Vydac C18 
column (214TP54)) using a gradient from 30-40% MeCN in 20 mM ammonium acetate, pH 5.5, 
over 30 min. The combined fractions were lyophilized yielding 6 mg of impure lacticin 481. 
 
RP-HPLC purification of lacticin 481 isolated from L. lactis subsp. lactis 481. 
 To the lyophilized impure lacticin 481 (2 mg) from above was added H2O (4 mL) and the 
peptide was purified by preparative RP-HPLC on a C18 column (solvent A = 0.1% TFA in H2O; 
solvent B = 80% acetonitrile in H2O, 0.086% TFA). Product eluted from 26.5-27.0 min yielding 
300 µg of pure lacticin 481. This peptide was then used for MIC studies.    
 
Purification and yield of LanA analogues produced in large scale. 
His6-LctA. RP-HPLC: Rt = 29.0-34.0 min (C4, Waters Delta-pak™). 
3.2-LctA(A–1I). RP-HPLC: Rt = 32.7-35.7 min (C4, Waters Delta-pak™). 
3.4-LctA(A–1I). RP-HPLC: Rt = 34.0-37.0 min (C4, Waters Delta-pak™). 
3.6-LctA(A–1I). RP-HPLC: Rt = 31.0-36.0 min (C4, Waters Delta-pak™). 
His6-LctNukA. RP-HPLC: Rt = 28.0-33.0 min (C4, Waters Delta-pak™). 
3.2-NukLctA (A–1I). RP-HPLC: Rt = 28.0-35.0 min (C4, Waters Delta-pak™). 
Δ1-lacticin 481. Yield: 0.16 mg/L culture; RP-HPLC: Rt = 27.9-28.3 min (C18, Phenomenex). 
HO-lacticin 481. Yield: 0.10 mg/L culture; RP-HPLC: Rt = 27.2-28.2 min (C18, Phenomenex). 
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3.4-HO-lacticin 481. Yield: 0.04 mg/L culture; RP-HPLC: Rt = 31.8-32.3 min (C18, 
Phenomenex). 
3.6-HO-lacticin 481. Yield: 0.045 mg/L culture; RP-HPLC: Rt = 30.4-31.0 min (C18, 
Phenomenex). 
Δ1-3-nukacin ISK-1. Yield: 0.07 mg/L culture; RP-HPLC: Rt = 24.9-25.4 min (C18, 
Phenomenex) 
HO-nukacin ISK-1. Yield: 0.05 mg/L culture; RP-HPLC: Rt = 22.8-23.4 min (C18, 
Phenomenex) 
 
Minimum inhibitory concentration determination. 
Ninety six-well microtiter plates (Corning Costar) were utilized for anaerobic cultures. Each well 
contained 90 µL of an overnight culture containing L. lactis HP (approximately 1×108 CFU    
mL-1) and a 10x stock of peptide (10 µL) of the desired concentration. The plates were incubated 
at 30 ºC overnight with no agitation. In addition, each plate contained several blank (growth 
media with no bacteria) and control (SDW in place of peptide) wells. The optical density at 600 
nm (OD600) was recorded at hourly intervals from 0-8 h for nukacin ISK-1 analogues and after 
16 h for lacticin 481 analogues. The MIC was determined as the lowest concentration at which 
no cell growth was observed after 16-18 h. 
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Chapter 4: A General Method for Fluorescent Labeling of the N-termini of 
Lanthipeptides and Its Application to Visualize their Cellular Localization 
Reprinted (adapted) with permission from Bindman and van der Donk, J. Am. Chem. Soc., 2013, 
135 (28), 10362-10371. Copyright © (2013) American Chemical Society.1 
 
4.1. INTRODUCTION 
Currently, the mode(s) of action of only a small subset of lantibiotics has been deduced, 
including the best studied family member nisin. Labeling of natural products with biophysical probes has 
aided investigations of their modes of action and has provided tools for visualization of their targets. For instance, 
fluorescent microscopy studies with fluorescently labeled nisin has greatly contributed to 
understanding its mechanism of action.2 Site-specific labeling of nisin was possible because it 
contains only a single carboxylate (the C-terminus). However, for most 
lantibiotics/lanthipeptides, no such chemoselective handle for convenient modification is 
available because they contain multiple reactive groups, and hence to date, biophysical labeling 
studies of lanthipeptides have been limited. For instance, labeling of the lanthipeptides 
duramycin and nukacin ISK-1 with amine-reactive probes resulted in labeling of at least two 
positions.3,4 Similarly, most lanthipeptides contain multiple dehydroamino acids, and therefore 
the use of Michael-type additions to introduce biophysical probes5 would also result in multiple 
sites of labeling. In recent years, complete chemical synthesis of lantibiotics on a solid support 
has been reported6-8 and could potentially be a viable route to lanthipeptides carrying biophysical 
probes, but such an application has not been reported to date and would not be a source of 
renewable materials. Therefore, development of a general means to label lantibiotics while only 
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minimally affecting their bioactivities would aid the investigation of this large and promising 
class of compounds.9,10    
One approach that might allow site specific labeling of either the N- or C-termini of 
lanthipeptides involves removal of any Lys, or Asp and Glu residues. Indeed, because of their 
ribosomal origin, site directed mutagenesis has been applied extensively to lanthipeptides and 
generally (but not always) does not affect the posttranslational modification process.11-14 
Unfortunately, Lys and Asp/Glu residues have been shown to be very important for the activities 
of many lantibiotics,15-23 rendering this approach ineffective for most applications. 
Many site-specific peptide- and protein-labeling techniques have emerged in recent years 
that use either chemical or enzymatic methods to introduce chemical handles for derivatization.24 
For most enzymatic approaches, a peptide tag is incorporated into a protein or peptide of interest 
at the gene level.25-29 Through site-specific enzymatic modification of the tag, a reactive 
chemical functionality is introduced that may be used for a ‘bioorthogonal’ conjugation with a 
reporter molecule carrying a suitable complementary functionality. The termini of peptides and 
proteins have been particularly attractive for the incorporation of chemical probes because it 
generally minimizes undesired effects of the probe on function.30-34 Many of these labeling 
strategies have incorporated a ketone or aldehyde into a peptide or protein of interest followed by 
bioconjugation with an aminooxy-, hydrazine-, or alkoxyamine-containing biophysical 
probe.25,35-37 These reactions are chemoselective with respect to most peptides and proteins 
because the twenty canonical amino acids do not contain reactive carbonyl groups. However, 
introduction of a peptide tag at the N- or C-terminus of a lanthipeptide is still a considerable 
perturbation in structure because lanthipeptides are typically only 20-25 amino acids in length. 
Interestingly, an N-terminal ketone (2-oxobutyryl or pyruvyl) is a naturally occurring post-
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translational modification in some lanthipeptides, including Pep5,38 plantaracin-W β,39 and 
prochlorosin 1.7 (Pcn1.7; Figure 4.1).40 The N-terminal ketone arises from a dehydrated Ser/Thr 
at position 1 of the core peptide. After proteolytic removal of the leader peptide, the N-terminal 
dehydro amino acid hydrolyzes to an α-ketoamide (Scheme 4.1). We hypothesized that such a 
ketone handle could be used to site-specifically label this subset of lanthipeptides with minimal 
perturbation, and that a similar approach might be used for the installation of a 2-oxobutyryl 
group onto the N-termini of lanthipeptides that naturally lack this functionality. We demonstrate 
here that this methodology is successful for prochlorosins 1.7 and 2.8, nisin, lacticin 481, 
haloduracin α, and haloduracin β (for structures, see Figures 4.1 & 4.2). The resulting ketones of 
the latter three compounds were conjugated to a fluorescent probe, and the distribution of the 
fluorescent lantibiotic analogues in bacteria was visualized by confocal fluorescence microscopy. 
 
Figure 4.1. Biosynthesis of Pcn1.7 with its naturally occurring N-terminal 2-oxobutyryl group 
(red). For the sequence of the leader peptide, see Figure 4.4. Scheme adapted from Bindman and 
van der Donk.1 
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Scheme 4.1. Proposed installation of an N-terminal 2-oxobutyryl group. Dehydration of a Thr at 
the N-terminus of the core peptide followed by proteolysis yields the core peptide with an N-
terminal enamine. In aqueous conditions the enamine spontaneously converts to a 2-oxobutyryl 
group. Scheme adapted from Bindman and van der Donk.1 
 
 
Figure 4.2. Structures of the lanthipeptides Pcn2.8, lacticin 481, Halα, Halβ, and nisin. Scheme 
adapted from Bindman and van der Donk.1 
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4.2 RESULTS 
4.2.1. Installation of a ketone on the N-terminus of Pcn1.7. 
The proposed methodology requires solutions to two hurdles. The first is to successfully 
install a dehydroamino acid at the first amino acid of the core peptide, and the second is to site 
specifically remove the leader peptide through proteolysis after residue –1. We first investigated 
the site-specific labeling of a lanthipeptide with a naturally occurring N-terminal 2-oxobutyryl 
group for which the first hurdle is already solved in nature. We chose Pcn1.7 (Figure 4.1) 
because it has been produced by coexpression of the precursor peptide ProcA1.7 with the 
lanthionine synthetase ProcM in Escherichia coli,41 and because biophysical labeling of 
prochlorosins may help in elucidating their biological functions, which at present are unknown.40 
The second hurdle, site-specific removal of the leader peptide in vitro, is challenging for Pcn1.7. 
As mentioned in Chapter 2, the cognate proteases that remove the leader peptides in 
lanthipeptide-producing bacteria are not a general solution for in vitro removal of leader 
peptides. Instead, incorporation of Lys or Glu at the –1 position, followed by treatment with 
endoproteases trypsin, LysC, or GluC, has been often used.42-45 
For Pcn1.7, leader peptide removal by inserting a Lys at position –1 and treatment of the 
ProcM-modified ProcA1.7 mutant with LysC was unsuccessful in previous work as cleavage at a 
Lys in the core peptide was observed.41 An alternative approach was therefore used in this study, 
involving mutation of the last residue of the ProcA1.7 leader peptide from Gly to Glu.40 The 
gene encoding His6-ProcA1.7(G–1E) was inserted into multiple cloning site 1 (MCS1) of a 
pRSFDuet plasmid in which the gene encoding the modification enzyme ProcM was inserted in 
MCS2. Coexpression in E. coli resulted in the desired five-fold dehydrated His6-ProcA1.7(G–
1E). After GluC cleavage, the major ion observed by matrix-assisted laser desorption ionization 
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time-of-flight mass spectrometry (MALDI-TOF MS) corresponded to a peptide that still showed 
the loss of five water molecules, indicating no proteolysis occurred following Glu12, likely 
because the residue was deactivated by the overlapping ring system in Pcn1.7. Unfortunately, the 
GluC-cleaved peptide had been proteolyzed after Glu–6 in the leader peptide, rather than after 
Glu–1, resulting in Pcn1.7 with a five amino acid overhang (Figure 4.3, left). We next mutated 
Thr1 to Ser in an attempt to decrease the steric bulk around the cleavage site. The mutant peptide 
His6-ProcA1.7(G–1E/T1S) was coexpressed with the modification enzyme ProcM, and the 
resulting product, as analyzed by MALDI-TOF MS, was dehydrated 5 times. However, 
proteolysis with GluC still resulted in cleavage after Glu–6 with very little cleavage after Glu–1 
(Figure 4.3, right). This reluctance of a protease to cleave next to a posttranslationally modified 
amino acid (Dhb1 for Pcn1.7), and therefore prefer alternative cleavage sites in the leader 
peptide, is a common observation41,45,46 that hampers the generality of the proposed 
methodology. Similar difficulties were also observed with use of a larger recognition sequence 
such as the IleGluGlyArg motif that is recognized by Factor Xa.45 
 
Figure 4.3. MALDI-TOF mass spectra of GluC-cleaved ProcA1.7 mutants failing to yield 
Pcn1.7. Left, GluC-cleaved and ProcM-modified His6-ProcA1.7(G–1E). Right, GluC-cleaved 
and ProcM-modified His6-ProcA1.7(G–1E/T1S). [M+H]+ corresponds to proteolysis after Glu–6. 
GluC-cleaved (G–1E) [M+H]+ calc’d = 2579.3 Da.; GluC-cleaved (G–1E/T1S) [M+H]+ calc’d = 
2565.3 Da. 
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To overcome these obstacles, we envisioned a two-stage leader peptide removal strategy 
in which most of the leader peptide is initially removed by trypsin, GluC, or LysC, and an 
aminopeptidase is used subsequently to remove the remaining amino acids of the leader peptide. 
Aminopeptidase activity was expected to self-terminate after reaching the first dehydrated amino 
acid (Dha1 or Dhb1) assuming that the conversion of the N-terminal enamine to an α-ketoamide 
(Scheme 4.1) occurs faster than aminopeptidase-catalyzed hydrolysis. The use of an 
aminopeptidase in lanthipeptide cleavage reactions has been employed previously to remove the 
NisA leader peptide from various core peptides and to study how the N-terminal lactate in 
epilancin 15X protects the peptide from degradation.47,48 The last two amino acids of the leader 
peptide of many lanthipeptides consist of the “double-glycine” motif,49 which poses a problem 
because commercial Leu-selective aminopeptidase from Aeromonas proteolytica is not very 
effective at removing this sequence.48 Thus, two new mutants, His6-ProcA1.7(G–2A/G–1A) and 
His6-ProcA1.7(G–2L/G–1L) (Figure 4.4), were generated. Coexpression of these double mutants 
with ProcM resulted in five-fold dehydrated ProcA peptides, demonstrating that neither the two 
Ala nor Leu residues interfered with posttranslational processing. The peptides were purified by 
immobilized metal affinity chromatography (IMAC) and RP-HPLC resulting in a typical yield of 
about 8 mg/L of purified product. The double Ala mutant peptide was then treated with GluC 
first (cleaves after Glu –6) and then aminopeptidase (Figure 4.5, left). The product was analyzed 
by MALDI-TOF MS and the aminopeptidase was found to remove residues GVAA but did not 
hydrolyze Ala–1, generating Pcn1.7 with an Ala overhang (Ala-Pcn1.7). The double Leu mutant 
was then successively treated with GluC and aminopeptidase and analyzed by MALDI-TOF MS. 
The product mass was found to be identical to the anticipated mass of Pcn1.7 without a leader 
peptide overhang signifying the removal of GVALL by the aminopeptidase (Figure 4.5, right). 
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ProcA1.7(–68)-(–20)QANSQKNLSDAELEGVALLTIGGTIVSITCETCDLLVGKMC 
ProcA2.8(–64)-(–20)LNSHRQNLSDDELEGVAGKTACHNHAPSMPPSYWEGEC 
LctA(–24)-(–15)QEVTESELDLILGAKAAALLKTAGSGVIHTISHECNMNSWQFVFTCCS 
HalA1(–41)-(–20)GDIFQELEDQDILAGVNGETCAWYNISCRLGNKGAYCTLTVECMPSCN 
HalA2(–41)-(–20)EVNEKELSSLAGSGDVHAETATTWPCATVGVSVALCPTTKCTSQC 
NisA(–23)-(–15)LVSVSKKDSGASPRLTSISLCTPGCKTGALMGCNMKTATCHCSIHVSK 
 
Figure 4.4. Optimized peptide sequences that yield lanthipeptides with an N-terminal 2-
oxobutyryl group. Native core peptides are underlined. Red, inserted Thr; blue, protease cleavage 
site; green, aminopeptidase cleavage sequence; brown, other amino acid insertions or mutations 
(see text). The Thr at the N-terminus of the core peptides ProcA1.7 and nisin are naturally 
occurring. The leader peptide segments that are not shown in the figure are: ProcA1.7(–
68)MSEEQLKAFIAKVQADTSLQEQLKVEGADVVAIAKASGFAITTEDLKAH(-20), 
ProcA2.8(–64)MSEEQLKAFLTKVQADTSLQEQLKIEGADVVAIAKAAGFSITTED(–20), 
LctA(–24)MKEQNSFNLL(–15), HalA1(–41)MTNLLKEWKMPLERTHNNSNPA(–20),  
HalA2(–41)MVNSKDLRNPEFRKAQGLQFVD(–20), and NisA(–23)MSTKDFNLD(–15). Figure 
adapted from Bindman and van der Donk.1 
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Figure 4.5. MALDI-TOF mass spectra of GluC-cleaved ProcA1.7 analogues yielding Ala-
Pcn1.7 and Pcn1.7. Left, GluC-cleaved and ProcM-modified His6-ProcA1.7(G–2A/G–1A) 
before (red) ([M+H]+ calc’d = 2536.3 Da) and after (blue) ([M+H]+ calc’d = 2238.1 Da.) 
treatment with aminopeptidase. Right, GluC-cleaved His6-ProcA1.7(G–2L/G–1L) before (red) 
([M+H]+ calc’d = 2620.3 Da.) and after (blue) ([M+H]+ calc’d = 2168.1 Da ) treatment with 
aminopeptidase. 
  
The successful conversion of the N-terminal dehydro amino acid to an α-ketoamide was 
demonstrated in two ways. In the first method the orthogonal reactivity of the ketone was 
exploited by reacting GluC- and aminopeptidase-cleaved ProcA1.7(G–2L/G–1L) with 1,2-
phenylenediamine followed by analysis by MALDI-TOF MS (Figure 4.6). Although this 
reaction should produce Δ1-Pcn1.7 as the sole product, peaks corresponding to Δ1-2- and Δ1-3-
Pcn1.7 were also present because the aminopeptidase was not removed prior to addition of 1,2-
phenylenediamine and, after reaction with 1,2-phenylenediamine, the N-terminal ketone was no 
longer present to stall aminopeptidase activity. The phenylenediamine assay was necessary 
because detection of the mass difference between an N-terminal ketone and dehydrated amino 
acid (ketone is 1 Da larger) was not possible using the available MALDI-TOF instrument. 
However, a more sensitive MALDI-TOF instrument (Bruker Ultraflex) recently became 
available. Using this new instrument, the exact mass (0.1 Da error) of the GluC- and 
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aminopeptidase-cleaved His6-ProcA1.7(G–2L/G–1L) peptide was determined. This product mass 
was found to be identical to the anticipated mass of Pcn1.7 with an N-terminal ketone (Figure 
4.7, red). 
 
 
Figure 4.6. Reaction between Pcn1.7 and 1,2-phenylenediamine promotes loss of 2-oxobutyryl 
group. Top, Schematic representation of the reaction between 1,2-phenylenediamine and Pcn1.7. 
Bottom, MALDI-TOF mass spectra of Pcn1.7 before (red) and after (blue) the addition of 1,2-
phenylenediamine in the presence of aminopeptidase. 
 
4.2.2. Synthesis of aminooxy-alkyne (4.1) and its use in a site-specific oxime bioconjugation 
with Pcn1.7. 
As a way to take advantage of the minimal cross-reactivity between the ketone 
functionality and the side chains of the proteinogenic amino acids, a bioconjugation reaction 
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specific for the N-terminal ketone of Pcn1.7 was attempted. Pcn1.7 was reacted with aminooxy-
linked alkyne (4.1), rather than a hydrazine-linked alkyne, because of the increased hydrolytic 
stability of the oxime compared to the hydrazone.50 Aminooxy-alkyne tag 4.1 was synthesized 
by first reacting propargyl bromide with N-hydroxyphthalimide in an SN2 displacement reaction, 
followed by removal of the phthalimide by methylhydrazine (Scheme 4.2). Acidification 
produced the HCl salt 4.1. The synthetic aminooxy alkyne was then reacted with RP-HPLC-
purified Pcn1.7 (Scheme 4.3). Analysis of the product by MALDI-TOF MS indicated that the 
alkyne-functionalized Pcn1.7 (alk-Pcn1.7) was indeed generated (Figure 4.7).  Addition of 
aniline (100 mM) to the buffered solution of peptide and 4.1 dramatically increased the product 
yield (Figure 4.7).51 When the bioconjugation was attempted with GluC-cleaved ProcA1.7(G–
1E), an analogue lacking the N-terminal ketone, no reaction occurred demonstrating that oxime 
formation was specific for the N-terminus of Pcn1.7 (Figure 4.8). 
 
 
Figure 4.7. MALDI-TOF mass spectra of the products of the reaction between Pcn1.7 and 
aminooxy alkyne (4.1). Reaction was attempted with (blue) and without (red) the addition of 
aniline (100 mM). Pcn1.7 [M+H]+ calc’d = 2168.1 Da.; Alk-Pcn1.7 [M+H]+ calc’d = 2221.1 Da. 
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Scheme 4.2. Synthetic scheme towards aminooxy alkyne 4.1. 
 
 
Scheme 4.3. Production of alkyne and fluorescently labeled lanthipeptides by oxime 
bioconjugation. Aniline- or p-phenylenediamine-catalyzed oxime bioconjugation between keto-
LanA core and an aminooxy moiety functionalized with either an alkyne (alk, 4.1) or the 
fluorophores (fluor) rhodamine B (4.2) or Cy5 (4.3). Scheme adapted from Bindman and van der 
Donk.1 
 
Figure 4.8. MALDI-TOF mass spectrum of the reaction between GluC-cleaved and ProcM-
modified His6-ProcA1.7(G–1E) and 4.1. ([M+H]+ calc’d = 2580.3 Da.) 
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4.2.3. Installation of a non-native N-terminal 2-oxobutyryl group in lanthipeptides. 
Unlike Pcn1.7, most lanthipeptides do not contain an N-terminal 2-oxobutyryl group. 
Therefore, to make the labeling strategy general for other lanthipeptides, a ketone needs to be 
appended to their N-termini. Harnessing the well-established promiscuity of the lanthipeptide 
synthetases,12 we hypothesized that installation of a Ser or Thr between the leader and core 
peptides or replacing the first residue of the core peptide with a Ser or Thr might result in 
dehydration by the cognate dehydratase. Proteolytic removal of the leader peptide would then 
afford the modified core peptide with an N-terminal ketone. We chose to install a Thr rather than 
Ser because an analysis of almost 40 lanthipeptides found that Ser escaped dehydration more 
than twice as often as Thr.52 
 
4.2.3.1. Installation of a ketone on the N-terminus of prochlorosin 2.8 and its 
bioconjugation with aminooxy-alkyne 4.1. 
We tested the methodology with prochlorosin 2.8 (Pcn2.8) (Figure 4.2). Because the core 
peptide of Pcn2.8 does not contain a Lys, a G–1K mutation was introduced in addition to 
replacement of Ala1 with Thr (Figure 4.4). The His6-ProcA2.8(G–1K/A1T) mutant peptide was 
coexpressed with the modification enzyme ProcM in E. coli cells. After purification by IMAC 
and cleavage of the leader peptide from the modified core peptide with trypsin, analysis by 
MALDI-TOF MS demonstrated a major ion corresponding to the core peptide with three 
dehydrations and a minor, although significant, ion with only two dehydrations (Figure 4.9, left); 
the core peptide of wild-type (wt) Pcn2.8 contains two dehydrations (Figure 4.2). The mass of 
the product peak with three dehydrations was 1 Da larger than the calculated peptide mass 
containing an N-terminal enamine, demonstrating the formation of a 2-oxobutyryl group on the 
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N-terminus of Pcn2.8 (keto-Pcn2.8) (Figure 4.9, left). Keto-Pcn2.8 was obtained in a typical 
yield of 3 mg/L after RP-HPLC purification, and was site-specifically labeled with 4.1 in an 
aniline-catalyzed conjugation (Figure 4.9, right). As with Pcn1.7, the alkyne added only once to 
keto-Pcn2.8. 
 
Figure 4.9. MALDI-TOF mass spectra of alk- and keto-Pcn2.8. Left, keto-Pcn2.8 ([M+H]+ 
calc’d = 2063.8 Da.). Right, alk-Pcn2.8 ([M+H]+ calc’d = 2116.8 Da.). The peak at +17 Da 
represents incomplete dehydration of the inserted Thr based on MS/MS analysis (the incomplete 
dehydration also prevents the hydrolysis to the ketone, hence a difference of 17 Da and not 18 
Da). Na+ represents a sodium adduct. The MALDI MS spectrometer used (Bruker UltraFlex) has 
sufficient resolution to distinguish peptides differing by 1 Da if calibrated, such as peptides with 
an N-terminal 2-aminobutyric acid and an N-terminal 2-oxobutyric acid group. 
 
As discussed above, a significant portion of the ProcA2.8 core region, after modification 
by ProcM, contained two dehydrations. We hypothesized that modifying the residues flanking 
the inserted Thr might increase the efficiency of its dehydration. Indeed, dehydration of Ser or 
Thr residues in lanthipeptides occurs more often when the dehydratable residue is flanked by 
hydrophobic amino acids.52 Unfortunately, most commercial proteases hydrolyze the amide bond 
immediately C-terminal to a charged amino acid side chain. Thus, in the current methodology, 
the insertion of Thr immediately after the protease cleavage site may decrease the efficiency of 
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dehydration of that residue. However, if a hydrophobic amino acid were inserted between the 
proteolytic cleavage site and the Thr, the residue was expected to be dehydrated to a greater 
extent. Proteolysis would then afford the modified core region with a hydrophobic residue 
overhang, which could be removed with an aminopeptidase. When the mutant peptide His6-
ProcA2.8(G–1K-A1T ins LL), with two Leu residues inserted between Lys and Thr, was 
coexpressed with ProcM, MALDI-TOF MS analysis of the trypsin-cleaved product showed 
almost complete modification of the N-terminal Thr (three dehydrations compared with two for 
wt ProcA2.8; Figure 4.10). Subsequent aminopeptidase cleavage of the Leu-Leu overhang 
afforded keto-Pcn2.8. Although the increase in dehydration efficiency of His6-ProcA2.8(G–1K-
A1T ins LL) was advantageous, when the extra time required and the expense of the 
aminopeptidase and purification steps were taken into consideration the original method, trypsin 
cleavage of His6-ProcA2.8(G–1K/A1T), was deemed superior with regard to synthesizing keto-
Pcn2.8. 
 
Figure 4.10. MALDI-TOF mass spectrum of trypsin-cleaved His6-ProcA2.8(G–1K-A1T ins 
LL). [M+H]+ of –3 H2O calc’d = 2289.0 Da. Instrument was not calibrated prior to analysis.  
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4.2.3.2. Installation of a ketone on the N-terminus of haloduracin α and its bioconjugation 
with aminooxy-alkyne 4.1. 
The experiments with the two prochlorosins established the feasibility of the site-specific 
labeling approach, but because their bioactivities are unknown, we could not assess whether N-
terminal labeling interfered with activity. The two-peptide systems are an interesting subclass of 
lantibiotics, which achieve maximum antimicrobial activity from the synergistic activity of two 
disparate peptides that are produced by the same organism. One example is haloduracin (Figure 
4.2), consisting of Halα, produced from the HalA1 precursor peptide by the lanthionine 
synthetase HalM1, and Halβ, generated from the HalA2 precursor peptide by the synthetase 
HalM2.53,54  
To synthesize keto-Halα, a gene encoding His6-HalA1(A–1-C1 ins IEGRT) was 
generated by site-directed mutagenesis in which the Factor Xa recognition sequence (Ile-Glu-
Gly-Arg) and a Thr were inserted between the last residue of the leader peptide (Ala) and the 
first residue of the core peptide (Cys). The gene was inserted into MCS1 of a pRSFDuet plasmid 
and the gene encoding HalM1 was inserted in MCS2. Coexpression of the mutant HalA1 peptide 
with HalM1, followed by exposure to Factor Xa, resulted in no discernable formation of keto-
Halα, as assessed by MALDI-TOF MS. However, the successful dehydration of the inserted Thr 
in HalM1-modified His6-HalA1(A–1-C1 ins IEGRT) was determined by MALDI-TOF MS 
analysis after cleavage of the peptide by the endoprotease GluC. The major mass ion 
corresponded to four-fold dehydrated Halα with a Gly-Arg overhang (Figure 4.11) (wt Halα 
contains three dehydrations; Figure 4.2). No cleavage was observed after Glu22 in the HalA1 
core region as the residue was likely deactivated to proteolysis by the proximal 
methyllanthionine ring. Removal of the Gly-Arg overhang with aminopeptidase was attempted, 
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however aminopeptidase activity halted after hydrolysis of Gly–2, and keto-Halα was not 
produced. 
 
Figure 4.11. MALDI-TOF mass spectrum of GluC-cleaved His6-HalA1(A–1-C1 ins IEGRT). 
[M+H]+ calc’d = 3342.6 Da. Instrument was not calibrated prior to analysis. 
 
The experiments with His6-HalA1(A–1-C1 ins IEGRT) illustrated that the synthetase 
HalM1 could modify a Thr inserted at the N-terminus of the HalA1 core peptide and that GluC 
could cleave off most of the HalA1 leader peptide without disruption of the core region. 
However, the leader peptide could never be fully removed. To achieve this goal, a gene encoding 
His6-HalA1(A–1E-C1 ins T) (Figure 4.4), where Ala–1 was mutated to Glu for leader peptide 
removal and a Thr was incorporated between this Glu and the first residue of the core peptide 
(Cys1), was inserted into MCS1 of a pRSFDuet vector with halM1 in MCS2. Because of the 
relatively low yield of haloduracin production in E. coli in this and a previous study,42 a second 
copy of the halA1 mutant was inserted into a pET15b plasmid in an attempt to increase the 
peptide yield. Coexpression of the HalA1 peptide with HalM1, and purification by IMAC and 
RP-HPLC, resulted in a fully modified peptide with a yield of about 8 mg/L. Subsequent 
cleavage of its leader peptide with the endoprotease GluC yielded a Halα analogue containing an 
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N-terminal 2-oxobutyryl moiety (keto-Halα) (Figure 4.12, left). The keto analogue was reacted 
with 4.1 in an aniline-catalyzed conjugation to yield alkyne-labeled alk-Halα (Figure 4.12, right). 
 
 
Figure 4.12. MALDI-TOF mass spectra of keto- and alk-Halα. Left, keto-Halα ([M+H]+ calc’d 
= 3130.3 Da.). Right, alk-Halα ([M+H]+ calc’d = 3181.3 Da). 
 
4.2.3.3. Installation of a ketone on the N-terminus of haloduracin β and its bioconjugation 
with aminooxy-alkyne 4.1. 
To obtain keto-Halβ, a gene encoding His6-HalA2(Q–1E-T1 ins T) was generated by site-
directed mutagenesis. In this mutant peptide, the last residue of the leader peptide of HalA2 
(Gln–1) was mutated to Glu and a Thr was inserted between the Glu and the first residue of the 
core peptide (Thr1). The halA2 mutant gene was inserted into MCS1 of a pRSFDuet plasmid 
containing the halM2 gene in MCS2. Coexpression of the HalA2 mutant peptide with HalM2, 
and purification by IMAC and RP-HPLC was followed by leader peptide cleavage with 
endoprotease GluC. MALDI-TOF MS analysis of the ensuing product demonstrated successful 
modification of the inserted Thr. Unfortunately, only partial proteolytic leader peptide removal 
was observed; a large mass peak corresponding to peptide cleavage after Glu–14, but not after 
Glu–1, was detected (Figure 4.13A). We hypothesized that the lack of cleavage after Glu–1 was 
because the D-stereocenter of the N-terminal lanthionine ring interfered with protease activity. 
 134 
This problem was overcome by coexpressing HalM2 with His6-HalA2(Q–1E-T1 ins TA) (Figure 
4.4), a mutant incorporating a ThrAla sequence between Glu–1 and Thr1 to separate the cleavage 
site from the N-terminal methyllanthionine ring. The peptide was purified as described above 
resulting in a fully modified peptide with a yield of about 10 mg/L. Subsequent cleavage of the 
HalA2 leader peptide with GluC yielded a Halβ analogue containing an N-terminal 2-oxobutyryl 
moiety (keto-Halβ) as the only observed product (Figure 4.13B). The keto analogue was reacted 
with 4.1 in an aniline-catalyzed conjugation to yield alk-Halβ (Figure 4.13C).  
 
 
 
Figure 4.13. MALDI-TOF mass spectra of Halβ analogues. A) GluC-cleaved His6-HalA2(Q–
1E-T1 ins T) (the peak at 3638 Da corresponds to cleavage after Glu–14) ([M+H]+ calc’d = 
3637.7 Da.), B) keto-Halβ ([M+H]+ calc’d = 2486.2 Da.), and C) alk-Halβ ([M+H]+ calc’d = 
2539.1 Da). Instrument was not calibrated before analysis of spectrum A. 
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4.2.3.4. Installation of a ketone on the N-terminus of lacticin 481 and its bioconjugation 
with aminooxy-alkyne 4.1. 
Previous work determined that Ser4 is not modified in wt lacticin 481 (Figure 4.2) 
because it is both too close to the leader peptide and because it is flanked by two Gly residues.55 
This Ser was only dehydrated by the synthetase LctM when three Ala residues were inserted 
between the leader and core peptides and Gly3 and Gly5 were mutated to Ile and His, 
respectively.55 We therefore anticipated that a Thr inserted directly between the leader and core 
peptides in lacticin 481 would not be dehydrated based on its close proximity to the leader 
peptide and its flanking amino acids. Taking these previous studies as a guideline, a gene 
encoding the peptide His6-LctA(K1-G2 ins AAAKT), was prepared. In this peptide, the sequence 
AAAKT was inserted between residues 1 and 2 of the core peptide to place the inserted Thr at a 
longer distance from the end of the leader peptide. Furthermore, a Lys was placed before the 
inserted Thr such that the leader peptide could be removed with LysC or trypsin. The mutant 
LctA peptide and its cognate synthetase LctM were coexpressed from a pRSFDuet plasmid in E. 
coli cells.56 After LysC cleavage of LctM-modified His6-LctA(K1-G2 ins AAAKT), MALDI-
TOF MS analysis of the resulting peptide showed the majority of product contained four 
dehydrations, the number of dehydrations in wt lacticin 481, with a very small peak 
corresponding to the desired five dehydrations (Figure 4.14A). It was likely that the amino acid 
escaping dehydration was the inserted Thr between the core and the leader peptide. 
In a second attempt to synthesize keto-lacticin 481, a gene encoding the peptide mutant 
His6-LctA(K1-G2 ins AAAKLLT) was generated. This mutant further separated the inserted Thr 
from the leader peptide by the introduction of two Leu residues and introduced a hydrophobic 
Leu immediately before Thr1, which helped increase the dehydration efficiency of Thr1 in 
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ProcA2.8. Removal of the leader peptide could be achieved by a combination of the protease 
LysC and aminopeptidase. After LysC cleavage of the peptide coexpressed with LctM, MALDI-
TOF MS analysis demonstrated the majority of the product still corresponded to four 
dehydrations, however a larger portion had the desired five dehydrations (Figure 4.14B). 
To confirm the amino acid escaping dehydration in four-fold dehydrated His6-LctA(K1-
G2 ins AAAKLLT) was Thr1, the LysC-cleaved peptide was incubated with an aminopeptidase. 
If Thr1 had been dehydrated successfully by LctM, aminopeptidase hydrolysis would stop after 
the removal of the two N-terminal Leu residues (Leu–2 and Leu–1) because an N-terminal α-
ketoamide would have formed. However, if Thr1 was not dehydrated the aminopeptidase would 
likely remove that residue as well as the residues immediately succeeding it. MALDI-TOF MS 
analysis of the aminopeptidase reaction on LysC-cleaved His6-LctA(K1-G2 ins AAAKLLT) 
demonstrated that the aminopeptidase removed the LeuLeuThr sequence as well as several 
subsequent amino acids, finally halting at Ile7 and His8, just before the methyllanthionine ring 
(Figure 4.14C). Thus, the amino acid escaping dehydration in four-fold dehydrated His6-
LctA(K1-G2 ins AAAKLLT) was Thr1. 
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Figure 4.14. MALDI-TOF mass spectra of LysC- and/or aminopeptidase-cleaved and LctM-
modified LctA analogues in an attempt to produce keto-lacticin 481. A) LysC-cleaved and LctM-
modified His6-LctA(K1-G2 ins AAAKT), B) LysC-cleaved and LctM-modified His6-LctA(K1-
G2 ins AAAKLLT), and C) LysC- and aminopeptidase-cleaved and LctM-modified His6-
LctA(K1-G2 ins AAALLKT). 
 
 We suspected that the modest increase in dehydration efficiency between His6-LctA(K1-
G2 ins AAAKT) and His6-LctA(K1-G2 ins AAAKLLT) was due to the increased distance 
between the leader and core regions and the insertion of a hydrophobic amino acid immediately 
preceding the inserted Thr. To further enhance dehydration of the inserted Thr, we hypothesized 
that mutating the Gly immediately succeeding the inserted Thr to a hydrophobic residue might 
further increase the dehydration efficiency. Therefore, the peptides His6-LctA(K1-G2A ins 
AAAKLLT) and His6-LctA(K1-G2L ins AAAKLLT), with Gly2 mutated to Ala and Leu 
respectively, were coexpressed with LctM and modified precursor peptides were cleaved by 
LysC and analyzed by MALDI-TOF MS. The G2L mutation had no distinguishable impact on 
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the dehydration of Thr1 (Figure 4.15, red), however when Gly2 was mutated to Ala, Thr1 was 
dehydrated to a larger extent (Figure 4.15, blue). Purification of the LysC cleaved G2A mutant 
yielded LctA core with a Leu–2/Leu–1 overhang. The peptide was then subjected to 
aminopeptidase cleavage to remove the remaining two amino acids of the leader peptide. 
Unfortunately, even at high aminopeptidase concentrations Leu–1 was not successfully removed 
in the 5-fold dehydrated species. 
 
 
Figure 4.15. MALDI-TOF mass spectra of LysC-cleaved LctA(K1-G2X ins AAAKLLT) in an 
attempt to produce keto-lacticin 481. Red, X = L. Blue, X = A); the G2L mutant is cleaved after 
Lys–7 rather than Lys–3. 
 
As a final attempt to synthesize keto-lacticin 481, the construct His6-LctA(K1-G2A ins 
AAALLKT) (Figure 4.4) was inserted into MCS1 of a pRSFDuet vector with LctM in MCS2. 
Compared to the previous construct, the inserted Thr was of equal distance to the end of the 
leader peptide, however the order of the Leu and Lys residues were switched so LysC cleavage 
of the modified peptide would directly form keto-lacticin 481. The mutant LctA peptide was 
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coexpressed with LctM in E. coli cells and the leader peptide was removed with LysC. Analysis 
of the product by MALDI-TOF MS showed that a small portion was successfully dehydrated 
five times (Figure 4.16A, red), indicating that the amount of Thr1 dehydrated had decreased 
compared to His6-LctA(K1-G2A ins AAAKLLT), a result likely due to the removal of the 
hydrophobic Leu directly preceding Thr1. Further analysis of the five-fold dehydrated species 
showed that an N-terminal 2-oxobutyryl had been introduced onto lacticin 481 (keto-lacticin 481 
is the product). 
We hypothesized that an increase in the concentration of LctM in the coexpression 
system would lead to an enhancement in dehydration efficiency of the inserted Thr. We 
increased the concentration of LctM by adding copies of lctM to pCDFDuet and pACYCDuet 
vectors. Coexpression of the his6-lctA(K1-G2A ins AAALLKT) construct with 3 copies of lctM 
afforded the posttranslationally modified LctA in a typical yield of 3 mg/L, and with the five-
fold dehydrated peptide as the major product (Figure 4.16A, blue). Treatment of the five-fold 
dehydrated product with LysC followed by aniline-catalyzed conjugation with 4.1 resulted in the 
desired alkyne-conjugated-lacticin 481 (alk-lacticin 481; Figure 4.16B). We note that this 
analogue lacks the N-terminal Lys that is found in wt lacticin 481. However, my studies in 
Chapter 3 have shown the Δ1K analogue to be as active as the wt compound. Using an analogous 
strategy, we also generated keto-lacticin 481-E13A from the corresponding LctA mutant 
(4.16C). This analogue was important for mode of action studies as discussed in section 4.2.7. 
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Figure 4.16. MALDI-TOF mass spectra of keto- and alk-lacticin 481 and keto-lacticin 481-
E13A. A) LysC-cleaved His6-LctA(K1-G2A ins AAALLKT) overexpressed in E. coli with 3 
copies (blue) and 1 copy (red) of the lctM gene ([M+H]+ of –5 H2O calc’d = 2870.2 Da.), B) alk-
lacticin 481 ([M+H]+ calc’d = 2923.2 Da.), and C) keto-lacticin 481-E13A ([M+H]+ of –5 H2O 
calc’d = 2812.2 Da.) Figure adapted from Bindman and van der Donk.1 
 
4.2.3.5. Installation of a ketone on the N-terminus of nisin and its bioconjugation with 
aminooxy-alkyne 4.1. 
Posttranslational modification of NisA, the precursor peptide for the class I lantibiotic 
nisin, relies on two enzymes, the dehydratase NisB and the cyclase NisC, compared to class II 
lanthipeptides whose modification depends on one bifunctional enzyme (e.g. LctM). Previously, 
the coexpression of nisin in E. coli was successful by employing a two-vector system in which 
nisA and nisB were introduced into MCS1 and MCS2, respectively, of a pRSFDuet vector and 
nisC was incorporated into MCS2 of a pACYCDuet vector.42 In an attempt to synthesize keto-
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nisin, the gene sequence encoding the peptide NisA(R–1-I1 ins IT) was incorporated into MCS1 
of a pRSFDuet vector with NisB in MCS2. In this peptide, an IleThr sequence was inserted 
between the NisA leader and core regions. This insertion mimics Ile1 and Dhb2 of wt nisin and 
we anticipated that the inserted Thr, flanked by two hydrophobic Ile residues, would be 
dehydrated. No artificial cleavage site was introduced into the NisA mutant because the entire 
leader sequence could be cleaved off after Arg–1 by the endoprotease trypsin. After coexpression 
of the NisA mutant peptide with NisB and NisC, IMAC purification, and trypsin cleavage, 
analysis of the product by MALDI-TOF MS displayed a major mass ion corresponding to 
dehydration of seven of the desired nine amino acids with smaller peaks accounting for six and 
eight dehydrations (Figure 4.17, black). We anticipated that along with Thr1, Ser33 escaped 
dehydration as this residue is not always dehydrated in the native producer.57 
 Due to the positive affect the additional copies of lctM had in obtaining the maximum 
number of dehydrations in the biosynthesis of keto-lacticin 481, we conjectured that increasing 
the concentration of NisB would boost the number of dehydrations during coexpression with the 
NisA mutant. Indeed, in previous work certain nisin analogues were dehydrated to a greater 
extent when the concentration of NisB was increased in vivo.57 Thus, a copy of the gene 
encoding the protein NisB was incorporated into MCS1 of the pACYCDuet vector with NisC in 
MCS2. NisA(R–1-I1 ins IT) was then coexpressed with NisC and two copies of NisB. When 
compared to the overexpression with one copy of NisB, the dehydration efficiency of the NisA 
peptide was increased; the major peak, again, consisted of seven dehydrations but larger peaks 
were seen corresponding to eight and nine dehydrations (Figure 4.17, red). When NisA(R–1-I1 
ins IT) was coexpressed with NisC and three copies of NisB (the additional copy of nisB was 
incorporated into MCS2 of a pCDFDuet vector), MALDI-TOF MS analysis exhibited a major 
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ion corresponding to the NisA mutant peptide with nine dehydrations (Figure 4.17, blue). IMAC 
purification, followed by removal of the leader peptide by trypsin and then aminopeptidase 
yielded keto-nisin-1. Unfortunately, this nisin mutant was not bioactive against Lactococcus 
lactis HP, a result that was somewhat expected as modification of the N-terminus of nisin has 
been shown previously to abolish bioactivity.58 
 
 
Figure 4.17. Modification of His6-NisA(R–1-I1 ins IT) with multiple copies of NisB. MALDI-
TOF mass spectra of trypsin-cleaved His6-NisA(R–1-I1 ins IT) overexpressed in E. coli with 1 
(black), 2 (red), or 3 (blue) copies of the nisB gene. [M+H]+ of –9 H2O calc’d = 3548.8 Da. 
 
 To increase the probability of bioactivity of nisin with an N-terminal ketone, the 
biosynthesis of NisA(I1L) was attempted. The second amino acid in the core peptide of wt nisin 
is a Dhb, so aminopeptidase cleavage of the first amino acid (Leu) would yield Δ1 nisin with an 
N-terminal 2-oxobutyryl group. Unlike keto-nisin-1, this peptide would not be elongated at the 
N-terminus and therefore might still be bioactive. NisA(I1L) was coexpressed with only one 
copy of NisB due to its similarity with wt nisin. After IMAC purification and trypsin cleavage of 
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the leader peptide, the main product, as shown by MALDI-TOF MS, had the desired eight 
dehydrations. Aminopeptidase cleavage of the N-terminal Leu and RP-HPLC purification 
yielded keto-nisin-2 (Figure 4.18, left), which was bioactive (Figure 4.19A). keto-Nisin-2 was 
then reacted with 4.1 in an aniline catalyzed oxime bioconjugation to yield alk-nisin (Figure 
4.18, right). 
 
 
Figure 4.18. MALDI-TOF mass spectra of keto-nisin-2 and alk-nisin. Left, keto-nisin-2 
([M+H]+ calc’d = 3238.5 Da) Right, alk-nisin ([M+H]+ calc’d = 3291.5 Da). 
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Figure 4.19. Bioactivities of nisin, lacticin 481 and haloduracin analogues against L. lactis HP or 
B. subtilis. A) Zones of growth inhibition displayed by wt nisin (row 1; concentrations from left 
to right: 4 µM, 2 µM, 1 µM, 0.5 µM), keto-nisin-2 (row 2; concentrations from left to right: 200 
µM, 100 µM, 50 µM, 25 µM), and alk-nisin (red star; concentration was greater than 100 µM) 
against L. lactis HP. A total of 10 µL of compound was added to each well. B) Zones of growth 
inhibition displayed by wt lacticin 481 (row 1), alk-lacticin 481 (row 2) and rho-lacticin 481 
(row 3) against B. subtilis 168. Concentrations from left to right: 50, 25 and 12.5 µM. A total of 
20 µL was added to each well. C) Zones of growth inhibition displayed by haloduracin analogues 
against B. subtilis 168. Top left, zones-of-growth inhibition of alk-haloduracin. Clockwise from 
red star: alk-Halα + alk-Halβ (12.5 µM each), alk-Halβ (12.5 µM), alk-Halα (12.5 µM), alk-Halα 
+ alk-Halβ (25 µM each), alk-Halβ (25 µM), alk-Halα (25 µM). Top right, zones-of-growth 
inhibition of rho-Halα. Each peptide was added at a concentration of 5 µM. Clockwise from red 
star: rho-Halα, rho-Halα + wt Halβ, rho-Halα + rho-Halβ, rho-Halα + Cy5-Halβ, wt Halα + wt 
Halβ. Bottom left, zones-of-growth inhibition of rho-Halβ. Each peptide was added at a 
concentration of 5 µM. Clockwise from red star: rho-Halβ, rho-Halβ + wt Halα, wt Halα, wt 
Halβ, wt Halα + wt Halβ. Spot 6 was not used. Bottom right, zones-of-growth inhibition of Cy5-
Halβ. Each component was added at a concentration of 5 µM. Clockwise from red star: Cy5-
Halβ, Cy5-Halβ + wt Halα, wt Halα, wt Halβ, wt Halα + wt Halβ. Spot 6 was not used. A total of 
10 µL was added to each spot. 
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4.2.4. Bioactivities of alkyne-labeled lacticin 481, haloduracin α, haloduracin β, and nisin. 
alk-Lacticin 481, alk-Halα, alk-Halβ, and alk-nisin were used for agar well-diffusion 
antimicrobial assays against Bacillus subtilis 168. The zones of growth inhibition compared with 
those obtained with the wt standard showed that alk-lacticin 481 retained its activity (Figure 
4.19B). Because haloduracin is a two-component lantibiotic, both components, alk-Halα and alk-
Halβ, were administered individually and in tandem to B. subtilis 168. Like wt haloduracin, alk-
Halα and alk-Halβ alone displayed little bioactivity. However, the alk-Halα and alk-Halβ 
peptides exhibited potent antibacterial activity when combined (Figure 4.19C). In contrast, alk-
nisin exhibited no bioactivity against L. lactis HP (Figure 4.19A), demonstrating that the labeling 
methodology to insert an N-terminal 2-oxobutyryl group may not be suitable for lantibiotics 
whose N-termini are important for bioactivity. 
 
4.2.5. Fluorescent labeling of lacticin 481, lacticin 481-E13A, haloduracin α, and 
haloduracin β. 
Aminooxy-rhodamine (4.2) and aminooxy-Cy5 (4.3) were synthesized using published 
procedures with minor changes (Schemes 4.4 and 4.5).59-61 Briefly, Boc-protected linker 4.5 was 
synthesized from 1,6-dibromohexane via successive nucleophilic substitution reactions first with 
N-Boc-hydroxylamine and then with piperazine. Next, the secondary amine of 4.5 was coupled 
to the free carboxylate of either rhodamine B or Cy5 followed by Boc removal to yield the 
fluorescent aminooxy derivatives 4.2 and 4.3. Very recently, p-phenylenediamine was reported 
to be an improved catalyst over aniline for oxime bioconjugations, in part because of its 
increased water solubility.62 Therefore, keto-lacticin 481 and keto–Halα were labeled with 4.2 
via p-phenylenediamine-catalyzed oxime bioconjugations, providing rho-lacticin 481 and rho-
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Halα in modestly improved yields compared to using aniline as catalyst (Scheme 4.3). Similarly, 
keto-Halβ was ligated with 4.2 or 4.3 yielding rho- or Cy5-Halβ. The purity of each peptide was 
assessed by analytical RP-HPLC (Figure 4.20) and analysis by MALDI-TOF MS showed that 
the aminooxy-fluorophore added only once (Figure 4.21). Reaction of Δ1-lacticin 481, which 
lacked the N-terminal ketone, with 4.2 did not yield an addition product, indicating the 
fluorophore was incorporated at the N-terminus of the lantibiotic analogue. Reaction of the 
analogue keto-lacticin 481-E13A with 4.2 also resulted in the desired rho-lacticin 481-E13A 
(Figure 4.21). 
 
 
Scheme 4.4. Synthetic scheme towards aminooxy-rhodamine (4.2). 
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Scheme 4.5. Synthetic scheme towards aminooxy-Cy5 (4.3). 
 
 
Figure 4.20. Analytical RP-HPLC traces of fluorescent lantibiotics. A) rho-Halα, B) rho-Halβ, 
C) Cy5-Halβ, and D) rho-lacticin 481. The two isobaric products observed for rho- and Cy5-
Halβ presumably represent the two diastereomers formed during oxime bioconjugation. We did 
not attempt to separate these two products. 
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Figure 4.21. MALDI-TOF mass spectra of fluorescent lantibiotics. A) rho-Halα ([M+H]+ calc’d 
= 3735.7 Da.), B) rho-Halβ ([M+H]+ calc’d = 3093.5 Da.), C) Cy5-Halβ ([M+H]+ calc’d = 
3119.5 Da.), D) rho-lacticin 481 ([M+H]+ calc’d = 3477.6 Da.), and E) rho-lacticin 481-E13A 
([M+H]+ calc’d = 3419.6 Da.). 
 
The bioactivities of the fluorescently labeled peptides were tested by agar diffusion and 
liquid media growth assays and compared to their respective wt peptides. Rho-lacticin 481 was 
active at micromolar concentrations against B. subtilis 168 (Figure 4.19B) and L. lactis HP but 
with a minimum inhibitory concentration (MIC) that was increased 6-fold compared to wt 
lacticin 481 (Table 4.1). Rho-Halα and rho/Cy5-Halβ displayed antimicrobial activity against B. 
subtilis 168 when added together with their unlabeled partner (Halβ and Halα, respectively), but 
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exhibited only low level bioactivity when administered alone, as is also observed for the wt 
peptides (Figure 4.19C). The MICs of rho-Halα when coincubated with wt Halβ and of rho- or 
Cy5-Halβ when coincubated with wt Halα were increased about 8 to 15-fold compared to the wt 
peptides (Table 4.1). Although, not surprisingly, the bioactivities of the analogues were 
decreased, a similar mode of action of the fluorescently labeled peptides compared to the wt 
lantibiotics is suggested by additional experiments discussed later. 
 
Peptide (indicator strain) MIC (µM) 
lacticin 481 (L. lactis HP) 2.50 
rho-lacticin 481 (L. lactis HP) 15.0 
wt Halα w/ 2.5 µM wt Halβ (B. subtilis 168) 0.16 
wt Halβ w/ 2.5 µM wt Halα (B. subtilis 168) 0.16 
rho-Halα w/ 2.5 µM wt Halβ (B. subtilis 168) 1.25 
rho-Halβ w/ 2.5 µM wt Halα (B. subtilis 168) 1.25 
Cy5-Halβ w/ 2.5 µM wt Halα (B. subtilis 168) 2.50 
 
Table 4.1. Minimum inhibitory concentrations of wt and fluorescently labeled lantibiotics 
against B. subtilis 168 or L. lactis HP. When determining the MIC of Halα or Halβ and 
analogues, the concentration of one peptide was held constant at 2.5 µM while the other was 
varied. Neither wt Halα nor wt Halβ were active by themselves against B. subtilis 168 cells at a 
concentration of 2.5 µM. 
 
4.2.6. Lacticin 481 binds to lipid II on cell surfaces. 
Lacticin 481 was recently shown to inhibit the transglycosylation step of peptidoglycan 
biosynthesis, most likely by binding to the cell wall precursor lipid II.22 This hypothesis is also 
supported by a recent study that showed using ITC that nukacin ISK-1, a close structural 
analogue of lacticin 481, binds to lipid II.63 Therefore, analysis of the interaction of rho-lacticin 
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481 with sensitive bacteria by confocal fluorescence microscopy was anticipated to show 
preferential staining of lipid II. 
Previous studies of the peptidoglycan architecture in B. subtilis using fluorescently 
labeled vancomycin and ramoplanin, two lipid II-binding antibiotics, demonstrated intense 
staining at the midcell, corresponding to new division sites, and at the poles, corresponding to 
old division sites.64,65 In addition, staining of the bacterial sidewalls was observed as peripheral 
dots connected by weak transverse bands, suggesting a ring-type structure. More recently, two 
research groups used the cellular biosynthetic machinery to incorporate alkyne, azide, and 
fluorescently functionalized D-alanine analogues into the lipid II of several bacteria, including B. 
subtilis.66,67 The alkyne and azide analogues were then visualized in living cells with azide- or 
alkyne-linked fluorophores via click chemistry. Analysis of these bacteria by fluorescence 
microscopy also showed a punctate distribution of the lipid II analogues with intense bands at the 
midcell of the bacteria. Thus, these metabolic labeling studies provide an independent and 
complementary determination of lipid II localization. In the current work, rho-lacticin 481 was 
incubated with B. subtilis 168 at sublethal concentrations and the staining pattern was examined 
by confocal fluorescence microscopy (Figure 4.22A). In most bacteria, the fluorescence intensity 
was greatest at midcell (Figure 4.22A, green arrows). We also observed peripheral dots with 
weak transverse bands along the longitudinal axis of the rod-shaped bacilli. These results are 
very similar to the patterns seen with the lipid II-binding antibiotics and fluorescent lipid II 
analogues in B. subtilis, strongly suggesting that lacticin 481 binds lipid II in living cells. 
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Figure 4.22. Cellular distribution of fluorescent lacticin 481 analogues. A) Staining of B. subtilis 
168 with rho-lacticin 481 (1 µM). B) Staining of B. subtilis 168 with rho-lacticin 481-E13A (top, 
brightfield; bottom, rhodamine channel). New and old cellular division sites are represented by 
green and white arrows, respectively. Figure adapted from Bindman and van der Donk.1 
 
4.2.7. Lacticin 481-E13A does not localize in a specific pattern on cell surfaces. 
A conserved Glu/Asp is found in several class II lantibiotics and is integral to their 
bioactivities.15,17,18,21,22 In lacticin 481, this residue is Glu13 and a Glu13Ala mutant abolished 
antimicrobial activity.22 Thus, a fluorescent analogue of this mutant was used to confirm that the 
observed localization of rho-lacticin 481 is mediated by the peptide and not the fluorophore. rho-
Lacticin 481-E13A was incubated with B. subtilis 168, and the staining pattern was examined by 
confocal fluorescence microscopy. Very little staining was observed (Figure 4.22B), even at 
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concentrations 20 times larger than that used to stain B. subtilis 168 with rho-lacticin 481, 
demonstrating that Glu13 is essential for the localization of lacticin 481 and that the rhodamine 
in rho-lacticin 481 is not responsible for the observed localization pattern. 
 
4.2.8. Haloduracin β colocalizes with haloduracin α. 
The two components of haloduracin act synergistically to achieve their bioactivity. Halα 
binds to lipid II with high affinity to inhibit peptidoglycan biosynthesis.21 Halβ either does not 
bind to lipid II or has a much reduced affinity, but it is required for optimal bioactivity. These 
and other observations68-70 have led to a model that Halα binds lipid II and that this complex is 
recognized by Halβ, but experimental evidence of the binding interactions of Halβ are lacking.  
To probe Halα localization on bacterial cells, we added rho-Halα at sublethal 
concentrations to B. subtilis 168 cells and analyzed the cells, fixed to a cover slip by 1% agarose, 
by confocal fluorescence microscopy. Similar to the results seen with rho-lacticin 481, the most 
intense fluorescent signal was at midcell (Figure 4.23A). In addition, a staining pattern of 
peripheral dots with weak transverse bands was seen on the bacterial sidewall, consistent with 
binding of Halα to lipid II. However, when the experiment was repeated in the presence of 50 
equivalents of wt Halα, no fluorescent staining was observed, suggesting that the unlabeled 
peptide competes for the same binding site on the cell surface (Figure 4.24A). When rho-Halα 
was preincubated with 50 equivalents of wt Halβ (25 µM), rho-Halα still localized at the midcell 
and poles (Figure 4.24B), but the transverse bands were less frequently observed. These 
observations suggest that Halβ does not compete with Halα for its binding target. We next 
administered Cy5-Halβ to B. subtilis cells. Consistent with the model, no specific fluorescent 
pattern was observed (Figure 4.23B). Some non-specific labeling was seen, likely because of a 
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hydrophobic interaction between the lantibiotic and bacterial membrane. This interaction is 
expected to increase upon addition of the hydrophobic Cy5 functionality. Interestingly, when 
Cy5-Halβ and unlabeled Halα were added in concert, the Halβ analogue did localize in a specific 
pattern (Figure 4.23C). Preferential staining was observed at midcell and poles. Furthermore, 
coincubation of rho-Halα and Cy5-Halβ with B. subtilis cells showed colocalization of Halα and 
Halβ (Figure 4.23D). To rule out a role for the cyanine group of Cy5-Halβ, the microscopy 
experiments were also conducted with rho-Halβ. As anticipated, rho-Halβ localized in a site-
specific pattern on B. subtilis cells only in the presence of Halα (Figure 4.25A). The localization 
of rho-Halβ in the presence of wt Halα was not altered in the presence of 50 equivalents of 
unlabeled Halβ (25 µM) (Figure 4.25B); higher concentrations could not be used because of 
toxicity to the cells, which is already starting to be visible at 25 µM Halβ. Although this result 
was not anticipated, it may be due to an increased binding affinity to the bacterial membrane of 
rho-Halβ compared to wt Halβ. Thus, the addition of 50 equivalents of wt Halβ may not be 
enough to outcompete the fluorescently labeled analogue. 
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Figure 4.23. Cellular distribution of haloduracin analogues. A) Staining of B. subtilis 168 with 
0.25 µM rho-Halα (red). B) Staining of B. subtilis 168 with 4 µM Cy5-Halβ (blue). C) Staining 
of B. subtilis 168 with 1 µM each of wt Halα + Cy5-Halβ (blue). D) Staining of B. subtilis 168 
with 1 µM each of rho-Halα (red) + Cy5-Halβ (blue). Top, rhodamine channel (red); center, Cy5 
channel (blue); bottom, merge of rhodamine and Cy5 (purple). New and old cellular division 
sites are represented by green and white arrows, respectively. Figure adapted from Bindman and 
van der Donk.1 
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Figure 4.24. Cellular distribution of rho-Halα. A) Confocal fluorescence microscopy of B. 
subtilis 168 stained with 0.5 µM rho-Halα (white) preincubated with wt Halα (25 µM). B) 
Confocal fluorescence microscopy of B. subtilis 168 stained with 0.5 µM rho-Halα (white) 
preincubated with wt Halβ (25 µM). 
 
 
Figure 4.25. Cellular distribution of rho-Halβ. A) Confocal fluorescence microscopy of B. 
subtilis 168 stained with 0.5 µM rho-Halβ. B) Confocal fluorescence microscopy of B. subtilis 
168 stained with 0.5 µM rho-Halβ (white) preincubated with wt Halα (0.5 µM). 
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4.3. SUMMARY AND OUTLOOK 
This study demonstrates the successful use of the biosynthetic machinery of six different 
lanthipeptides to introduce a ketone group at their N-termini, and illustrates the utility of the 
method for site-specific labeling of this class of compounds. This strategy has a distinct 
advantage over other lanthipeptide-specific labeling techniques, such as introduction of non-
proteinogenic amino acids,42,71 because of its generality, scalability, and relatively high yields. 
Several structurally unique N-termini were successfully modified including lanthipeptides 
containing an N-terminal disulfide bond (Halα) and an N-terminal lanthionine crosslink (Halβ). 
To produce keto-Pcn2.8 and keto-Halα, the only perturbation compared to our previously 
developed lanthipeptide coexpression system was the insertion of a Thr directly after the 
proteolytic cleavage site. In these peptides the modification enzyme successfully dehydrated the 
inserted Thr, and proteolytic removal of the leader peptide yielded the lanthipeptide with an N-
terminal ketone. In the biosynthesis of Pcn1.7, keto-Halβ, and nisin, the inserted Thr was 
successfully dehydrated but the cleavage of the leader peptide from the core peptide occurred at 
an undesired location, giving the modified core peptide with an N-terminal amino acid overhang 
originating from the leader peptide. This problem was overcome in Halβ by inserting an Ala 
directly after the N-terminal Thr, which distanced the proteolytic cleavage site from the 
lanthionine ring at the N-terminus of Halβ (Figure 4.2). The protease, GluC, could then cleave 
the leader peptide at the desired site, presumably because the D-stereocenter of the lanthionine 
ring no longer interfered with protease binding. Conversely, in ProcA1.7 the two amino acids 
immediately preceding the inserted Thr were mutated to Leu and the leader peptide was removed 
in a two-step procedure of treatment with GluC and aminopeptidase. This two-step procedure 
was also utilized in the biosynthesis of keto-nisin-2, where most of the leader peptide was 
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removed with trypsin followed by hydrolysis of the N-terminal Leu by aminopeptidase. The 
biosynthesis of keto-lacticin 481 proved to be the most challenging and required distancing the 
inserted Thr from the leader peptide and introduction of two extra copies of the lctM gene into 
the coexpression system.  
Using the fluorescent labeling strategy, we were able to visualize the distribution of 
lacticin 481 and haloduracin on B. subtilis 168 cells. The most intense labeling with rho-lacticin 
481 was at the new cell division sites at the bacterial midcell, which we believe represents the 
relatively large amounts of lipid II present during cell division. In most cases, rho-lacticin 481 
also stained the sidewall of B. subtilis as peripheral dots, which in some images could be seen to 
be linked by transverse bands. In contrast, incubation of B. subtilis with the Glu13Ala mutant of 
lacticin 481 did not result in a specific pattern, consistent with the previous proposals that this 
conserved residue is critical to mediate interactions with lipid II in a variety of 
lantibiotics.15,17,18,21,22 The results with the fluorescently labeled lacticin 481 mutant also strongly 
suggest that the observed specific localization pattern is a consequence of the activity of lacticin 
481 and not the fluorophore.  
We also gained a deeper understanding of the mode of action of the two-component 
lantibiotic haloduracin using the fluorescently labeled analogues. Incubation of sublethal 
concentrations of rho-Halα with B. subtilis cells showed a staining pattern similar to that seen 
with rho-lacticin 481, consistent with binding to lipid II. This conclusion is also supported by the 
observation that unlabeled wt Halα abolished the specific labeling pattern of rho-Halα. Rho- and 
Cy5-Halβ did not exhibit a specific localization pattern unless wt Halα was also present. In the 
presence of Halα, the fluorescently labeled Halβ analogues localized at the poles and midcell, 
suggesting co-localization. Localization in transverse bands was also observed but less 
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frequently for unknown reasons. Simultaneous use of rho-Halα and Cy5-Halβ showed co-
localization at the midcell and poles. Fluorescently labeled Halβ in the presence of Halα could 
not be displaced from these sites by unlabeled Halβ at the maximum non-toxic concentrations 
achievable, possibly because of the higher affinity of the fluorescently labeled analogues for the 
membrane. Collectively, these results support the previously proposed model of synergistic 
activity, in which Halα binds to lipid II, followed by the binding of Halβ to the Halα-lipid II 
complex (Figure 4.26), although the resolution of confocal microscopy is such that co-
localization in these experiments does not necessarily mean complex formation. Further 
experiments will be needed to confirm or refute a direct molecular interaction between Halβ and 
the Halα-lipid II complex. 
In summary, we report a general labeling strategy for lanthipeptides, which may be used 
for studies on family members for which the mode(s) of action and targets are currently 
unknown, such as the prochlorosins and the Pep5/epilancin class of lantibiotics. Potential 
applications also include use of 99mTc-labeled lanthipeptides for imaging purposes3 and 
introduction of photoaffinity probes. 
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Figure 4.26. Proposed mode of action of the two-component lantibiotic haloduracin. First, Halα 
associates with the cell wall precursor lipid II. Then, Halβ binds to the Halα-lipid II complex 
causing pore formation. GlcNAc, N-acetylglucosamine (blue squares labeled G); MurNAc, N-
acetylmuramic acid (blue squares labeled M). The molecular details of the binding interaction of 
Halα and lipid II are not known. Figure adapted from Bindman and van der Donk.1 
 
4.4. EXPERIMENTAL 
4.4.1. Materials. 
 All compounds used in the synthetic schemes were purchased from Sigma Aldrich with the 
exception of propargyl bromide (TCI America), p-phenylenediamine (TCI America), N-Boc-
hydroxylamine (Alpha Aesar), sodium iodide (J.T. Baker Chemical Company), 
tetramethylfluoroformamidinium hexafluorophosphate (TFFH) (Chem Impex) and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Fisher Scientific). Solvents commonly 
used in peptide purification, including trifluoroacetic acid (TFA) and acetonitrile (MeCN), were 
obtained in HPLC grade or better and used directly without further purification. Oligonucleotide 
primers used for molecular cloning were purchased from Integrated DNA Technologies. Phusion 
High-Fidelity DNA polymerase, T4 DNA ligase, DpnI, and all restriction endonucleases were 
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purchased from New England Biolabs. Gel extraction, plasmid miniprep, and PCR purification 
kits were purchased from QIAGEN. Terrific broth (TB) and LB broth were purchased from 
Fisher Scientific. Endoproteases LysC, GluC, and trypsin were purchased from Roche Applied 
Science and aminopeptidase from Aeromonas proteolytica was purchased from Sigma Aldrich 
(A8200). Other items procured for cell culture and peptide work included isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Gold Biotechnology), kanamycin monosulfate (IBI Scientific), 
chloramphenicol (IBI Scientific), spectinomycin dihydrochloride pentahydrate (Sigma Aldrich), 
ampicillin sodium salt (Fisher Scientific) and tris-(2-carboxyethyl)phosphine·HCl (TCEP·HCl) 
(Molecular Probes). Agarose with low gelling temperature used in bacterial imaging was 
purchased from Sigma Aldrich. MALDI-TOF MS analyses were conducted at the Mass 
Spectrometry Facility (UIUC) using an UltrafleXtreme TOF/TOF (Bruker Daltonics) or 
Voyager-DE STR. Fluorescence confocal microscopy analyses were conducted at the core 
facility at the Institute of Genomic Biology (UIUC) using a Zeiss LSM 700 Confocal 
Microscope. Rhodamine B analogues were excited using a 555 nm laser and emission was 
detected at wavelengths between 560 and 625 nm. Cy5 analogues were excited using a 639 nm 
laser and emission was detected at wavelengths between 640 and 735 nm. Images were 
deconvoluted using the program AutoQuant X3 (Media Cybernetics). 
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4.4.2. Synthesis of aminooxy derivatives 4.1, 4.2, and 4.3. 
 
Synthetic design of aminooxy-alkyne (4.1). 
 
 
2-(Prop-2-yn-1-yloxy)isoindoline-1,3-dione (4.1a). 
Into a 50 mL round-bottomed flask was added N-hydroxyphthalimide (2.78 g, 17.1 
mmol, 1 equiv) followed by DMSO (30 mL). To this solution was added K2CO3 (1.52 g, 11.0 
mmol, 0.64 equiv) and the reaction immediately turned dark red. Finally, propargyl bromide (4.0 
g, 3.0 mL, 33.6 mmol, 1.92 equiv) was added dropwise and the solution was stirred overnight at 
room temperature. The solid residue was then removed by filtration followed by the addition of 
ice water (200 mL) to the filtrate. The resulting solid was filtered and recrystallized from hot 
ethanol yielding compound 4.1a as a light brown solid (2.7 g, 80%). Characterization data 
matched that previously reported.72 See also Notebook VIII, Page 53. 
 
 
O-(Prop-2-yn-1-yl)hydroxylamine (4.1). 
Into a 25 mL round-bottomed flask was added 4.1a (500 mg, 2.5 mmol, 1 equiv) 
followed by hydrazine monohydrate (64-65%, 0.135 mL, 139.3 mg, 2.78 mmol, 1.11 equiv). To 
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this mixture was added diethyl ether (2.5 mL), the large clumps were broken with a spatula, and 
the reaction mixture was stirred for 2 h at room temperature. The solid residue was then removed 
by filtration, and HCl in ether (2 M, 1.8 mL) was added to the filtrate with continuous stirring. 
After a few moments a solid precipitated from the ethereal solution. The reaction was stirred for 
an additional 2 h and the resulting solid was filtered and dried yielding 4.1 (200 mg, 75%) as a 
light yellow solid. Characterization data matched that previously reported.73 See also Notebook 
XII, Page 07. 
 
 
Synthetic design of aminooxy-rhodamine B (4.2). 
 
 
tert-Butyl-(6-bromohexyl)oxycarbamate (4.4). 
Into a 50 mL round-bottomed flask was added N-Boc-hydroxylamine (0.67 g, 5 mmol, 1 
equiv) in DMF (5 mL). To this solution was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) 
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(0.91 g, 0.90 mL, 6.0 mmol, 1.2 equiv). The mixture was then slowly added to a solution of 1,6-
dibromohexane (2.44 g, 1.54 mL, 10 mmol, 2 equiv) in DMF (5 mL) via cannula. The reaction 
was stirred overnight at room temperature. The following morning more 1,6-dibromohexane 
(200 µL) and DBU (200 µL) were added and the reaction was again stirred overnight. The DMF 
was then concentrated to 5 mL under reduced pressure, the solution was combined with 9:1 
EtOAc:MeOH (50 mL), and was washed with H2O (3 × 30 mL). The organic layer was dried 
with MgSO4 and concentrated. The product was purified by SiO2 gel column chromatography. 
The column was washed with 100% hexanes (200 mL), and 5% EtOAc in hexanes (100 mL) and 
product eluted in 10% EtOAc in hexanes (100 mL) (Rf = 0.5, 3:1 EtOAc:Hex) yielding 4.4 (600 
mg, 41%) as a clear oil. Characterization data matched that previously reported.59 See also 
Notebook XII, Page 13 
 
 
tert-Butyl (6-(piperazin-1-yl)hexyl)oxycarbamate (4.5). 
Into a 50 mL round-bottomed flask equipped with a reflux condenser was added 
piperazine (585.6 mg, 6.8 mmol, 10 equiv) in THF (5 mL) and the solution was heated to reflux. 
To the heated solution was added 4.4 (200 mg, 0.68 mmol, 1 equiv) in THF (5 mL) via a syringe 
pump over 30 min. The reaction was stirred at reflux overnight. The solid residue was filtered 
and the supernatant was concentrated and partitioned between Et2O (30 mL) and sat. aqueous 
NaCl (30 mL). The aqueous layer was extracted with Et2O (3 × 30 mL) and the combined 
organic layers were dried with MgSO4 and concentrated under reduced pressure yielding 4.5 
(195 mg, 95%, Rf = 0.5 (4:1 EtOAc:Hex with 0.5% NEt3)) as a yellow oil. See also Notebook 
XII, Page 16. 
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1H NMR: (500 MHz, CDCl3) δ = 3.81-3.78 (t, J = 6.5 Hz, 2H); 2.87-2.85 (t, J = 5 Hz, 4H); 2.37 
(bs, 4H); 2.28-2.25 (m, 2H); 1.62-1.56 (p, J = 6.9 Hz, 2H); 1.49-1.43 (m, 11H); 1.37-1.25 (m, 
5H); 1.22 (s, 1H). 
13C NMR: (500 MHz, CDCl3) δ = 157.2, 81.5, 76.9, 59.5, 54.7, 46.1, 28.5, 28.2, 27.6, 26.7, 26.1. 
HRMS  [M+H]+ C15H32N3O3 calc’d = 302.2444, found = 302.2451. 
 
 
Boc-protected aminooxy-rhodamine B (4.6). 
Into a 50 mL round-bottomed flask was added rhodamine B (312 mg, 0.704 mmol, 2 
equiv), triphenylphosphine (277 mg, 1.056 mmol, 3 equiv) and dry dichloromethane (DCM) (7 
mL, from a solvent dispensing system (SDS)). This solution was cooled to 0 oC, N-
bromosuccinimide (220 mg, 1.232 mmol, 3.5 equiv, recrystallized) was added, and the solution 
was stirred for 15 min. At this time, 4.5 (107 mg, 0.352 mmol, 1 equiv) and pyridine (97.5 mg, 
0.1 mL, 1.232 mmol, 35 equiv) in dry DCM (5 mL) were added and the reaction was allowed to 
warm to room temperature and stirred overnight. The solvent was then removed under reduced 
pressure, and the residue partitioned between EtOAc (50 mL) and saturated aqueous NaHCO3 
(50 mL). The aqueous layer was extracted with EtOAc (6 × 30 mL), and the combined organic 
layers were dried with MgSO4 and concentrated under reduced pressure. The product was 
purified by SiO2 gel column chromatography by dissolving in 5% dry methanol (from SDS) in 
dry DCM (5 mL). The column was washed with 5% dry methanol in DCM (200 mL) and 
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product was eluted with 10% dry methanol in DCM (200 mL). The fractions containing product 
were concentrated under reduced pressure yielding 4.6 (128 mg, 50% yield) as a metallic red 
solid. Characterization data matched that previously reported.59 See also Notebook X, Page 43. 
Note: Dry MeOH was necessary because propionaldehyde and formaldehyde impurities in 
technical grade MeOH react with 4.2. 
 
 
Aminooxy-rhodamine B (4.2). 
Into a 20 mL scintillation vial was added 4.6 (10 mg) in dry DCM (2 mL). To this 
solution was added TFA (2 mL) and the solution was left unperturbed for 5 min, at which time 
the solvent was removed under reduced pressure. DCM (5 mL) was then added, and the solvent 
was again removed under reduced pressure. The addition of DCM and concentration to dryness 
was repeated three times, at which point the metallic red solid was dried at a vacuum line (8.5 
mg, quantitative). Characterization data matched that previously reported.59 See also Notebook X, 
Page 44. 
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Synthetic design of aminooxy-Cy5 (4.3). 
 
Aminooxy-Cy5 was synthesized following published procedures with some variations.61 
 
1-(4-Carboxybutyl)-2,3,3-trimethyl-3H-indol-1-ium (4.7). 
Into a 15 mL round-bottomed flask was added 5-bromovaleric acid (1.58 g, 1.59 mL 9.94 
mmol, 1.2 equiv) and 2,3,3-trimethylindolenine (1.5 g, 8.29 mmol, 1.0 equiv). The reaction was 
heated to 100 ºC with stirring for 3 h. The red solid was treated with 6 mL of EtOAc, heated at 
reflux for 2 min, and cooled allowing the solid product to settle at the bottom of the reaction 
vessel. The red supernatant was then removed from the solid and discarded. This solvent 
treatment and removal was repeated once more with EtOAc and six times with acetone. After the 
final wash, the light pink solid was filtered and dried yielding 4.7 (1.17 g, 54%). Characterization 
data matched that previously reported.61 See also Notebook XII, Page 10. 
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N-Valeric acid-Cy5 (4.9). 
Into a 25 mL round-bottomed flask was added malonaldehyde bis(phenylimine) 
monohydrochloride (466 mg, 1.93 mmol) and KOAc (183 mg, 2.0 mmol). To this solution was 
then added acetic anhydride (10 mL) and the mixture was heated to 110 ºC for 15 min. 
Compound 4.7 (100.0 mg, 0.32 mmol) was then added in small aliquots over 30 min until the 
reaction had a light green color. (Note: the color of the solution of the product of a single 
addition of 4.7 to malonaldehyde bis(phenylimine) monohydrochloride was yellow, whereas the 
color of the product of addition of a second molecule of 4.7 was blue. Hence, when the solution 
turned green, the addition of compound 4.7 was terminated.) The reaction was stirred at 110 ºC 
for 2 h at which point the green solution was concentrated by azeotropic removal of acetic 
anhydride with heptanes (30 mL aliquots until dryness) on a rotary evaporator. The resulting 
solid was dissolved in DCM and product was extracted with sat. aqueous NaHCO3 (2 × 50 mL). 
The aqueous layer was then acidified with 1 M HCl (until the pH reached 2-3) and product was 
extracted with DCM (2 × 100 mL). The organic layer was concentrated yielding crude 
intermediate 4.8 (76 mg). To the intermediate was added KOAc (40 mg, 0.41 mmol, 2.0 equiv), 
NaI (450 mg, 3.0 mmol, 15 equiv), and tert-butanol (12 mL). 1,2,3,3-Tetramethyl-3H-indolium 
iodide (121 mg, 0.4 mmol, 2.0 equiv) was then added and the reaction was stirred under reflux 
for 1.5 h. The reaction was concentrated to dryness and the metallic blue solid residue was 
dissolved in DCM (50 mL), washed with saturated aqueous NaCl (2 × 50 mL), dried with 
MgSO4, and concentrated under reduced pressure. Product was purified by silica gel column 
chromatography using a gradient from 2-10% methanol in DCM. Product eluted between 5-10% 
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methanol in DCM and was concentrated yielding 4.9 as a metallic blue solid (70 mg, 47% in two 
steps; Rf = 0.15 (10% MeOH in DCM)). Characterization data matched that previously 
reported.61 See also Notebook XII, Page 60. 
 
 
Boc-protected aminooxy-Cy5 (4.10). 
Into a 25 mL round-bottomed flask was added 4.9 (20 mg, 0.04 mmol, 1.0 equiv) in 
DCM (8 mL). To this solution was added tetramethylfluoroformamidinium hexafluorophosphate 
(TFFH) (13.6 mg, 0.04 mmol, 1.0 equiv) and DIPEA (5.56 mg, 0.04 mmol, 1.0 equiv) and the 
reaction was stirred for 15 min. At this time, 4.5 (38 mg, 0.12 mmol, 3.0 equiv) was added in 
DCM (2 mL) and the reaction was stirred for an additional 30 min. The solvent was then 
removed under reduced pressure, and the crude product purified by silica gel column 
chromatography using a gradient from 0-7% dry MeOH in DCM. The product fractions were 
concentrated yielding 4.10 as a dark metallic blue solid (16 mg, 50%; Rf = 0.2 (5% MeOH in 
DCM)). See also Notebook XI, Page 15. 
Note: TLC of column-purified 4.10 showed two product spots. These two species may represent 
different protonation states. Wash of 4.10 with 5% citric acid converted all product to the top 
spot on TLC. Wash of 4.10 with 5% NaHCO3 converted all product to the bottom spot on TLC. 
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1H NMR: (500 MHz, Methanol-d4) δ=8.26-8.21 (t, J = 12.5, Hz, 1H); 7.60-7.57 (t, J = 7.5 Hz, 
1H); 7.54-7.51 (d, J = 7.5 Hz, 0.5H); 7.49-7.48 (d, J = 7.5 Hz, 1.5H); 7.43-7.40 (dt, J = 7.5, 3 Hz, 
1.5H); 7.31-7.24 (m, 5H); 6.66-6.61 (t, J = 12.5 Hz, 0.5H); 6.32-6.23 (m, 2H); 4.15-4.12 (t, J = 
7.0 Hz, 1H); 3.77-3.74 (t, J = 6.5 Hz, 3H); 3.62 (s, 3H); 3.60-3.58 (bt, J = 6 Hz, 2H); 3.56-3.54 
(bt, J = 6 Hz, 2H); 2.50-2.41 (m, 6H); 2.39-2.36 (m, 3H); 1.94-1.84 (m, 2.0H); 1.77-1.71 (m, 
9.0H); 1.63-1.57 (p, J = 6.5 Hz, 3H); 1.56-1.49 (p, 7.5 Hz, 3H); 1.46 (s, 12H); 1.42-1.32 (m, 4H) 
HRMS [M]+ C46H66N5O4+ calc’d = 752.5115, found = 752.5115  
 
 
Aminooxy-Cy5 (4.3). 
Into a 20 mL scintillation vial was added Boc-protected aminooxy-Cy5 (4.10, 10 mg, 
0.013 mmol) in dry DCM (2 mL). To this solution was added TFA (2 mL), and the reaction was 
left unperturbed for 5 min, which turned into a clear and colorless solution. The dark blue color 
returned upon removing the solvent under reduced pressure. DCM (5 mL) was then added and 
the solution was concentrated again. The addition of DCM and concentration to dryness was 
repeated three times, at which point the metallic blue solid was dried on a vacuum line yielding 
4.3 (7.0 mg, 83%). See also Notebook XI, Page 19. 
 
1H NMR: (500 MHz, Methanol-d4) δ = 8.29-8.22 (dt, J = 12.5, 3 Hz, 1H); 7.61-7.57 (t, J = 7.5 
Hz, 1H); 7.55-7.53 (d, J = 7.5 Hz, 0.5H); 7.50-7.48 (d, J = 7.5 Hz, 1.5H); 7.44-7.38 (m, 1.5H); 
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7.36-7.35 (d, J = 3 Hz, 0.5 H); 7.33-7.25 (m, 4.5H); 6.65-6.59 (t, J = 12.5 Hz, 0.5H); 6.32-6.25 
(m, 2H); 4.15-4.11 (t, J = 7.5 Hz, 2H); 4.05-4.01 (dt, J = 6, 1.5 Hz, 3H); 3.70-3.40 (b, 3H); 3.63 
(s, 3H); 3.2-2.9 (b, 4H), 3.17-3.11 (m, 2H); 2.55-2.52 (t, J = 7 Hz, 2H); 1.95-1.82 (m, 4.0H); 
1.80-1.67 (m, 14.0H); 1.52-1.38 (m, 6H). 
HRMS [M]+ C41H58N5O2+ calc’d = 652.4590, found = 652.4580 Da. 
 
4.4.3. Construction of plasmids for coexpression. 
DNA constructs were assembled by QuikChange site directed mutagenesis using the 
appropriate primers or by overlap extension PCR, followed by digestion and ligation of the PCR 
product into the appropriate plasmid. 
 
QuikChange Site Directed Mutagenesis (Stratagene). 
The entire template plasmid was amplified by QuikChange site directed mutagenesis 
using the appropriate mutant forward and reverse primers (see Table 4.2). The DNA was purified 
using the QIAquick PCR Purification Kit, eluting into a 1.6 mL Eppendorf tube with buffer EB 
(35 µL, provided by the supplier). To the elution was added DpnI (1 µL; 20,000 U/mL) and 
digestion buffer (4 µL, provided with DpnI). The reaction was incubated at 37 oC for 1-2 h and 
then at 80 oC for 20 min to heat-inactivate the enzyme. Chemically competent E. coli DH5α cells 
were transformed with plasmid DNA, plated on LB-agar with the appropriate antibiotic marker, 
single colonies were picked, and clones were analyzed by sequencing at ACGT, Inc. 
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Overlap extension PCR. 
A 5’ gene fragment was amplified by PCR using Phusion High-Fidelity DNA polymerase 
from a template containing the sequence of interest using a forward primer with the desired 
restriction site and a reverse primer either incorporating the internal mutation or insertion or 
beginning at the first nucleotide immediately after the internal mutation or insertion. An 
overlapping 3’ gene fragment was amplified by PCR from the same template using a reverse 
primer with the desired restriction site and a forward primer incorporating the internal mutation. 
For primers used, see Table 4.2. Then, a PCR with the overlapping gene fragments and the 
primers with the desired restriction sites, was used to generate the full length mutants; the 
overlapping gene fragments were first added to the PCR mixture and after 8 rounds of 
amplification the primers with the desired restriction sites were added. After digestion of the 
mutant gene fragment and the appropriate vector with the desired restriction enzymes, the PCR 
products containing point mutations, insertions, or deletions were ligated into the plasmid using 
T4 DNA ligase. Incorporation of the correct mutation into the plasmid DNA was determined by 
sequencing at ACGT, Inc. 
 
General protocol for PCR: 
To a 0.2 mL PCR tube was added H2O (34 µL), buffer HF (10 µL, 5X stock solution, 
provided with Phusion High-Fidelity DNA polymerase), template (0.5 µL, 100 ng/µL), primers 
(1 µL each, 100 µM), DMSO (1 µL), dNTPs (1 µL, 10 mM), and Phusion High-Fidelity DNA 
polymerase (0.5 µL, 2,000 U/mL, NEB). The DNA template was amplified using the following 
protocol. The reaction was 1) heated to 95 ºC for 2 min; 2) heated at 95 ºC for 30 s; 3) heated at 
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annealing temperature (see individual cases below) for 30 s; 4) heated at 72 ºC for the elongation 
time (see below); 5) steps 2-4 were repeated for 29 cycles; 6) heated at 72 ºC for 10 min. 
 
Construction of plasmids pRSFDuet(procA1.7(G–1E/T1S)/procM), pRSFDuet(procA1.7(G–
2A/G–1A)/procM), pRSFDuet(procA1.7(G–2L/G–1L)/procM). 
The procA1.7 mutants were generated in MCSI of a pRSFDuet vector with procM in 
MCS2 using pRSFDuet(procA1.7(G–1E)/procM) (unpublished work) as template by 
Quikchange mutagenesis. The primers used were procA1.7(mutant) 5’ and 3’ (see primer Table). 
The PCR conditions were as described above with an annealing temperature of 60 oC and an 
elongation time of 2 min. 
 
Construction of inserts for plasmids pRSFDuet(procA2.8(G–1K/A1T)/procM) and 
pRSFDuet(procA2.8(G–1K/A1T ins LL)/procM). 
The procA2.8 mutants were generated in MCS1 of a pRSFDuet vector with procM in 
MCS2 using pRSFDuet(procA2.8(G–1K)/procM) as template by overlap extension PCR. The 
primers procA2.8 EcoRI FMP 5’ and procA2.8(G–1K/A1T) FMP (or LL FMP) 3' were used to 
make the 5’ overlapping fragment and the primers procA2.8(G–1K/A1T) RMP (or LL RMP) 5' 
and procA2.8 NotI RMP 3' were used to make the 3’ overlapping fragment. The restriction sites 
were EcoRI and NotI. The annealing temperature was 60 oC with an elongation time of 20 s. 
After overlap extension PCR, the full-length inserts were ligated into MCS1 of a pRSFDuet 
vector as described below. 
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Construction of plasmids pRSFDuet(lctA(K1-G2 ins AAAKT)/lctM), pRSFDuet(lctA(K1-G2 
ins AAAKLLT)/lctM), pRSFDuet(lctA(K1-G2A ins AAAKLLT)/lctM), pRSFDuet(lctA(K1-
G2L ins AAAKLLT)/lctM), pRSFDuet(lctA(K1-G2A ins AAALLKT)/lctM). 
The lctA mutants were cloned into MCSI of a pRSFDuet vector with lctM in MCS2 using 
pRSFDuet(lctAwt/lctM)56 as template by Quikchange mutagenesis. The primers used were 
lctA(mutant) 5' and 3’. The annealing temperature was 58 oC with an elongation time of 2 min. 
 
Construction of plasmids pACYCDuet(lctM) and pCDFDuet(lctM).  
lctM was cut out of MCSII of pRSFDuet(lctA(K1-G2A ins AAALLKT)/lctM) using 
restriction enzymes BglII and XhoI. The gene fragment was then ligated into either a 
pACYCDuet or a pCDFDuet vector that had been treated with the same enzymes, producing 
pACYCDuet(lctM) and pCDFDuet(lctM). 
 
Construction of plasmid pRSFDuet(lctA(K1-G2A ins AAALLKT/E13A)/lctM). 
The lctA mutant was generated from pRSFDuet(lctA(K1-G2A ins AAALLKT)/lctM) as 
template by Quikchange mutagenesis. The primers used were lctA(K1-G2A AAALLKT/E13A) 5' 
and 3’ (Table 4.2). The annealing temperature was 56 oC with an elongation time of 2 min. 
 
Construction of inserts for plasmids pRSFDuet(halA1(A–1-C1 ins IEGRT)/halM1), 
pRSFDuet(halA1(A–1E-C1 ins T)/halM1). 
The halA1 mutants were cloned into MCSI of a pRSFDuet vector that contained halM1 in 
MCS2 using pRSFDuet(halA1-Xa/halM1)42 as template by overlap extension PCR. The primers 
halA1 SacI FMP 5’ and halA1(G–1E-C1 ins T) FMP (or IEGRT FMP) 3’ were used to make the 
 174 
5’ overlapping fragment and the primers halA1(G–1E-C1 ins T) RMP (or IEGRT RMP) 5’ and 
halA1 SbfI RMP 3’ were used to make the 3’ overlapping fragment. The restriction sites used 
were SacI and SbfI. The annealing temperature was 64 oC with an elongation time of 20 s. The 
gene fragments were then ligated into MCS1 of a pRSFDuet vector as described below. 
 
Construction of plasmid pET15b(halA1(A–1E-C1 ins T)/halM1): 
The halA1 mutant DNA was constructed with a 5’ NdeI and 3’ XhoI restriction site by 
PCR with pRSFDuet(halA1(G–1E-C1 ins T)/halM1) as template. The PCR product and pET15b 
vector were separately digested and then ligated together. 
 
Construction of inserts for plasmids pRSFDuet(halA2(Q–1E-T1 ins T)/halM2) and 
pRSFDuet(halA2(Q–1E-T1 ins TA)/halM2). 
The halA2 mutants were cloned into MCS1 of a pRSFDuet vector that already contained 
halM2 in MCS2 using pRSFDuet(halA2-Xa/halM2)42 as template by overlap extension PCR. 
The primers halA2 BamHI FMP 5’ and halA2(Q–1E-T1 ins T(A)) FMP 5’ were used to make the 
5’ overlapping fragment and the primers halA2(Q–1E-T1 ins T(A)) RMP 3’ and halA2 SbfI RMP 
3’ were used to make the 3’ overlapping fragment. The restriction sites used were BamHI and 
SbfI. The annealing temperature was 60 oC with an elongation time of 20 s. After overlap 
extension PCR, the full length inserts were ligated into MCS1 of a pRSFDuet vector as described 
below. 
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Construction of plasmids pRSFDuet(nisA(R–1-I1 ins IT)/nisB) and 
pRSFDuet(nisA(I1L)/nisB). 
The nisA mutants were cloned into MCS1 of a pRSFDuet vector that already contained 
nisB in MCS2 using pRSFDuet(nisA/nisB)42 as template by Quikchange mutagenesis. The 
primers used were nisA(R–1-I1 ins IT) 5' and 3’ and nisA(I1L) 5’ and 3’. The annealing 
temperature was 60 oC with an elongation time of 2 min. 
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Table 4.2. Primers used in molecular cloning. 
procA1.7(G–1E/T1S) 5': CTG GAA GGT GTG GCT GGG GAA AGC ATT GGG GGA ACC AT 
procA1.7(G–1E/T1S)3’: CCC AGC CAC ACC TTC CAG CTC AGC ATC AGA 
procA1.7(G–2A/G–1A)5’: CTG GAA GGT GTG GCT GCG GCG ACC ATT GGG GGA ACC AT 
procA1.7(G–2A/G–1A)3’: AGC CAC ACC TTC CAG CTC AGC ATC AGA 
procA1.7(G–2L/G–1L) 5': CTG GAA GGT GTG GCT CTG CTG ACC ATT GGG GGA ACC AT 
procA1.7(G–2L/G–1L) 3': AGC CAC ACC TTC CAG CTC AGC ATC AGA 
    
procA2.8 EcoRI FMP 5': GCA ACC TAG AAT TCG ATG TCA GAA GAG CAA CTG AAG G 
procA2.8(G–1K/A1T) FMP 3': GGT TAT GAC AGG CGG TTT TCC CAG CCA CAC CTT C 
procA2.8(G–1K/A1T) RMP 5’: GAA GGT GTG GCT GGG AAA ACC GCC TGT CAT AAC C 
procA2.8(G–1K/A1T ins LL) FMP 3’: GGT TAT GAC AGG CGG TCA GCA GTT TCC CAG CCA CAC C 
procA2.8(G–1K/A1T ins LL) RMP 5’: GGT GTG GCT GGG AAA CTG CTG ACC GCC TGT CAT AAC C 
procA2.8 NotI RMP 3': ATA TAA TGC GGC CGC TTA GCA CTC ACC CTC 
  
lctA(K1-G2 ins AAAKT) 5’: TTA GGT GCA AAA GCA GCA GCA AAA ACC GGC GGC AGT GGA GTT 
lctA(K1-G2 ins AAAKT)3’: TTT TGC ACC TAA AAT AAG GTC CAA TTC ACT 
lctA(K1-G2 ins AAAKLLT) 5’: GGT GCA AAA GCA GCA GCA AAA CTG CTG ACC GGC GGC AGT 
lctA(K1-G2 ins AAAKLLT 3’: TGC TGC TGC TTT TGC ACC TAA AAT AAG GTC 
lctA(K1-G2A ins AAAKLLT) 5’: GGT GCA AAA GCA GCA GCA AAA CTG CTG ACC GCG GGC AGT 
lctA(K1-G2A ins AAAKLLT) 3’: TGC TGC TGC TTT TGC ACC TAA AAT AAG GTC 
lctA(K1-G2L ins AAAKLLT) 5’: GGT GCA AAA GCA GCA GCA AAA CTG CTG ACC CTG GGC AGT 
lctA(K1-G2L ins AAAKLLT) 3’: TGC TGC TGC TTT TGC ACC TAA AAT AAG GTC 
lctA(K1-G2A ins AAALLKT) 5': GGT GCA AAA GCA GCA GCA CTG CTG AAA ACC GCG GGC AGT 
lctA(K1-G2A ins AAALLKT) 3': TGC TGC TGC TTT TGC ACC TAA AAT AAG GTC 
lctA(K1-G2A ins AAALLKT/E13A) 5’: CAT ACA ATT TCT CAT GCG TGT AAT ATG AAT AGC 
lctA(K1-G2A ins AAALLKT/E13A) 3’: ATG AGA AAT TGT ATG AAT AAC TCC ACT GCC 
  
halA1 SacI FMP 5’: CGC CAC TCG GAG CTC GAT GAC AAA TCT TTT AAA AG 
halA1(G–1E-C1 ins T) FMP 3’: GAT ATT CTA GCT GGG GTG AAC GGT GAA ACC TGC GCA TGG TAC 
halA1(G–1E-C1 ins T) RMP 5’: CCC AGC TAG AAT ATC TTG GTC TTC TAA CTC 
halA1(G–1E-C1 ins IEGRT) FMP 3’: 
GAT ATT CTA GCT GGG ATT GAA GGT CGT ACC TGC GCA TGG TAC 
AAC 
halA1(G–1E-C1 ins IEGRT) RMP 5’: 
GTT GTA CCA TGC GCA GGT ACG ACC TTC AAT CCC AGC TAG AAT 
ATC 
halA1 SbfI RMP 3’: ATA GTG ATC CTG CAG GTT AGT TGC AAG AAG GCA TG 
  
halA2 BamHI FMP 5’: GGA TCC GAT GGT AAA TTC AAA AGA TTT GCG TAA TCC 
halA2(Q–1E-T1 ins TA) FMP 3’: ATC TCC TGA ACC AGC TAG AGA CGA AAG TTC CTT CTC 
halA2(Q–1E-T1 ins TA) RMP 5’: TTC AGG AGA TGT GCA TGC GGA AAC CGC GAC AAC TTG G 
halA2(Q–1E-T1 ins T) FMP 3’: TTC AGG AGA TGT GCA TGC GGA AAC CAC AAC TTG G 
halA2(Q–1E-T1 ins T) RMP 5’: ATC TCC TGA ACC AGC TAG AGA CGA AAG TTC CTT CTC 
halA2 SbfI RMP 3’: ATA ATG ATC CTG CAG GTT AGC ACT GGC TTG TAC 
  
nisA(R–1-I1 ins IT 5’: CA GGT GCA TCA CCA CGC ATT ACC ATT ACA AGT ATT TCG CTA  
nisA(R–1-I1 ins IT 3’: TAG CGA AAT ACT TGT AAT GGT AAT GCG TGG TGA TGC ACC TG 
nisA(I1L) 5’: CA GGT GCA TCA CCA CGC CTG ACA AGT ATT TCG CTA  
nisA(I1L)3’: TAG CGA AAT ACT TGT CAG GCG TGG TGA TGC ACC TG 
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Digestion of plasmids and DNA inserts. 
To a 1.7 mL Eppendorf tube with insert or plasmid DNA (40 µL, 100-250 ng/µL) was 
added digestion buffer (5 µL; NEB, provided with the restriction enzymes), digestion enzyme(s) 
(1.5 µL, concentrations are below), BSA (if necessary, 0.5 µL, 100X, provided with digestion 
enzyme), and H2O (to 50 µL). The components were incubated at 37 oC for 2-4 h. At this time 
calf intestine phosphatase (CIP) (1 µL) was added to plasmid DNA only and the sample was 
incubated for an additional 1 h. The samples were then analyzed by DNA gel electrophoresis and 
the desired band was purified by a QIAGEN Gel Extraction kit eluting in buffer EB (30 µL). 
Note: Both digestion enzymes were added in one single digest if the buffer was compatible. If 
buffer was not compatible, two successive digests were performed. 
 
BamHI = 20,000 U/mL, NotI = 10,000 U/mL, XhoI = 20,000 U/mL, BglII = 10,000 U/mL, 
EcoRI = 20,000 U/mL, SacI = 20,000 U/mL, SbfI = 10,000 U/mL, CIP = 10,000 U/mL. 
 
Ligation of digested plasmid and DNA insert. 
To three 0.6 mL Eppendorf tubes was added plasmid DNA (1 µL, 100 ng/µL). Insert 
DNA (1 mL of a solution of different concentrations to give a ratio of plasmid to insert of 1:1, 
1:10 and 1:100) was then added as well as T4 DNA ligase reaction buffer (0.7 mL, provided with 
the ligation enzyme), T4 DNA ligase (0.8 mL, 400,000 cohesive end U/mL), and H2O (to 5 µL). 
The samples were incubated at 18 oC for 16-20 h at which time the entire reactions were used to 
transform E. coli DH5a cells. 
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4.4.4. Heterologous production, purification, and characterization of LanA analogues. 
The lanthipeptides were expressed using E. coli BL21 cells transformed with a single 
pRSFDuet plasmid containing the lanA and lanM genes. For keto-Halα, two plasmids were used 
to increase the yield of production (pRSFDuet(halA1(G–1E-C1 ins T)/halM1 and 
pET15b(halA1)G–1E-C1 ins T)) and for keto-lacticin 481 and keto-nisin-1 three plasmids were 
used (pRSFDuet(lctA(K1-G2A ins AAALLKT)/lctM, pACYCDuet(lctM), and pCDFDuet(lctM); 
pRSFDuet(nisA(R–1-I1 ins IT)/lctM, pACYCDuet(nisB/nisC), and pCDFDuet(nisB)). 
 
Overexpression and purification of His6-tagged modified peptide mutants. 
An overnight culture of E. coli BL21 (DE3) cells carrying the desired plasmids was 
added to an overexpression culture flask containing either terrific broth (TB) or LB broth (1:100; 
volume overnight culture: volume overexpression culture) and appropriate antibiotics depending 
on the plasmids used (1:1000 v:v; kanamycin (50 mg/mL), chloramphenicol (25 mg/mL), 
spectinomycin (25 mg/mL, ampicillin (100 mg/mL)). The culture was then incubated in a 37 ºC 
shaker (220 rpm) until the optical density reached 0.6 (LB) or 1.0 (TB). For HalA1 and HalA2, 
overexpression was immediately induced with isopropyl β-D-1-thiogalactopyranoside (IPTG, 
0.25 mM final concentration) and the flask was incubated for 4 h in a shaker at 37 ºC and 220 
rpm. Conversely, for ProcA1.7, ProcA2.8, and LctA, the culture was first placed on ice (15 min). 
Overexpression was then induced by the addition of IPTG and the flask was incubated overnight 
in a shaker at 18 ºC and 220 rpm. The following morning the cells were harvested by 
centrifugation (11,867 ×g, 4 ºC, 20 min), the supernatant was discarded and the cells were lysed 
using a cell homogenizer (Avestin Emulsiflex-C3; 5,000 PSI) in LanA start buffer (1 mL per 100 
mL culture; 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol, pH 7.5). The 
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soluble and insoluble layers were then separated by centrifugation (22,789 ×g, 4 oC, 20 min) and 
the soluble layer was saved for purification. The insoluble layer was suspended in LanA lysis 
buffer (1 mL per 100 mL culture; 6 M guanidine HCl, 20 mM NaH2PO4, pH 7.5, 500 mM NaCl, 
0.5 mM imidazole) and the cells were lysed by sonication. The soluble and insoluble layers were 
again separated by centrifugation (22,789 ×g, 4 oC, 20 min) and the modified His6-LanA peptide 
was purified from the filtered soluble layers (0.45 µm) using a Ni HisTrap HP column (5 mL, 
GE Healthcare). The column was washed with LanA wash buffer (4 M guanidine-HCl, 20 mM 
NaH2PO4, pH 7.5, 500 mM NaCl, 30 mM imidazole) to remove non-specific binding proteins. 
The His6-LanA peptide was eluted with LanA elute buffer (3 × 5 mL, 20 mM NaH2PO4, 100 mM 
NaCl, 500 mM imidazole, pH 7.5). Finally, the peptide was further purified by preparative 
reversed phase high-performance liquid chromatography (RP-HPLC) and lyophilized. 
 
Proteolytic cleavage of LanA mutants. 
To lyophilized peptide was added HEPES buffer (1 mL per 5 mg of peptide, pH 7.5, 50 
mM final concentration) and the necessary protease (5 µL/L overexpression culture; stock 
solutions used: LysC = 3 U/100 µL, GluC = 2 mg/mL, trypsin = 40 µM). To the HalA1 mutant 
reaction was also added TCEP (1 mM final concentration). The reaction was incubated overnight 
at room temperature (GluC, trypsin) or at 37 ºC (LysC). The following morning the progress of 
the reaction was analyzed by MALDI-TOF MS and additional enzyme was added in 5 µL 
aliquots if the reaction was not complete. Once complete, the reaction was purified by 
preparative RP-HPLC. 
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Aminopeptidase cleavage of GluC-cleaved ProcA1.7(G–2L/G–1L). 
To a reaction vessel was added HPLC-purified GluC-cleaved ProcA1.7(G–2L/G–1L), 
HEPES buffer (1 mL per 5 mg of peptide, pH 7.5, 100 mM final concentration), and 
aminopeptidase (A8200, 6 µL/1 mg peptide, 100 U/mL stock solution). The reaction was 
incubated at 37 ºC for 24 h. The reaction product was used in a bioconjugation reaction with 4.1 
without further purification. 
 
Representative bioconjugation of keto-LanA and 4.1. 
To a reaction vessel was added keto-LanA (1.45 µmol) and 4.1 (14.5 µmol, 1.54 mg, 10 
equiv). Next, a solution of H2O (2.04 mL), acetate buffer (75 µL, 4 M, pH 4.75, final 
concentration 100 mM), and aniline (885 µL, 339 mM, final concentration 100 mM) was added. 
This solution was degassed with N2 prior to addition to prevent formation of large amounts of 
oxidized product. The reaction was stirred for 4 h at room temperature. The crude material was 
then purified by preparative RP-HPLC.  
 
Representative bioconjugation of keto-LanA and 4.2 or 4.3. 
To keto-LanA (0.48 µmol) in a 15 mL conical vial was added 4.2 or 4.3 (24.2 µmol, 50 
equiv) dissolved in a degassed solution of acetate buffer (100 mM, 2 mL). To this solution was 
added p-phenylenediamine (86.4 mg, 400 mM final concentration) and the reaction was vortexed 
to dissolve the catalyst. The reaction was incubated for 3 h and diluted with 60% MeCN, 0.1% 
TFA (2 mL). The crude material was then purified by preparative RP-HPLC, except rho-Halα, 
which was purified by several rounds of analytical RP-HPLC to separate the fluorescently-
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labeled peptide from a rhodamine impurity. Excess 4.2 or 4.3 were recovered during HPLC 
purification and used in subsequent reactions. 
 
Purification of LanA analogues by RP-HPLC. 
The cleavage and bioconjugation reactions were directly purified by preparative RP-
HPLC on a Phenomenex C18 column (1.0 cm × 25.0 cm) (except for the purification of rho-Halα 
which was purified by analytical RP-HPLC) employing a water-acetonitrile solvent system. The 
linear gradient used was from 2-80% solvent B in 45 min (solvent A = 0.1% TFA in H2O; 
solvent B = 80% acetonitrile in H2O, 0.086% TFA). Peptides were monitored by their 
absorbance at 220 nm. Fractions containing product as analyzed by MALDI-TOF MS were 
collected and lyophilized. 
 
4.4.5. Yield and purification of LanA analogues. 
His6-ProcA1.7. Yield: 8.5 mg/L. RP-HPLC: Rt = 28.0-32.0 min (C4, Waters Delta-pak™). 
His6-ProcA2.8(G–1K-A1T). Substrate was cleaved by protease immediately after Ni2+ 
purification. 
His6-HalA1(G–1E-C1 ins T). Yield: 7.6 mg/L. RP-HPLC: Rt = 29.0-33.0 min (C4, Waters 
Delta-pak™).  
His6-HalA2(Q–1E-T1 ins TA) Yield: 10 mg/L. RP-HPLC: Rt = 31.8-36.3 min (C4, Waters 
Delta-pak™). 
His6-LctA(K1-G2A ins AAALLKT). Yield: 3.1 mg/L mixture of product with 4 and 5 
dehydrations. RP-HPLC: Rt = 33.0-37.0 min (C4, Waters Delta-pak™). 
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His6-LctA(K1-G2A ins AAALLKT/E13A). Yield: 1.2 mg/L mixture of product with 4 and 5 
dehydrations. RP-HPLC: Rt = 31.0-35.0 min (C4, Waters Delta-pak™). 
Pcn1.7. RP-HPLC: Rt = No HPLC was performed before bioconjugation with 1. 
keto-Pcn2.8. Yield: 3 mg/L culture. RP-HPLC: Rt = 25.7-27.7 min (C18, Waters Delta-pak™). 
keto-Halα. Yield: 0.9 mg/L culture. RP-HPLC: Rt = 24.5-27.0 min (C18, Phenomenex). 
keto-Halβ. Yield: 1.55 mg/L culture. RP-HPLC: Rt = 38.6-41.6 min (C18, Waters Delta-pak™). 
keto-lacticin 481. Yield: 0.1 mg/L culture. RP-HPLC: Rt = 30.0-30.8 min (C18, Phenomenex). 
keto-lacticin 481/E13A. RP-HPLC: Rt = 30.1-30.7 min (C18, Phenomenex). 
alk-Pcn1.7. RP-HPLC: Rt = 37.5-38.2 and 39.0-39.8 min (C18, Phenomenex). Two 
diastereomers are formed during the oxime bioconjugation (E and Z). Only in alk-Pcn1.7 and 
alk-Halβ were the isomers distinguishable by preparative HPLC. 
alk-Pcn2.8. RP-HPLC: Rt = 28.0-29.0 min (C18, Phenomenex). 
alk-Halα. Bioconjugation yield after HPLC: 5%. RP-HPLC: Rt = 32.0-32.8 min (C18, 
Phenomenex). 
alk-Halβ. Bioconjugation yield after HPLC: 10%. RP-HPLC: Rt = 41.0-42.3 min (C18, 
Phenomenex).  
alk-lacticin 481. Bioconjugation yield after HPLC: 30%. RP-HPLC: Rt = 31.2-31.6 min (C18, 
Phenomenex).  
rho-Halα. Bioconjugation yield after HPLC: 12.5%. RP-HPLC: Rt = 32.6-33.2 min (C18, 
Phenomenex, analytical). 
rho-Halβ. Bioconjugation yield after HPLC: 28%. RP-HPLC: Rt = 38.2-39.0 and 40.6-40.9 min 
(C18, Phenomenex, analytical). 
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Cy5-Halβ. Bioconjugation yield after HPLC: 16%. RP-HPLC: Rt = 39.0-39.8 and 39.8-40.4 min 
(C18, Phenomenex, analytical). 
rho-lacticin 481. Bioconjugation yield after HPLC: 47%. RP-HPLC: Rt = 35.2-35.6 min (C18, 
Phenomenex, analytical). 
rho-lacticin481/E13A. RP-HPLC: Rt = 35.0-35.3 min (C18, Phenomenex). 
 
4.4.6. Confocal fluorescence microscopy with B. subtilis. 
A 150 µL aliquot from an overnight culture of B. subtilis 168 was used to inoculate LB (5 
mL) and the culture was grown to an OD of 0.5. This culture was transferred into 2.0 mL 
Eppendorf tubes (1.5 mL) and centrifuged at 1,431 ×g for 2 min in a microfuge. Into the tubes 
with cells were added cold solutions of fluorescently-labeled lantibiotic at the desired 
concentration in 1X Dulbecco’s Phosphate-Buffered Saline (D-PBS) (1 mL, Fisher Scientific). 
The reactions were kept on ice for 30 min. At this time the reactions were centrifuged at 4 ºC (1 
min, 1,431 ×g). The supernatant was carefully removed and the cells were carefully suspended in 
1 mL of 1X D-PBS. The solution was again centrifuged, the supernatant was removed and cells 
were carefully suspended in 1 mL of 1X D-PBS. Finally, the suspension was centrifuged and D-
PBS was removed to give a suspension of around 200 µL. Aliquots of the suspension (10 µL) 
and liquified low gelling temperature agarose (10 µL, 1.5%) were added to a microscopy plate 
and the localization of the lantibiotic was analyzed by confocal fluorescence microscopy using a 
Zeiss LSM 700 Confocal Microscope. Rhodamine B analogues were excited using a 555 nm 
laser and emission was detected at wavelengths between 560 and 625 nm. Cy5 analogues were 
excited using a 639 nm laser and emission was detected at wavelengths between 640 and 735 
nm. Images were deconvoluted using the program AutoQuant X3 (Media Cybernetics). 
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4.4.7. Minimum inhibitory concentration determination. 
Ninety six-well and forty eight-well microtiter plates (Corning Costar) were utilized for 
anaerobic and aerobic cultures, respectively. For ninety six-well plates, each well contained 90 
µL of an overnight culture containing L. lactis HP (approximately 1×108 CFU mL-1) and a 10x 
stock of peptide (10 µL) of the desired concentration. The plates were incubated at 30 ºC 
overnight with no agitation. For forty eight-well plates, each well contained 180 µL of an 
overnight culture containing B. subtilis 168 (approximately 1×108 CFU mL-1) and a 10x stock of 
peptide (20 µL) of the desired concentration. The plates were incubated at 30 ºC overnight with 
moderate shaking. In addition, each ninety six and forty eight-well plate contained several blank 
(growth media with no bacteria) and control (SDW in place of peptide) wells. The optical density 
at 630 nm (OD630) was recorded at hourly intervals from 0-6 h and a final recording at 22-24 h. 
For experiments with Cy5-Halβ, the optical density was read at 570 nm (OD570) to minimize the 
undesired excitation of Cy5. The MIC was determined as the lowest concentration at which no 
cell growth was observed after 22-24 h. 
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